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Obesity is a chronic disorder characterized by a tonic low-grade 
activation of the innate immune system that affects steady-state measures of 
metabolic homeostasis over time. In addition, obesity is often accompanied by 
elevations in tissue and circulating FFA concentrations. Systemic levels of 
FFAs can induce inflammatory cascades in adipocytes and macrophages 
through TLR4-dependent effect. Signaling through TLR4 activates a broad 
range of intracellular cascades that include stimulation of IKK-β, NF-kB, JNK 
and AP1. Indeed, in addition to store excess calories in the form of lipid, 
adipose tissue produces classical cytokines and chemokines such as MCP-1, 
IL-8 and CCL5. CCL5, as other chemokines, participates in mediating 
leukocyte infiltration of adipose tissue. Moreover circulating CCL5 
concentrations are elevated in obesity, impaired glucose tolerance (IGT) and 
type 2 diabetes. In this study I have investigated the molecular mechanisms 
involved in the metabolic control of CCL5 expression in adipocytes. 
Cytokine/growth factor screening of conditioned media from 3T3-L1 pre-
adipocytes and adipocytes revealed that adipocytes secreted higher amount of 
CCL5 compared to their undifferentiated precursors. Higher concentrations of 
glucose and fatty acids (oleate and palmitate) increased CCL5 secretion by 
3T3-L1 adipocytes. Moreover, both oleate and palmitate enhanced CCL5 
mRNA levels and induced an activation of JNK, NF-kB, MAPK and 
PI3K/AKT pathways. In cells treated with JSH23, a NF-kB inhibitor, the 
effect of FFAs on CCL5 mRNA levels was reduced thus indicating a direct 
involvement of NF-kB. Treatment of the cells with SP600125, a JNK 
inhibitor, also significantly reduced the stimulatory effect of oleate and 
palmitate on CCL5 mRNA and interestingly prevented FFA-induced NF-kB 
binding to CCL5 promoter. I have also obtained evidence that insulin exerted 
an inhibitory effect on CCL5 mRNA and counteracted fatty acid-induced 
stimulation. Both PD98059 and LY294002, inhibitors of MAPK and PI3K, 
respectively, increased CCL5 expression levels reverted anti-inflammatory 
effect of insulin in presence of fatty acids. Consistently, insulin exposure 
reduced NF-kB recruitment onto CCL5 promoter, and almost completely 
prevented fatty acid effect. In conclusion, oleate and palmitate induce CCL5 
mRNA, possibly via JNK and NF-kB pathways. Fatty acid effect on CCL5 is 
largely prevented by insulin and may involve PI3K/AKT and MAPK.







L’obesità è una malattia cronica caratterizzata da un’infiammazione di basso 
grado e da elevate concentrazioni tissutali e plasmatiche di acidi grassi liberi. 
Gli acidi grassi possono indurre la stimolazione di recettori posti sulla 
membrana di adipociti e macrofagi, come ad esempio il TLR4, e attivare 
pathway infiammatori (IKK-β, NF-kB, JNK e AP1). Il tessuto adiposo 
immagazzina l’eccesso di calorie sotto forma di lipidi e produce numerose 
citochine e chemochine come ad esempio MCP-1, IL-8 e CCL5. CCL5, come 
altre chemochine, è coinvolta nei processi di infiltrazione leucocitaria del 
tessuto adiposo. Sono stati riscontrati elevati livelli circolanti di CCL5 in 
soggetti obesi, in individui con alterata tolleranza al glucosio e pazienti con 
diabete mellito di tipo 2. In questo studio, ho indagato i meccanismi 
molecolari coinvolti nel controllo metabolico dell’espressione di CCL5 negli 
adipociti. L’analisi di sovranatanti cellulari ha rivelato che adipociti murini 
3T3-L1 rilasciano elevati livelli di CCL5 rispetto ai loro precursori 
indifferenziati. Il trattamento con alte concentrazioni di glucosio e acidi grassi 
(oleato e palmitato) aumenta la secrezione di CCL5 da parte degli adipociti 
3T3-L1. Inoltre, sia oleato che palmitato incrementano i livelli di mRNA di 
CCL5 e inducono un’attivazione dei pathway di JNK, NF-kB, MAPK e 
PI3K/AKT. In cellule trattate con l’inibitore specifico di NF-kB, JSH23, 
l’effetto degli acidi grassi sui livelli di mRNA di CCL5 è ridotto, suggerendo 
un diretto coinvolgimento di NF-kB. Anche il trattamento con SP600125, 
inibitore specifico di JNK, riduce significativamente l’effetto di oleato e 
palmitato sul messaggero di CCL5 e, inoltre, previene il binding di NF-kB sul 
promotore di CCL5. Sono state anche ottenute evidenze che l’insulina esercita 
un effetto inibitorio sull’espressione di CCL5 e contrasta la stimolazione 
indotta dagli acidi grassi. Il trattamento con gli inibitori delle vie delle MAPK 
e della PI3K, PD98059 e LY294002, rispettivamente, aumenta l’espressione di 
CCL5 opponendosi all’effetto anti-infiammatorio dell’insulina. Infine, il 
trattamento con l’insulina riduce il reclutamento di NF-kB sul promotore di 
CCL5, e previene quasi completamente l’effetto degli acidi grassi. In 
conclusione, oleato e palmitato inducono il messaggero di CCL5 via JNK e 
NF-kB. L’insulina previene l’effetto degli acidi grassi su CCL5 e questo 
meccanismo potrebbe essere mediato da PI3K/AKT e MAPK .  








1.1 Adipose tissue 
 
Energy stores are depleted intermittently during sleep-wake cycles and 
over prolonged periods during famine or illness. To maintain vital cellular 
functions, human and other mammals consume more calories than is required 
for immediate metabolic needs and store excess calories as glycogen, protein 
and lipids. Adipose tissue, commonly called ‘fat’, is a type of loose connective 
tissue comprised of lipid-filled cells (adipocytes) surrounded by a matrix of 
collagen fibers, blood vessels, fibroblasts and immune cells (Ahima and Flier 
2000). There are different kinds of adipose tissues that are generally regarded 
as connective tissues without a specific anatomy (Figure 1). 
 
Figure 1: Comparative image of two different kinds of adipose tissue. White adipose has 
little cytoplasm and has huge oil droplet (A). Brown adipose tissue has more capillaries and 
has much more cytoplasm (B). 
 
However, accumulating data support the idea that adipose tissues are 
organized to form a large organ with discrete anatomy, specific vascular and 
nerve supplies, complex cytology, and high physiological plasticity (Cinti 
2011).  
Among adipose tissue kind, Brown adipose tissue (BAT) is a specialized 
tissue whose main function is to produce heat. In small mammals, it is located 
in discrete depots and has largely been investigated for its role in 
thermogenesis (Richard et al. 2012). There are many evidences that BAT is 
not only found in small mammals but also in adult humans. A number of 
B A 






studies involving imaging procedures such as positron emission 
tomography/computed tomography (PET/CT) scanning have revealed 
symmetrical distribution of metabolically active brown fat depots around 
cervical, clavicular, and paraspinal regions in humans (Richard at al 2012). 
White adipose tissue (WAT), the predominant type of adipose tissue in 
humans, provides a virtually limitless storage site for triglycerides. It is 
characterized by adipocytes with a single lipid inclusion and eccentrically 
located nucleus, whereas brown adipocytes are polygonal cells with a roundish 
nucleus and several cytoplasmic lipid droplets (Cinti 2012).  
Thus, white and brown adipocytes are not only different in their morphology 
but also in their physiology: white adipocytes store energy for the metabolic 
needs of the organism, whereas brown adipocytes burn energy for 
thermogenesis (Cinti 2012). Both cell types are contained in the multiple 
depots of the adipose organ. White adipocytes of different sizes are present in 
subcutaneous depots (mainly large adipocytes) and visceral depots (mainly 
small adipocytes). Brown adipocytes in visceral depots are mainly found near 
aorta. Paucocilocular adipocytes, which are cells with intermediate 
morphology between that of white and brown adipocytes, are also present in 
the adipose organ. It should be noted that some groups also refer to ‘beige’ 
(Ishibashi and Seale 2010) or ‘brite’ (brown in white) (Petrovic et al. 2010) 
regions of white adipose tissue, containing brown or brown-like adipocytes. 
Adipocytes in visceral depots are sensitive to lypolitic stimuli, whereas 
adipocytes from structural depots (such as around the eyes and in the heel 
pads) do not release stored lipid easily. 
Classically thought of as a tissue mass that stores excess energy and provides 
insulation and padding to the body, adipose tissue is now accepted to be an 
endocrine organ that secretes numerous hormones, growth factors, cytokines, 
matrix proteins, enzymes and complement factors (Figure 2). For instance, 
classical cytokines include tumor necrosis factor-α (TNF-α) and interleukin-1, 
6, 10, and 18 (IL-1, IL-6, IL-10, IL-18), whereas monocyte chemoattractant 
protein-1 (MCP-1), macrophage migration inhibitory factor (MIF), regulated 
on activation normal T cell expressed and secreted/CCL5 (RANTES/CCL5) 
and interleukin-8 (IL-8) belong more to the subgroup of chemokines 
(D’Esposito et al. 2012). The diversity of secreted molecules includes also 
factors involved in lipid and glucose metabolism such as lipoprotein lipase 
(LPL), apolipoprotein E (apoE), cholesteryl ester transfer protein, peroxisome 






proliferator-activated receptor (PPAR), glucocorticoids, sex steroids, 
prostaglandins, adipsin, acylation stimulating protein, leptin, resistin, 
adiponectin/Acrp30/adipoQ, osteonectin, and cathepsins, among others. 
Finally, secreted growth factors include insulin-like growth factor 1 (IGF1), 
nerve growth factor (NGF), macrophage colony-stimulating factor, 
transforming growth factor-β (TGF-β), vascular endothelial growth factor 
(VEGF), heparin-binding epidermal growth factor, leukemia inhibitory factor, 

















Figure 2: Adipokines secreted by white adipose tissue. White adipose tissue (WAT) 
secretes various humoral factors called adipokines. Adipokines have important effects on lipid 
and glucose metabolism, and so on.  
Adapted from Ravussin. Pharmacogenomics J. 2002;2(1):4-7. 
 
The secreted factors identified to date play a role in fat mass regulation and 
regulation of adipocyte differentiation, vascular and blood flow regulation, 
lipid and cholesterol metabolism, and immune system function. With such 
varied biological functional roles, it is likely that these adipokines have a 
significant role in disease processes known to be metabolic consequences of 
obesity, such as insulin resistance, cardiovascular disease, and altered lipid 
homeostasis (Poulus et al. 2009). 
 








Obesity is characterized by excessive fat accumulation in adipose tissue 
and other organs. It is a major cause of morbidity and mortality, associated 
with an increased risk of cardiovascular disease, metabolic syndrome and 
certain forms of cancer. The BMI (Body Mass Index), calculated as weight 
(kg) divided by height squared (m2), is used as a measurement of body fat in 
clinical and epidemiologic studies. The National Heart, Lung and Blood 
Institute and the world Health Organization (WHO) define overweight as a 
BMI equal to or greater than 25 Kg/m2 and obese as a BMI equal to or greater 
than 30 Kg/m2. The WHO estimates that 1.5 billion people are overweight and 
more than 500 million are obese worldwide (Gilbert and Slingerland 2013). 
Once considered a problem only in the USA and other high-income countries 
of the Western world, obesity has become a major contributor to the global 
burden of disease (Misra and Khurana 2008). The worldwide increase in the 
incidence of obesity and related chronic diseases has largely been driven by 
global trade liberalization, economic growth and rapid urbanization, which 
continue to fuel dramatic changes in living environments as well as in diets 
and lifestyles that promote positive energy balance. Positive energy balance 
occurs when individual’s caloric intake exceeds their energy expenditure, 
leading to weight gain (Haweks 2006; Malik et al. 2012). Indeed the balance 
between energy intake (food consumption) and energy expenditure (basal 
metabolic rate) is tightly regulated (Singla et al. 2010). Combined with 
reduction in physical activity, these factors are driving the global obesity 
epidemic (Fuster and Kelly 2010). 
The global effect of the obesity epidemic was formally recognized by the 
WHO during a special obesity consultation in 1997. National survey data 
show that obesity epidemic began in the USA over 40 years ago, with the 
estimated prevalence having more than doubled in the USA from 1980 to 2010 
and worldwide from 1980 to 2008. In the USA alone in 2009-2010, 35.5% of 
men and 35.8% of woman had obesity (Flegal et al. 2012). In 2008 it was 
estimated that 500 million adults had obesity, which represents 10-14% of the 
world’s population. Among women, obesity prevalence increased in all 
regions. The greatest magnitudes of increase were observed in central Latin 
America, North America and North Africa and the Middle East. The 
Caribbean, Oceania and Southern Africa had magnitudes of increase ranging 






from around 14% to 18%. Other regions had increases ranging from <3% in 
east Asia to close to 7% in Western Europe. For men, obesity increased in all 
regions except South Asia. The greatest magnitude of increase was observed 
in North America, with an increase of <18%. In central Latin America, 
Southern Africa, Oceania, north Africa and the Middle East, Western Europe 
and the Caribbean prevalence increased by <9-15%. In the remaining regions, 
prevalence increased by between 1.4% in East Africa and <6% in Eastern 
Europe. In the 2008, the sex-specific prevalence of obesity was highest in 
North America (men: 29.2%) and in southern Africa (women: 36.5%) (Figure 

























Fig. 3: Global trends in the prevalence of obesity among women and men in 1980 and 
2008 from select regions of the world. Estimates of obesity prevalence in women (A) and 
A 
B 






men (B) are shown. Among women, obesity prevalence increased in all regions. For men, 
obesity increased in all regions except South Asia.  
Adapted from Finucane et al. Lancet. 2011 Feb 12;377(9765):557-67.  
 
The prevalence of obesity is higher in adults than in children but the increase 
in the incidence of obesity among children has occurred more rapidly than that 
among adults in some countries, such as the USA, Brazil and China (Popkin et 
al. 2006). The worldwide prevalence of childhood overweight and obesity 
increased from 4.2% to 6.7% between 1990 and 2010 (de Onis et al. 2010).  
Genetic predisposition is a key contributing factor in obesity, as has been 
demonstrated by familial aggregation, twin and adoption studies. Estimates for 
a genetic basis for obesity range from approximately 40% to 70%. The idea 
that genetic loci alter body fat content has been substantiated by the 
identification of mutations that cause low- or high-fat phenotypes in rodents 
and humans (Friedman 2000).  
The hypothalamus is the major nervous centre controlling food intake. It has 
two major areas that play an important role in maintaining the normal energy 
homeostasis of the body by controlling the hunger and satiety centres. The 
portion of hypothalamus, called the ventro-medial hypotalamic nucleus 
(VMN), is known as the ‘satiety centre’. Stimulation of VMN causes 
suppression of food intake, whereas a bilateral VMN lesion induces 
hyperphagia and obesity. On the contrary, stimulations or any lesion of lateral 
hypotalamic area, known as ‘hunger centre’, induce the opposite set of 
responses. Various neuropeptides (e.g. the melanocortin system, neurpeptide 
Y) and neurotrasmitters (e.g. serotonin, dopamine, and noradrenaline) along 
with insulin and leptin molecules function in hypothalamus and thus 
coordinate the behavioral, physiological and metabolic responses (Singla et al. 
2010). In addition to these long-term adiposity signals, short-term meal related 
signals are also transmitted to the central nervous system (CNS) through 
afferent nerves or gut-secreted peptides (e.g. cholecystockinin, ghrelin). In the 
CNS neurons are also directly sensitive to carbohydrates and fats (Arora et 
Anubhuti 2006). 
Adipose tissue is major endocrine organ, producing various hormones that 
regulate body metabolism. An increase in the fat cell mass leads to an 
alteration of hormone-adipose tissue release, which can have various 
metabolic effects. The metabolic complications of obesity, often referred to as 






the metabolic syndrome, consist of insulin resistance, often culminating in β-
cell failure, impaired glucose tolerance and type 2 diabetes, dyslipidemia, 
hypertension and premature heart disease (Singla et al. 2010). Moreover 
obesity is characterized by a low-grade inflammation not only in adipose 
tissue but also in others organs. 
 
1.3 Adipose tissue inflammation in obesity 
 
Over the past decade, the search for a potential unifying mechanism 
behind the pathogenesis of obesity-associated diseases has revealed a close 
relationship between nutrient excess and derangements in the cellular and 
molecular mediators of immunity and inflammation. The inflammatory 
response triggered by obesity involves many component of the classical 
inflammatory response to pathogens and includes systemic increases in 
circulating inflammatory cytokines and acute phase proteins (e.g. C-reactive 
protein), recruitment of leukocytes to inflamed tissue, activation of tissue 
leucocytes and generation of reparative responses (e.g. fibrosis) (Spencer et al. 
2010). The chronic nature of obesity produces a tonic low-grade activation of 
the innate immune system that affects steady-state measures of metabolic 
homeostasis over time. Superimposed on this chronic inflammation are 
recurrent acute episodes of nutrition-related immune activation induced by 
nutrient availability (fasting or high-fat meals) (Lumeng and Saltiel 2011). 
Adipose tissue can respond rapidly and dynamically to alternations in nutrient 
deprivation and excess through adipocyte hypertrophy and hyperplasia that 
can both contribute to adipose tissue expansion (Sun et al. 2011). It has been 
described that macrophage infiltration has a key role into expanding of adipose 
tissue, causing inflammation and linking obesity to insulin resistance. Several 
mechanisms including fatty acid flux, hypoxia, adipocyte cell death and 
augmented chemokine and adipokine secretion have been proposed to be 
initiators of macrophage infiltration (Weisberg et al. 2003; Xu et al. 2003). 
Plasma Free fatty acids (FFAs) concentrations are chronically elevated in 
human obesity because of the blunted capacity of insulin to inhibit lipolysis 
and the excessive consumption of dietary lipids (Cnop 2008).  
FFAs, stored in the form of triglycerides in adipose tissue, are released from 
hypertrophic adipocytes through lipolysis during fasting. Some of these FFAs 
are shunted to the liver and stored in lipid droplets, while some of them are 






oxidized in other organs. However, many of them are locally re-esterified in 
adipocytes. Those FFAs that escape re-esterification play a critical role in 
several organs as a primary energy source during prolonged fasting (Sun et al. 
2011). However, FFAs can also serve as ligands for the toll like receptor 4 
(TLR4) complex, thereby activating the classical inflammatory response in the 
context of increased local extracellular lipid concentrations, which ultimately 
drives adipose tissue macrophage accumulation. Even though adipose tissue is 
not considered as a conventional tissue suffering from lipotoxic side effects, 
either high rates of lipolysis or an influx of saturated FFAs into adipocytes do 
cause temporary inflammation within the tissue (Shi et al. 2006). FFAs cause 
inflammation via TLR4 in all cellular fractions of adipose tissue. Thus, FFAs 
induce a pro-inflammatory pattern of adipokine production in primary 
adipocytes or adipocyte cell line (Nguyen et al. 2005; Shi et al. 2006). FFAs 
also activate macrophages, especially the CD11c+ subset, thereby exacerbating 
their pro-inflammatory activity (Suganami et al. 2007). Many of the metabolic 
stresses, through activation of TLR4, promote inflammation and induce 
several kinases, such as IkB kinase-β (IKK-β) and C-Jun N-terminal kinase 
(JNK), which may have key roles in pathogenesis of insulin resistance. Indeed, 
IKK-β activates the transcription factor nuclear factor-kB (NF-kB), and 
obesity induces the expression of NF-kB target genes, such as pro-
inflammatory cytokines, in the liver and adipose tissue. These cytokines, 
including TNF-α, IL-6, IL-8 and IL-1β, may promote insulin resistance in the 
tissues where they are produced, such as the liver and adipose tissue, and may 
also be transported through the circulation to affect more distant sites, 
including the vessel walls, skeletal and cardiac muscle, the kidneys and 
circulating leukocytes. The other potentially important kinase, JNK, activates 
transcription factors such as ETS domain-containing protein (Elk-1), 
activating transcription factors 2 (ATF2) and Jun (Osborn and Olefsky 2012). 
IKK-β and JNK belong to group of kinases that phosphorylate on serine 307 
the insulin receptor substrate (IRS) leading to an alteration of insulin 
signaling. Insulin signaling involves a complex signaling cascade downstream 
of the insulin receptor. This signaling cascade branches into two main 
pathways. The first is the phosphatidylinositol 3-kinase (PI3K)/AKT (also 
called protein kinase B (PKB)) pathway that is largely responsible for insulin 
action on glucose uptake, as well as other metabolic actions of insulin, 
including the suppression of gluconeogenesis. The second pathway is the Ras-






mitogen-activated protein kinase (MAPK) pathway, which mediates gene 
expression, but also interacts with PI3K-AKT pathway to control cell growth 
and differentiation. The common intermediate to these pathways is IRS, which 
include four distinct family members, IRS-1-4. Activation of the insulin 
receptor leads to tyrosine phosphorylation of IRS-1 thereby initiating signal 
transduction. When IRS-1 is alternatively phosphorylated on serine 307, its 
downstream signaling ability is diminished (Figure 4) (de Luca and Olefsky 
2008). 
  
Figure 4: Direct interaction of insulin signaling and inflammatory pathways. Insulin 
signaling cascade branches into two main pathways. The PI3K/AKT pathway mediates insulin 
action on nutrient metabolism including glucose uptake. The Ras/MAPK pathway mediates 
insulin’s effect on gene expression, but also interacts with the PI3K-AKT pathway to control 
cell growth and differentiation. Activation of the insulin receptor leads to tyrosine 
phosphorylation of IRS1 thereby initiating signal transduction. Stimulation of the NF-kB and 
AP-1 Fos/Jun inflammatory pathways results in the activation of the serine kinases, Ikkb and 
Jnk1, which reduce the signaling ability of IRS-1. Additional inflammation-related negative 
regulators of IRS proteins include the Socs proteins and NO, which are induced in 
inflammation, and promote IRS degradation. NO also reduces PI3K/AKT activity by s-
nitrosylation of AKT. 
Adapted from de Luca and Olefsky. FEBS Lett. 2008 Jan 9;582(1):97-105. 
 
 






Adipose tissue inflammation probably results from a complex crosstalk 
between adipocytes, macrophages and other immune cells, with contributions 
from both the innate and adaptive arms of immune system (Sell et al. 2012).  
An important finding that helped elucidate the cause of adipose tissue 
inflammation from obese mice and humans is the infiltration with a large 
numbers of macrophages. These adipose tissue macrophages (ATMs) can 
comprise up to 40% of the cells in obese adipose tissue (Osborn and Olefsky 
2012). 
In the adipose tissue, macrophages have been shown to aggregate, forming 
crown-like structures (CLSs) surrounding necrotic adipocytes in advanced 
obesity. In this state they fuse to phagocyte the residual lipid droplet, forming 
large lipid-laden multinucleated syncytia in the process, a commonly accepted 
hallmark of chronic inflammation (Sun et al. 2011).  
 
Figure 5: Immune cells mediate inflammation in adipose tissue. In the lean state, adipose 
tissue TH2 T cells, TREG cells, eosinophils and M2-like resident macrophages predominate. 
TREG cells secrete IL-10 and also stimulate IL-10 secretion from resident M2-like 
macrophages. Eosinophils secrete IL-4 and IL-13 and further contribute to the anti-
inflammatory, insulin-sensitive phenotype. In obesity-induced inflammation, immune cells are 
recruited and contribute to adipose tissue inflammation. Monocytes respond to chemotactic 
signals and transmigrate into the adipose tissues and become polarized to the highly pro-
inflammatory M1-like state. Once recruited, these M1-like macrophages secrete pro-
inflammatory cytokines that work in a paracrine fashion. The eosinophil content declines in 
obese adipose tissue. Obesity also induces a shift in adipose tissue T cell populations with a 






decrease in TREG content and an increase in CD4+ TH1 and CD8+ effector T cells, which 
secrete pro-inflammatory cytokines. B cell numbers also increase and activate T cells, which 
potentiate M1-like macrophage polarization, inflammation and insulin resistance. Cytokines 
and chemokines from the adipose tissue can also be released into the circulation and work in 
an endocrine manner to promote inflammation in other tissues. 
Adapted from Osborn and Olefsky. Nat Med. 2012 Mar 6;18(3):363-74. 
 
Obesity is accompanied by a transformation in the polarized states of 
macrophages; from an anti-inflammatory “alternatively activated” M2 form 
that primarily accumulates during negative balance, to a more pro-
inflammatory classically activated M1 form (Sun et al. 2011). The M1 
population, CD11c+ macrophages, demonstrates a positive correlation with 
insulin resistance and dominates in states of overnutrition by targeting FFA-
mediated increases in pro-inflammatory responses (Lumeng et al. 2007; 
Shoelson et al. 2006). This phenotypic switch of macrophages could be a key 
step of adipose tissue inflammation and might provide a link to the 
involvement of cells of adaptive immune system (Figure 5) (Sell et al. 2012). 
In lean mice about 10% of the stroma-vascular fraction (SVF) from the 
visceral fat depot is composed of CD3+ T lymphocytes, with a 1:3 ratio of 
CD8+ to CD4+. Adipocytes themselves could have immune-cell-like functions 
that lead to CD4+ T-cell activation, potentially triggering inflammation 
independently of macrophage infiltration. The CD4+ T-cell compartment could 
be subdivided into pro-inflammatory T-helper type 1 (TH1) and TH17 cells, 
and anti-inflammatory TH2 and T-regulatory cells (TREG) that express forkhead 
box protein P3 (mFoxp3) (Feuerer et al. 2009).  
In mouse models of diet-induced obesity, T-cell populations differ in adipose 
tissue. A higher CD8+ and CD4+ T-cell ratio is found in visceral adipose tissue 
of high-fat diet fed mice compared with lean mice. Diet-induced obesity also 
leads to a dramatic increase in TH1-polarized cells, whereas the TH2-polarized 
fraction in significantly reduced by ≈ 50%. After feeding with a high-fat diet, 
moreover, the TH17 subset in visceral adipose tissue represents <1% of the 
CD4+ population and TREG cells are reduced by 70%. Unlike visceral adipose 
tissue, the proportions of CD4+ and CD8+ T-cell subsets in subcutaneous 
adipose tissue were reduced, whereas TREG numbers did not change during 
obesity (Feuerer et al. 2009; Caspar-Bauguil et al. 2005). 
Other immunity cells are implicated in inflammatory response to adipocyte 
hypertrophy such as CD8+, natural killer (NK), NKT and B cells. CD8+ are 






involved in macrophage differentiation, activation and migration, thereby 
initiating inflammatory cascades in adipose tissue that lead to insulin 
resistance. NK cells are present in large numbers in visceral adipose tissue 
where they might be involved in regulation of adipose tissue homeostasis and 
their number is decreased in a leptin-dependent manner. NKT cells are 
described as innate-like T lymphocytes, because they possess invariant pattern 
recognition receptors instead of antigen-specific T-cell receptors, and release a 
mixture of TH1 and TH2 cytokines such as IFN-γ and IL-4, thereby formation 
of subsequent adaptive immune responsive (Van Kaer 2007). Lymphocytes B 
are also involved in obesity-released inflammation. In fact, reconstitution with 
wild type B cells from high-fat-diet fed mice lead to impaired glucose 
metabolism and decreased insulin sensitivity as a result of the antigen-
dependent activation of T cells (TH1 and CD8+ T cells), pro-inflammatory M1 
macrophages and secretion of pathogenic IgG antibodies from B cells. 
Treatment with a B cell-depleting antibody attenuates these effects, whereas 
transfer of IgG from mice with diet-induced obesity quickly induces insulin 
resistance and glucose tolerance (Winer et al. 2011).     
Based on these studies in mouse models, lymphocytes infiltration in adipose 
tissue might occur in a chronological sequence that begins with B and T 
lymphocytes (TH1 and CD8+ cells) being rectruited during early obesity-
induced inflammation by preadipocytes or adipocytes-derived chemokines like 
CCL5, MCP-1 (CCL2), CXCL12 (also known as SDF-1α) and CXCL5 (Wu et 
al. 2007). These cells direct the local inflammatory process through the release 
of pro-inflammatory TH1 cytokines such as IFN-γ, which promote M1 
macrophage recruitment by inducing pre-adipocytes and adipocytes to release 
chemokines and activated macrophages (Sell et al. 2012). 
It has been suggested that a paracrine loop between adipocytes and 
macrophages establishes a vicious circle that aggravates the inflammatory 
changes in adipose tissue. Interactions between both cell types are critical. 
This paracrine loop involves FFAs and TNF-α (Figure 6). Enlarged adipocytes 
release in excess saturated FAs that activate macrophages via TLR4 signaling. 
As a result, macrophages secrete the pro-inflammatory adipokine TNF-α, 
which in turn acts on TNF-α receptor 1 (TNFR1) and induces inflammatory 
changes in hypertrophied adipocytes through activation of the  
NF-kB pathway and as well as enhanced FFA release (Suganami et al. 2007).   






There is considerable evidence for the pathophysiological role of macrophage 
and hypertrophic adipocyte-derived chemotactic MCP-1/CCR2 pathways in 
the regulation of monocyte accumulation in obese adipose tissue. In particular, 
increased expression levels of MCP-1, CXCL14, MIP-1α, MCP-2, MCP-3, 
and CCL5 can be observed in obese and diabetes mice adipose tissue (Sun et 




















Figure 6: Cross-talk between adipocytes and macrophages of adipose tissue in obesity. 
TNF-α, which is mainly overproduced by macrophages appears to be a crucial contributor to 
adipokine dysregulation in adipocytes. Adipocytes of obese subjects overproduce adipokines 
in response to TNF-α. This hyper-responsiveness is mediated by TNF-α-receptor-1 (TNFR1) 
and by hyper-activation of NF-kB pathway. TNF-α also induces lipolysis (FFA release). 
Saturated FFAs in turn activate the TLR4/NF-kB pathway in both macrophages and 
adipocytes, thereby further increasing the production of TNF-α and other pro-inflammatory 
adipokines. Some of these adipokines exert chemoattractant activity through binding to 
specific receptors (CXCR and CCR) of macrophages leading to their infiltration in obese AT. 
Adapted from Maury and Brichard. Mol Cell Endocrinol. 2010 Jan 15;314(1):1-16.   
 






1.4 Regulated on Activation, Normal T cell Expressed and 
Secreted/CCL5  (RANTES/CCL5) 
 
The chemokines are involved in many aspects of the immune response 
including lymphocyte chemo-attraction, adhesion, and activation. The family 
contains more than 40 members, which have been divided into subfamilies 
based on a conserved pattern of cysteines. Members of the CC subfamily have 
overlapping in vitro biological activities including chemo-attraction for 
monocytes and T cells (Makino et al. 2002). They also play a pivotal role in 
diseases such as autoimmune and allergic inflammatory disorders, cancer and 
organ transplant where excessive cellular recruitment plays a deleterious role. 
Their function is not limited to recruitment, since they also play a role in 
cellular activation, differentiation, degranulation and in processes such as 
organ development, angiogenesis, lymphogenesis and wound repair 
(Proudfoot 2006). CCL5 is a typical chemokine of 68 amino acids that is able 
to recruit leucocytes to sites of inflammation. It induces leucocyte migration 
by binding to specific receptors in the seven-transmembrane G-protein-
coupled receptor (GCPR) family, namely CCR1, CCR3, CCR4 and CCR5. In 
common whit other chemokines, there is a clear structural basis for the 
dimerization of CCL5, although dimer formation is not essential for its 
chemokine receptor interactions, and CCL5 can signal through its specific 
receptors as a monomer. However, a peculiar characteristic of CCL5 is its 
ability to self-aggregate, forming multimers at high concentrations. The amino 
acids involved in this self-aggregation, Glu66 and Glu26, are negatively 
charged residues. CCL5 also contains several positively charged residues on 
its surface, which makes it likely that ionic bindings are involved in the 






























Figure 7: Structure of a dimer of human CCL5. Positively charged residues are colored in 
blue and negatively charged residues are in red. The dimerization of CCL5 has a structural 
basis (white-colored residues belong to chain A, and yellow-colored residues belong to chain 
B) but, in addition, CCL5 self-aggregates to form multimers. The dimerization occurs at the 
N-terminal part of the molecule, which is also essential for receptor binding and signaling. 
The residues involved in the multimerization, Glu66 and Glu26, are found at the surface of the 
protein, suggesting that ionic binding with positively charged surface residues from other 
CCL5 molecules occurs and leads to self-aggregation. Changing these residues to serine 
abrogates aggregation. 
Adapted from Appay and Rowland-Jones. Trends Immunol. 2001 Feb;22(2):83-7. 
 
CCL5 mediates the trafficking and homing of classical lymphoid cells such as 
T cells and monocytes, but also acts on a range of other cells, including 
basophils, eosinophils, naural killer (NK) cells, dendritic cells and mast cells 
(Appay and Rowland-Jones 2001). It also promotes T cell adherence to 
activated endothelial cells (Taub et al. 1993) and stimulates T cell proliferation 
(Taub et al. 1996). 
To better define CCL5 in vivo activity Makino et al. have used gene targeting 
to produce CCL5-deficient (-/-) mice. Analysis of these mice reveals that 
CCL5 plays a role in the delayed-type hypersensitivity (DTH) response, T cell 
proliferation, and the production of IL-2 and IFN-γ. One of the functional 
consequences of the absence of CCL5 is an impaired DTH reaction. Because 
CCL5 plays a role in several aspects of the immune response, the decreased 
DTH response is likely the consequence of the sum of this effects including 






decreased T cell priming and proliferation as well as possible changes in the 
TH1 response as indicated by the decreases in IFN-γ production (Makino et al. 
2002). 
When CCL5 was identified, it attracted particular attention because it was 
demonstrated to be a potent inhibitor of HIV replication in vitro. In 1995 
CCL5 was shown to be the most potent member of a trio of CC chemokines 
released by CD8+ T cells that were able to suppress the replication of non-
syncitium-inducing (NSI) HIV-1 strains in vitro. The others chemokines were 
macrophage inflammatory protein 1 alpha (MIP-1α) and MIP-1β. The three 
chemokines bind to the CCR5 receptor on the surface of CD4+ T cells, and this 
receptor is also the means by HIV gains entry to the cell. The HIV-suppressive 
effect of CCL5 appears to be critically dependent on the presence of 
glycosamminoglycans (GAG) on the target cell surface (Appay and Rowland-
Jones 2001). 
Protein and RNA levels of CCL5 are increased in a gender-dependent fashion 
in white adipose tissue of obesity (Wu et al. 2007). CCL5 is expressed by 
adipocytes and has been hypothesized to mediate leukocyte infiltration of 
adipose tissue in obesity (Poulain-Godefroy and Froguel 2007; Wu et al. 
2007). Circulating CCL5 concentrations are elevated in obesity, impaired 
glucose tolerance (IGT) and type 2 diabetes (Nomura et al. 2000; Herder et al. 
2005). Moreover, in the Finish Diabetes Prevention Study, high CCL5 levels 
were associated with resistance to lifestyle intervention and higher incidence 
of type 2 diabetes in the intervention group (Herder et al. 2006). Wu et al. 
found higher CCL5 mRNA levels in visceral compared with subcutaneous 
adipose tissue in obese humans. In their studies, Madani et al. showed CCL5 
production by human subcutaneous adipose tissue in vivo and release of this 
chemokine in novel depots, the gastric fat pad and epicardial fat. They 
demonstrated that while epicardial CCL5 was related to obesity, neither 
systemic CCL5 nor its release from the subcutaneous and the abdominal 
visceral adipose tissue is a good marker of adiposity. There is significant 
heterogeneity in the release of CCL5 from the various depots, a finding that 
suggests differential regulation by autocrine/paracrine factors (Madani et al. 
2009)






2. AIM OF THE STUDY 
Obesity is associated with insulin resistance, hyperglycaemia, 
dyslipidemia, hypertension and other components of the metabolic syndrome 
(Sell and Eckel 2009). Enlargement of adipose tissue is the consequence of a 
sedentary lifestyle and increased energy intake, and is associated with a 
prominent inflammatory response in the visceral compartment that leads to 
adipose tissue dysfunction (Sell et al. 2012). Adipocytes, in addition to their 
storage function, are also active endocrine cells that produce and release 
various adipokines such as adiponectin, visfatin, resistin, adipsin, cytokines 
(TNF-α, IL-6, IL-1, IL-10, IL-18) and chemokines including MCP-1, IL-8 and 
CCL5 (D’Esposito et al. 2012). Chemokines may be directly linked to a 
chronic state of low-grade inflammation and macrophage infiltration in 
adipose tissue (Sell and Eckel 2009). Macrophage infiltration has a key role 
into expanding of adipose tissue, causing inflammation and linking obesity to 
insulin resistance (Weisberg et al. 2003; Xu et al. 2003). It has been described 
that several mechanisms may contribute to the initial adipose macrophage 
infiltration and impair adipocyte insulin signaling such as stressed adipocytes 
secreting multiple chemokines and cytokines, fatty acid flux, hypoxia and 
adipocyte cell death (Jiao et al. 2011). Obesity is characterized by chronically 
elevated concentrations of plasma FFAs caused in part by the blunted capacity 
of insulin to inhibit lipolysis and the excessive consumption of dietary lipids 
(Cnop 2008). Excessive overnutrition and macrophage infiltration in adipose 
tissue lead to an inflammatory pathway activation and cytokine/chemokine 
production in adipocytes. Recent interest has focused on CCL5 chemokine, 
and in particular, its role in regulating the recruitment of inflammatory cells 
into adipose tissue. CCL5 levels have been found elevated in serum of obese, 
impaired glucose tolerance (IGT) and type 2 diabetes patients (Nomura et al. 
2000; Herder et al. 2005; Wu et al. 2007). The aim of this study is to identify 
the molecular mechanisms involved in the metabolic control of CCL5 
expression in adipocytes. In particular, I have evaluated whether metabolic 
perturbations such as different concentrations of glucose and free fatty acids 
may affect CCL5 adipocyte production. Moreover, I have investigated the role 
of different pathways normally activated by FFAs in adipocytes in the 
regulation of CCL5 production. Finally, I have observed the effect of insulin 
















Media, sera, antibiotics for cell culture were from Lonza (Basel, 
Switzerland). Antibodies against specific phospho-Serine473-AKT/PKB, 
phospho-Threonine183/Tyrosine185-JNK, AKT/PKB, JNK, ERK, IkBα, NF-
kB, 14.3.3 and NF-kB activation inhibitor II (JSH23) were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Phospho-
Threonine202/Tyrosine204-ERK and phospho-Serine32-IkBα were obtained 
from Cell Signaling Technology (Denvers, MA, USA). JNK inhibitor 
(SP600125), MEK inhibitor (PD98059), PI3K inhibitor (LY294002), sodium 
oleate and sodium palmitate were purchased from Sigma-Aldrich (Steinhem, 
DE). Protein electrophoresis and real time RT-PCR reagents were purchased 
from Bio-Rad (Hercules, CA, USA), Western blotting and ECL reagents from 
Amersham Biosciences (Arlington Heights, IL, USA). 
  
3.2 Cell culture 
 
The 3T3-L1 murine fibroblast cells were available in host laboratory. 
They were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% calf serum (CS), 100 IU/ml penicillin, 100 IU/ml 
streptomycin, and 2% L-glutamine in a 5% humidified CO2 incubator. 3T3-L1 
cells were differentiated as previously described (Engelman et al. 1998). In 
brief, after 2 days from confluence (Day 0), the DMEM 10% FBS was 
changed and new DMEM 10% FBS was added to the cells with the addition of 
160 nm insulin, 250 nm dexamethasone, and 0.5mm 3-isobutyl-1-
methylxanthine. After 2 days (Day 2), this medium was replaced with fresh 
DMEM 10% FBS containing only 160 nm insulin. After another 2 days, the 
cells were then propagated in 10% FBS medium. Adipogenesis was scored by 
analysis of the expression of adipocyte-specific genes (aP2 and peroxisome 
proliferator-activated receptor γ (PPARγ)) (Chavey et al. 2003) and by lipid 
accumulation using microscopic analysis or oil red O staining (Ramirez-
Zacarias et al. 1992).  
 
 






3.3 Conditioned media system 
	  
The conditioned media was isolated in the following way: confluent 
3T3-L1 adipocyte plates were identified, the 10% FBS removed, the plates 
washed two times with sterile phosphate-buffered saline (PBS), and 3–5 ml of 
serum-free DMEM 0,25%BSA (DMEM-BSA) added to the plates and 
incubated for approximately 8h. After the incubation, the DMEM-BSA was 
collected and centrifuged at 14000xg to remove cellular debris. 
  
3.4 Bioplex cytokine and growth factor assay 
	  
Supernatants were collected after 8 h of plating the different cells. 
Concentrations of IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL- 
12 (p40), IL-12(p70), IL-13, IL-17, Eotaxin, G-CSF, GM-CSF, IFN-γ, KC/IL-
8, MCP-1, MIP-1α, MIP-1β,  CCL5, TNF-α, PDGF, VEGF and IGF1 were 
determined using the Bioplex multiplex Mouse Cytokine and Growth factor 
assay kits (Bio-Rad, Hercules, CA) according to the manufacturer’s protocol. 
Briefly, 50 µl of the culture supernatant or cytokine standard was plated in a 
96 well filter plate coated with a multiplex of beads coupled to antibodies 
against the above mentioned cytokines and incubated for 30 min on a platform 
shaker at 300 rpm at RT. After a series of washes to remove the unbound 
proteins, a mixture of biotinylated detection antibodies, each specific for a 
different epitope was added to the reaction resulting in the formation of 
antibodies assimilated around the target proteins. Streptavidin-phycoerythrin 
(streptavidin-PE) was then added to bind to the biotinylated detection 
antibodies on the bead surface. The data from the reaction were then collected 
and analyzed by using the Bio-Plex suspension array system (or Luminex 100 




CCL5 protein secreted into the cell culture supernatants was quantified 










3.6 Real-time RT-PCR analysis 
 
Total RNA was isolated from 3T3-L1 adipocytes by using the Rneasy 
Kit (Qiagen Sciences) according to the manufacturer’s instruction. For real-
time RT-PCR analysis, 1 µg cell RNA was reverse transcribed using 
SuperScript II Reverse Transcriptase (Invitrogen). PCR were analyzed using 
SYBR Green mix (Invitrogen). Reactions were performed using Platinum 
SYBR Green Quantitative PCR Super-UDG using an iCycler IQ multicolour 
Real-Time PCR Detection System (Biorad Hercules, CA). All reactions were 
performed in triplicate and ACTIN was used as an internal standards. Primer 
sequences used were as follows: CCL5 forward primer 5’- AGG AAC CGC 
CAA GTG TGT GCC -3’, reverse primer 5’- AGT GGC ATC CCC AAG 
CTG GC -3’; ACTIN forward primer 5’- CGC CCT AGG CAC CAG GGT 
GTG -3’, reverse primer 5’- TCG GTG AGC AGC ACA GGG TG-3’.  
 
3.7 Western Blot analysis  
 
3T3-L1 adipocytes were lysed in lysis buffer (50mM HEPES pH 7.6, 
150mM NaCl, 10mM EDTA, 10mM Na4P2O7, 2mM Na3VO4, 100mM NaF, 
10% glycerol, 1mM PMSF, 100 IU/ml aprotinin, 20µM leupetin, 1% Triton 
X-100), for 2 h at 4 °C and lysates were centrifuged at 14,000 x g for 15 
minutes to remove cellular debris. Cell lysates were separated by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed 
by western blot as previously described (Laemmli 1970). Nitrocellulose 
membranes were probed with antibodies for specific proteins. 
 
3.8 Chromatin Immunoprecipitation (ChIP) assay 
 
The cross-linking solution, containing 1% formaldehyde, was added 
directly to cell culture media. The fixation proceeded for 10 min and was 
stopped by the addition of glycine to a final concentration of 125 mM. 3T3-L1 
adipocytes were rinsed twice with cold phosphate buffered saline plus 1 mM 
phenylmethylsulfonyl fluoride and then scraped. Cells were collected by 
centrifugation at 800 X g for 5 min at 4 °C. Cells were swelled in cold cell 
lysis buffer containing 5 mM PIPES (pH 8.0), 85 mM KCl, 0.5% Nonidet P-
40, 1 mM phenylmethylsulfonyl fluoride, and inhibitors mixture (Sigma) and 
incubated on ice for 10 min. Samples were broken by sonication into 






chromatin fragments of an average length of 500/ 1000 bp and then 
microcentrifuged at 16,000 X g for 10 min at 4 °C. The sonicated cell 
supernatant was diluted 8-fold in chromatin immunoprecipitation (ChIP) 
dilution buffer containing 0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 
16.7 mM Tris- HCl (pH 8.0), and 167 mM NaCl and precleared by adding 
salmon sperm and conjugating protein at equimolar concentration for 90 min 
at 4 °C. Precleared chromatin from 1X106 cells was incubated with 1 g of 
polyclonal antibody (anti-NF-kB) or no antibody and rotated at 4 °C for 16 h. 
Mouse IgG antibody (Upstate Biotecnology/Millipore) was used as a non-
specific antibody control. Immunoprecipitates were washed five times with 
radioimmune precipitation assay buffer containing 10 mM Tris-HCl (pH 8.0), 
1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 
mM NaCl, and 1 mM phenylmethylsulfonyl fluoride, twice with LiCl buffer 
containing 0.25 M LiCl, 1% Nonidet P-40, 1% sodium deoxycholate, 1 mM 
EDTA, 10 mM Tris-HCl (pH 8.0), and then 3 times with TE (10 mM Tris-HCl 
(pH 8.0), 1 mM EDTA). Before the first wash, the supernatant from there 
action lacking primary antibody was saved as total input of chromatin and was 
processed with the eluted immunoprecipitates beginning at the cross-link 
reversal step. Immunoprecipitates were eluted by adding 1% SDS, 0.1 M 
NaHCO3, and reverse cross-linked by the addition of NaCl to a final 
concentration of 200 mM and by heating at 65 °C for at least 4 h. Recovered 
material was treated with proteinase K, extracted with phenol-chloroform-
isoamyl alcohol (25:24:1), and precipitated. The pellets were resuspended in 
30µl of TE and analyzed by PCR using specific primers for the analyzed 
regions. The input sample was resuspended in 30µl of TE and diluted 1:10 
before PCR.  
Eluited DNA amplified by real time RT-PCR with specific oligos: forward 
primer: 5’- TTT GGC CAG AGA GGG AGT CAT CCT -3’, reverse primer: 
5’- AGT CCT CTG CAA GGG GTG CTC T -3’. 
 
3.9 Statistical procedures 
 
Data were analyzed with the Stat view software (Abacus-concepts) by 
one-factor analysis of variance. P values of less than 0.05 were considered 
statistically significant. 








4.1 Analysis of cytokine and growth factor release by 3T3-L1 adipocytes 
and their precursors 
 
For decades, adipose tissue was considered an inert mass of stored 
energy with some advantageous properties, such as its function as an 
insulating substance and as a mechanical support for more important structure 
(Rosen and MacDougald 2006). Adipose tissue is now accepted to be an 
endocrine organ that secretes numerous hormones, growth factors, matrix 



















Table 1: Screening of cytokines and growth factors in 3T3-L1 pre-adipocyte and 
adipocyte CM. Supernatants from 3T3-L1 pre-adipocytes (3T3-L1 CM) and adipocytes (3T3-
L1 adipocyte CM) were collected after 8h of incubation with serum-free medium and tested 
for 23 cytokines and 4 growth factors by Bioplex multiplex assay. The table represents the 
concentration (pg/ml) of some of these cytokines and growth factors. Asterisks denote 
statistically significant values (*p < 0.05). 
 
In order to identify the factors released from adipocytes, I used 
ELISA/multiplex analysis. In particular, I analyzed the conditioned media for 
Cytokines and  








IL-2 ND ND 
IL-4 0.7±0.0008 0.10±0.02 
IL-6 23.6±1.13 22.37±3.47 
IL-10 3.70±0.86 15±2.6* 
GM-CSF ND ND 
IFN-γ 3.73±0.38 5.59±0.80 
KC/IL-8 989.14±100.62 10,343.72±1,551.53* 
MIP-1α 226.31±18.27 280±22.32 
MIP-1β 10.33±1.53 11.4±2 
RANTES/CCL5 1,960±235.2 4,770±524.7* 
TNF-α 143.54±18.66 162.88±25.92 
PDGF ND ND 
bFGF 200±18 666.70±2.67* 
VEGF 11,479.20±1,262.71 4,682.46±607.71* 
IGF-1 79.37±0.88 334.37±40.41* 






the content of growth factors and cytokines produced by both 3T3-L1 pre-
adipocytes and adipocytes. 
The cells were incubated with serum-free medium. After 8 h conditioned 
media (CM) were collected and tested for 23 cytokines and 4 growth factors 
by using the Bioplex multiplex cytokine assay kit and the Bioplex multiplex 
growth factor assay kit.  
Table 1 shows that both 3T3-L1 fibroblasts and 3T3-L1 adipocytes released 
detectable amounts of IL-4, IL-6, IL-10, IFN-γ, KC/IL-8, MIP-1α, MIP-1β, 
CCL5 and TNF-α. However the levels of KC/IL-8 and CCL5 were 
significantly higher in 3T3-L1 adipocytes compared with their precursors. 
Moreover, levels of IL-10, an anti-inflammatory cytokine, were also 
significantly higher in 3T3-L1 adipocytes compared with fibroblasts. 
I also screened for growth factor release and found that VEGF, bFGF and 
IGF-1 were detectable in both pre-adipocytes and adipocytes. However, bFGF 
and IGF-1 concentrations were significantly higher in CM of differentiated 
cells compared to fibroblasts, while the amount of VEGF was significantly 
reduced in adipocyte CM. 
 
4.2 Glucose and FFA effect on CCL5 secretion and mRNA levels  
 
Many adipokines synthesized by adipocytes are candidates to attract 
inflammatory cells in adipose tissue. It has been shown that chemotactic 
proteins, particularly those of the chemokine family, were related in vivo to the 
metabolic syndrome, obesity and type 2 diabetes. Among chemokines, CCL5 
is elevated in the serum of obese patients as compared with lean controls (Sell 
and Eckel 2009). 
Therefore, I examined whether perturbations of the metabolic environment 
may affect the CCL5 production by adipocytes.  
I evaluated the effect of free fatty acids and glucose on CCL5 secretion and 
mRNA levels in adipocytes. 3T3-L1 adipocytes were cultured for 24 h either 
in 5.5 mM glucose (LG, low glucose), a concentration corresponding to 
normal fasting glucose levels in humans, or in 25mM glucose (HG, high 
glucose), corresponding to the regular culture condition for this cell line, but 
resembling hyperglycaemia in humans. Moreover I added to culture media 
(LG) either 10 µM oleate or 100 µM palmitate, two major fatty acids whose 
plasma levels are increased in dysmetabolic conditions. Media were changed 






and cells were allowed to secrete factors into freshly added serum-free 
medium. After 8 h, media were collected and tested for the content of CCL5 
chemokine. Moreover, I also evaluated CCL5 mRNA in adipocytes after 24 h 


























Figure 8: FFA- and glucose-induced CCL5 secretion and mRNA levels in adipocytes. 
3T3-L1 adipocytes were incubated with either high glucose medium (25 mM-HG) or low 
glucose medium (5.5 mM-LG) in presence or absence of 10µM oleate (OLE (LG)) and 100µM 
palmitate (PAL (LG)). After 24 h media were collected and analyzed for the content of CCL5 
chemokine by ELISA assay (A). CCL5 mRNA levels were determined by real-time RT-PCR; 
bars represent the mRNA levels in these cells and are relative to those in cells incubated with 
HG medium (B). Asterisks denote statistically significant values (*p < 0.05). 
 
As shown 3T3-L1 adipocytes cultured in HG medium released significantly 
higher levels of CCL5 compared with those cultured in LG medium. Oleate 
and palmitate significantly increased CCL5 secretion (Figure 8A). No 
significant change was detected for CCL5 mRNA levels when cells were 
incubated in media containing different glucose concentrations while CCL5 
B 
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mRNA levels were significantly increased by oleate and palmitate (Figure 
8B). 
 
4.3 Molecular pathway activation in adipocytes: FFA effect 
 
Systemic levels of fatty acids (FAs) are increased in obesity and, through 
TLR4-dependent effects, FAs can induce the activation of proteins belonging 
to inflammatory cascades in adipocytes (Shi et al. 2006).  
In order to identify molecular pathways potentially involved in CCL5 
regulation, I initially investigated the effect of oleate and palmitate on 
PI3K/AKT, JNK, MAPK and NF-kB pathways in adipocytes. 
I evaluated the phosphorylation of AKT and ERK, proteins that are 

















Figure 9: Effect of oleate and palmitate on PI3K, MAPK, JNK and NF-kB signaling. 
3T3-L1 adipocytes were starved for 16 h and stimulate with either 10µM oleate or 100µM 
palmitate. After 24 h the cells were solubilized as described in Materials and Methods. Cell 
lysates were blotted whit specific anti-phospho-Serine473-AKT/PKB antibody (pAKT), anti-
phospho-Threonine183/Tyrosine185-JNK antibody (pJNK), anti-phospho-
Threonine202/Tyrosine204-ERK antibody (pERK) and anti-phospho-Serine32-IkBα antibody 
(pIkBα) and then reblotted whit anti-AKT/PKB (AKT), anti-JNK (JNK), anti-ERK (ERK) and 
anti-IkBα (IkBα). To ensure the equal protein transfer, membranes were blotted whit an anti-
14.3.3 antibody (14.3.3). 
 






In addition, I evaluated the activation of inflammatory pathways such as JNK 
and NF-kB signaling pathways investigating the phosphorylation of JNK and 
of nuclear factor kB inhibitor alpha (IkBα), a protein that inhibits NF-κB by 
masking the nuclear localization signals (NLS) of NF-κB proteins and keeping 
them sequestered in an inactive state in the cytoplasm. 
3T3-L1 adipocytes were treated with either 10µM oleate or 100µM palmitate 
for 24 h. As shown in Figure 9, both oleate and palmitate induced the 
phosphorylation of AKT on Ser473, JNK on Thr183/Tyr185, ERK on 
Thr202/Tyr204 and IkBα on Ser32. The treatment with palmitate, almost 
invariably, induced higher phosphorylation of all the proteins compared to 
oleate, but no statistically significant difference between oleate- and palmitate-
induced protein phosphorylation was detected. 
 
4.4 Role of JNK and NF-kB pathways on CCL5 mRNA levels induced by 
FFAs 
 
Specific inhibitors were used to characterize the potential role of oleate- 
and palmitate-activated JNK and NF-kB on CCL5 regulation. 
3T3-L1 adipocytes were pre-incubated with low glucose medium for 18 h. In 
order to block JNK and NF-kB pathways and then treated with either 20µM 
SP600125 or 5.5µM JSH23, JNK and NF-kB inhibitors respectively, for 1 h. 
Next, adipocytes were stimulated with either 10µM oleate or 100µM palmitate 













Figure 10: Effect of FFAs on CCL5 mRNA levels in adipocytes treated with JNK and 
NF-kB inhibitors. 3T3-L1 adipocytes were incubated with LG medium in presence or 
absence of 20µM SP600125 and 5.5µM JSH23, JNK and NF-kB inhibitors respectively, for 1 






h. Then adipocytes were incubated with either 10µM oleate or 100µM palmitate. After 24 h 
CCL5 mRNA levels were determined by real-time RT-PCR. Bars represent the mRNA levels 
in these cells and are relative to those in cells incubated with LG medium. * denote 
statistically significant values vs LG medium (p < 0,05). # denote statistically significant 
values vs OLE (p<0.05). § denote statistically significant values vs PAL (p<0.05).  
 
As also previously shown, free fatty acids induced a significant increase of 
CCL5 mRNA levels. JNK and NF-kB inhibitions reduced CCL5 mRNA 
levels, impairing the effect of both oleate and palmitate. In particular, 
SP600125 inhibitor reduced oleate- and palmitate-induced CCL5 mRNA 
levels by 46.3% and 35.6% respectively, while JSH23 reduced oleate- and 
palmitate-induced CCL5 mRNA levels by 26.2% and 40.6% respectively 
(Figure 10). 
Thus, JNK and NF-kB inhibitors reduced free fatty acid effect on CCL5 
mRNA levels in adipocytes.  
 
4.5 FFA effect on NF-kB binding to CCL5 promoter in adipocytes 
 
NF-kB is a transcription factor normally involved in regulation of pro-
inflammatory molecules. I hypothesized that oleate and palmitate activated 
NF-kB affecting CCL5 gene transcriptional control and that the NF-kB 
activation could be mediated by JNK. Indeed, I examined whether oleate and 
palmitate may affect NF-kB binding to CCL5 in presence or absence of the 
JNK inhibitor SP600125.  
Bioinformatic analysis revealed the presence of one binding site for NF-kB in 
the 2000 pair region upstream the CCL5 transcription initiation site (Figure 
11A; positions nucleotide -175 to -41). To evaluate NF-kB binding to CCL5 
promoter, I performed chromatin immunoprecipitation (ChIP) experiments in 
3T3-L1 adipocytes. The cells, previously incubated in LG medium, were 
treated with 20µM SP600125 for 1 h and then stimulated with either 10µM 





























Figure 11: Effect of SP600125 on FFA-induced NFkB binding to CCL5 promoter. 
Schematic representation of 5’ sequence upstream the putative CCL5 transcription start site 
that includes the binding site for NF-kB (A). 3T3-L1 adipocytes were treated for 1 h with 
20µM SP600125 and then incubated in presence or absence of 10µM oleate, 100µM palmitate. 
After 24 h the cells were processed to perform ChIP assay as described in Material and 
Methods. Soluble chromatin was immunoprecipitated with p65 NF-kB antibodies. Total and 
immunoprecipitated DNAs were amplified using primer pairs encompassing the CCL5 
promoter by real-time RT-PCR. Bars represent the p65 binding levels and are relative to those 
in cells maintained in LG medium. Asterisks denote statistically significant values (*p < 0.05) 
(B).  
  
I obtained evidence that oleate and palmitate significantly increased the NF-
kB binding to CCL5 promoter by 3- and 3.7-fold, respectively (Fig. 11B). 
When the cells were treated with JNK inhibitor, there was a significant 
reduction of oleate- and palmitate-induced NF-kB binding by 61.3% and 
51.2%, respectively (Figure 11B). 
 
4.6 CCL5 mRNA levels induced by FFAs: role of ERK and AKT  
 
I previously showed that, in 3T3-L1 adipocytes, oleate and palmitate 
activated the MAPK and PI3K/AKT signaling pathways increasing the 
phosphorylation of ERK and AKT, downstream proteins of these pathways, 
B 






respectively (Figure 8). To study the role of ERK and AKT in the control of 
CCL5 expression, I evaluated the CCL5 mRNA levels in adipocytes treated 
with specific inhibitors of MAPK and PI3K/AKT pathways. Cells were 
incubated with LG medium in presence or absence of either 25µM PD98059 
(MEK inhibitor) or 25µM LY294002 (PI3K inhibitor) and then stimulated 
with either 10µM oleate or 100µM palmitate. 
The inhibition of MAPK pathway in cells treated with oleate and palmitate 
induced a further significant increase of CCL5 mRNA levels by 2.6- and 1.3-
fold, respectively and consistently similarly, LY294002 treatment induced a 
significant increase of CCL5 mRNA levels compared to oleate and palmitate, 
by 2.2- and 1.2-fold, respectively (Figure 12).  
















Figure 12: CCL5 mRNA levels in adipocytes treated with FFAs in presence of MAPK 
and PI3K inhibitors. 25µM PD98059 and 25µM LY294002 in 3T3-L1 adipocytes 
maintained in LG medium were used for 1 h to block MEK and PI3K, respectively. Then 
adipocytes were incubated with either 10µM oleate or 100µM palmitate. After 24 h CCL5 
mRNA levels were determined by real-time RT-PCR. Bars represent the mRNA levels in 
these cells and are relative to those in cells incubated with LG medium. * denote statistically 
significant values vs LG medium (p < 0.05). # denote statistically significant values vs OLE 
(p<0.05). § denote statistically significant values vs PAL (p<0.05). 
 
Interestingly, the treatment of 3T3-L1 adipocytes with PD98059 and 
LY294002 induced a significant increase of CCL5 mRNA levels, even in the 






absence of fatty acids suggesting a constitutive involvement of MAPK and 
PI3K in CCL5 regulation.  
 
4.7 Insulin effect on CCL5 mRNA levels induced by fatty acids 
 
Insulin is a pleiotropic hormone that has diverse functions including 
stimulation of nutrient transport into cells, regulation of gene expression, 
modification of enzymatic activity. Insulin signaling involves a complex 
signaling cascade downstream of the insulin receptor branched in two main 
pathways: MAPK and PI3K/AKT pathways (de Luca and Olefsky 2009). 
Indeed, I evaluated whether insulin, activating MAPK and PI3K/AKT 
pathways could reduce CCL5 production in adipocytes treated with free fatty 
acids.  
First of all, I evaluated the effect of insulin on CCL5 mRNA levels in 3T3-L1 
adipocytes in presence or absence of oleate or palmitate. In details, the cells 
were pre-incubated in LG medium and then treated with 10µM oleate, 100µM 
palmitate and 100nM insulin. 
I observed that insulin significantly reduced CCL5 mRNA levels and inhibited 












Figure 13: Insulin effect on CCL5 mRNA levels. 3T3-L1 adipocytes were incubated in LG 
medium and treated with 10μM oleate, 100μM palmitate and 100nM insulin for 24 h. The 
amount of CCL5 mRNA was determined by real-time RT-PCR analysis of total RNA isolated 
from adipocytes. Bars represent the mRNA levels in these cells and are relative to those in 
cells incubated with LG medium. Asterisks denote statistically significant values (*p < 0.05). 
 






Next, I investigated whether the block of MAPK and PI3K/AKT pathways, by 
MEK (25µM PD98059) and PI3K (25µM LY294002) inhibitors, respectively, 
inhibited the effect of insulin and restored an increase of CCL5 mRNA levels 
in adipocytes in presence of palmitate. As shown in Figure 14, the treatment 
with PD98059 and LY294002, revert the effect of insulin both in the absence 
and in the presence of palmitate. Analogous results have been obtained with 
oleate (data not shown). 
Thus, insulin, activating MAPK and PI3K/AKT pathways, reduced CCL5 




















Figure 14: Insulin effect on CCL5 mRNA levels mediated by MAPK and PI3K/AKT 
pathways. 3T3-L1 adipocytes were incubated in LG medium and treated with 25μM 
PD98059 (PD) and 25μM LY294002 (LY), MEK and PI3K inhibitors respectively. After 1 h 
adipocytes were incubated with 100μM palmitate and 100nM insulin for 24 h. The amount of 
CCL5 mRNA was determined by real-time RT-PCR analysis of total RNA isolated from 
adipocytes. Bars represent the mRNA levels in these cells and are relative to those in cells 











4.8 Effect of insulin on NF-kB binding to CCL5 promoter 
 
Finally, I evaluated the effect of insulin on NF-kB binding to CCL5 
promoter in adipocytes in presence or absence of free fatty acids.  
3T3-L1 adipocytes were incubated with LG medium and then stimulated with 
10µM oleate, 100µM palmitate and 100nM insulin for 24h. Then, adipocytes 
were processed to perform chromatin immunoprecipitation (ChIP) 
experiments. 
Bar graph in Figure 15 shows that levels of NF-kB binding to CCL5 promoter 
were decreased in cells treated with insulin by 35%. Moreover insulin 
prevented both oleate and palmitate effect almost completely abrogating NF-
kB binding in presence of oleate and palmitate.  
Thus, in adipocytes, insulin affected CCL5 regulation by fatty acids reducing 
NF-kB recruitment onto CCL5 promoter. This result suggested a potential 

















Figure 15: Insulin effect on FFA-induced NF-kB binding to CCL5 promoter. 10µM 
oleate, 100µM palmitate and 100nM insulin were added to 3T3-L1 adipocytes pre-incubated 
with LG medium. After 24 h the cells were processed to perform ChIP assay as described in 
Material and Methods. Soluble chromatin was immunoprecipitated with p65 NF-kB 
antibodies. Total and immunoprecipitated DNAs were amplified using primer pairs 
encompassing the CCL5 promoter by real-time RT-PCR. Bars represent the p65 binding levels 
and are relative to those in cells maintained in LG medium. Asterisks denote statistically 













In obesity, the expanded adipose tissue is characterized by significant 
inflammatory infiltration and, via the secretion of multiple adipokines, 
contributes to chronic, low-grade inflammation and to obesity-associated 
pathologies such as type 2 diabetes and cardiovascular disease (Berg and 
Scherer 2005; Fontana et al. 2007). Adipose tissue macrophages may 
contribute to maintaining the low-grade inflammatory state linked to obesity 
activating the inflammatory program in neighboring adipocytes (Osborn and 
Olefsky 2012; Clément 2010).  
Overnutrition and obesity are often accompanied by elevations in tissue and 
circulating FFA concentrations, and saturated FFA can induce inflammatory 
cascades in vascular endothelial cells, adipocytes and myeloid-derived cells 
through activation of JNK and NF-kB pathways (Kim et al. 2005; de Luca and 
Olefsky 2008). At the level of adipocytes, FFAs induce secretion of several 
molecules (Vazquez-Vela et al 2008; D’Esposito et al 2012).  
Recent interest has focused on a salient member of CC chemokine beta 
subfamily, RANTES/CCL5, and its emerging role in regulating the 
recruitment of inflammatory cells into tissues. Several studies show that CCL5 
is implicated in atherogenesis, and that circulating levels of the chemokine are 
associated with impaired glucose tolerance, type 2 diabetes and other 
cardiovascular risk factors, indicating adipocyte CCL5 production as a 
molecular link between inflammation and obesity (Nomura et al. 2000; Herder 
et al. 2005; Matter and Handschin 2007; Wu et al. 2007; D’Esposito et al. 
2012).  
Thus, in this work I have investigated the molecular mechanisms involved in 
metabolic control of CCL5 adipocyte expression. To this end, initially, I have 
addressed whether different concentrations of glucose and fatty acids may 
affect adipocyte ability to secrete and express CCL5.  
I have showed that 3T3-L1 fibroblasts and 3T3-L1 adipocytes released 
detectable amounts of IL-4, IL-6, IL-10, IFN-γ, KC/IL-8, MIP-1α, MIP-1β, 
CCL5 and TNF-α VEGF, bFGF and IGF-1. The secretory patterns obtained by 
3T3-L1 adipocytes and fibroblasts were different and adipocytes secreted 
higher amount of several cytokines/growth factors compared to fibroblasts. In 
particular, the levels of CCL5 were significantly higher in 3T3-L1 adipocytes 
compared with their precursors. Interestingly, both glucose and fatty acids 






(oleate and palmitate) increased adipocyte-released CCL5, suggesting that the 
metabolic environment could further modify adipocyte releasing properties. 
Moreover oleate and palmitate, while not glucose, also increased CCL5 
mRNA levels. These data raise the possibility that glucose and fatty acids may 
regulate CCL5 at different levels. The mechanism responsible for these events 
has not been explained, but it may involve activation of the different molecular 
pathways in adipocytes.  
To clarify the possible mechanism responsible of CCL5 regulation by fatty 
acids, I have investigated the role of JNK, NF-kB, MAPK and PI3K/AKT 
pathways. These pathways resulted activated by fatty acids. I have obtained 
that the treatment of adipocytes with palmitate, almost invariably, induced 
higher phosphorylation of JNK, IkBα, ERK and AKT compared to oleate, but 
no statistically significant difference between oleate- and palmitate-induced 
protein phosphorylation was detected. Inhibition of JNK and NF-kB pathways 
resulted in a decrease of CCL5 mRNA levels induced by oleate and palmitate.  
Indeed, in this study, I have demonstrated that both JNK and NF-kB pathways 
mediated the effect of fatty acids on CCL5 mRNA levels. Moreover, I 
hypothesized that oleate and palmitate activated NF-kB affecting CCL5 gene 
transcriptional control and that the NF-kB activation could be mediated by 
JNK. The block of JNK reduced NF-kB binding to CCL5 promoter affecting 
the ability of fatty acids to promote NF-kB recruitment onto CCL5 promoter. 
These data confirmed the active involvement of NF-kB and JNK pathways in 
mediating the induction of CCL5 expression by fatty acids in adipocytes.  
At the opposite, inhibition of MAPK and PI3K/AKT pathways increased 
CCL5 mRNA levels in the presence of both oleate and palmitate. Interestingly, 
I have observed that even in the absence of fatty acids, the inhibitors of these 
pathways enhanced CCL5 mRNA levels suggesting that MAPK and 
PI3K/AKT pathways may also constitutively control CCL5 expression. These 
pathways represent two main pathways involved in a complex signaling 
cascade downstream of the insulin receptor (de Luca and Olefsky 2008). 
Indeed I have evaluated whether insulin, activating MAPK and PI3K/AKT 
pathways could reduce CCL5 production in adipocytes treated with oleate and 
palmitate.  
Ghanim et al. have demonstrated that low-dose insulin infusion in type 2 
diabetic patients suppressed expression and plasma concentrations of CCL5 
and the expression of its receptors (Ghanim et al. 2010). Moreover Andersson 






et al. have demonstrated an anti-inflammatory effect of insulin in 3T3-L1 
adipocytes through inhibition of IL-6 signaling (Andersson et al. 2007).  
In my work I have showed that insulin reduced mRNA levels of CCL5 and 
counteracted the stimulatory effect of oleate and palmitate on CCL5 
expression in adipocytes. 
Previous study reported that insulin inhibited NF-kB pathway and MCP-1 
chemokine expression in Human Aortic Endothelial Cells (HAEC) (Aljada et 
al. 2001). Indeed I have evaluated the effect of insulin on NF-kB binding to 
CCL5 promoter in 3T3-L1 adipocytes in presence or absence of free fatty 
acids. Insulin decreased NF-kB binding to CCL5 promoter by 35%. Moreover 
insulin prevented both oleate and palmitate effect almost completely 
abrogating NF-kB binding in presence of oleate and palmitate.  
Thus, in adipocytes, insulin affected fatty acid regulation of CCL5 and 













In conclusion, I have described that fatty acids induce expression and 
secretion of CCL5 in adipocytes. This effect is mediated by JNK, which 
regulates CCL5 transcription through NF-kB. In adipocytes, CCL5 mRNA is 
constitutively controlled by MAPK and PI3K/AKT pathway. Insulin inhibits 
FFA effect in part through these pathways and prevents FFA-induced 
recruitment of NF-kB onto CCL5 promoter. 
Thus, CCL5 could be a good candidate for new potential therapeutic strategies 
in optimizing the prevention of insulin-resistance and type 2 diabetes, in 
future. Finally, understanding adipose tissue inflammation and the molecular 
mechanisms involved in CCL5 expression in adipocytes could facilitate 
targeting specific pathways for the treatment of obesity-related diseases.
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Preliminary data on effects of metformin on PED/PEA-15 cellular
levels in obese women with polycystic ovary syndrome
ABSTRACT. Background: The cellular abundance of the phosphoprotein enriched in diabetes (PED/PEA-15), a 15 kDa protein
related to insulin resistance (IR), is increased in women with polycystic ovary syndrome (PCOS). Aim: To investigate whether
metformin (MET) has additive effects on PED/PEA-15 protein levels. Material/subjects and methods: This is an open label,
prospective clinical study over 6 months. Ten hyperandrogenic obese PCOS women [age: 24.6±1.6 yr; body mass index (BMI):
30.7±1.2 kg/m2] were treated with MET (1250 mg/day). Ten age- and BMI-matched normo-androgenic women were used as
controls. Outcome measures are: PED/PEA-15 protein levels, fasting plasma glucose and insulin (FPI), reciprocal index of
homeostasis model assessment of insulin resistance (1/HOMA-IR); quantitative insulin sensitivity check index (QUICKI); whole-
body insulin sensitivity index (ISI); SHBG; total testosterone; free androgen index (FAI). Results: At baseline FPI and PED/PEA-
15 protein levels were higher, while 1/HOMA-IR, QUICKI, and ISI were lower (p<0.001) in MET group than in controls. After
treatment, independently of body weight and hyperandrogenism, FPI, and PED/PEA-15 protein levels decreased (p=0.001
and 0.004, respectively), while, 1/HOMA-IR, QUICKI, and ISI increased (p<0.001). PED/PEA-15 protein levels correlated sig-
nificantly with ISI either before (r=0.636; p=0.048), and after treatment (r=0.758; p=0.011). Conclusions: PED/PEA-15 pro-
tein levels reduced after a short course of treatment with MET in a group hyperandrogenic obese PCOS women. This effect
was independent of body weight and hyperandrogenism, and correlated with ISI, thus adding a further benefit to obese
PCOS women.
(J. Endocrinol. Invest. 33: 446-450, 2010)
©2010, Editrice Kurtis
INTRODUCTION
Insulin resistance (IR) plays an important role in the phys-
iopathology of polycystic ovary syndrome (PCOS) (1). The
association with IR is considered to be responsible for an
increased susceptibility to Type 2 diabetes and cardio-
vascular disease (CVD) among adolescent and pre-men-
opausal women with PCOS also independent of obesity
and androgens levels, especially in patients with familial
history of Type 2 diabetes (2).
A number of post-receptor molecular defects responsible
for IR has been described in PCOS (3). The phosphopro-
tein enriched in diabetes (PED/PEA-15) is a 15 kDa cy-
tosolic scaffold protein related to insulin sensitivity, found
to be widely present in tissues, with an important role in
controlling glucose metabolism (4). In particular, PED/PEA-
15 is over-expressed in skeletal muscle and adipose tis-
sue in patients with Type 2 diabetes or at risk for diabetes
(5). PED/PEA-15 is also over-expressed in white blood cells
(WBC) in about 30% of Type 2 diabetic patients and their
first-degree relatives (6), as well as in PCOS women inde-
pendently of obesity (7).
Although not approved by the US Food and Drug Ad-
ministration for use in PCOS, metformin (MET) is recom-
mended as initial intervention in PCOS women who are
overweight and obese, with the additional positive effect
on improving glucose metabolism abnormality and men-
strual cyclicity (8).
Taking into account the high risk of PCOS women for de-
veloping Type 2 diabetes and CVD, and considering the
central role of PED/PEA-15 protein on IR, the aim of this
pilot clinical study was to evaluate the effects of MET on
the PED/PEA-15 protein levels in association with IR in-
dices and hyperandrogenism in obese PCOS women.
MATERIALS AND METHODS
Study design
This is an open label, prospective, clinical study based
on the evaluation of MET effects in the treatment of
obese PCOS women. The procedures used were in ac-
cordance with the guidelines of the Helsinki Declara-
tion on human experimentation. The study was con-
ducted without support from the pharmaceutical in-
dustry, after approval by the institutional review board
of the University of Naples, Italy. The purpose of the
protocol was explained to both the patients and the
controls, and written consent was obtained at the be-
ginning of the study.
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Outcome measures
The primary outcome measure was PED/PEA-15 protein
level in WBC lysates. Secondary outcomes were body
weight (BW), fasting plasma glucose (FPG), fasting plas-
ma insulin (FPI), insulin sensitivity indices [reciprocal in-
dex of homeostasis model assessment of IR (1/HOMA-
IR), quantitative insulin sensitivity check index (QUICKI),
whole-body insulin sensitivity index (ISI)], SHBG, total
testosterone (T), free androgen index (FAI).
Subjects
Between December 2006 and January 2009, 10 obese
PCOS women [age: 24.6±1.6 yr; body mass index (BMI):
30.7±1.2 kg/m2; range 30-33.8] were consecutively ad-
mitted to the Endocrinology Unit of the Department of
Molecular and Clinical Endocrinology and Oncology of
the Federico II University of Naples (Italy), and enrolled in
this clinical study, according to following inclusion crite-
ria: pre-menopausal women, with a strict age range (20-
30 yr) with diagnosis of PCOS; anovulatory oligo-amen-
orrhea; comparable clinical/biochemical hyperandro-
genism; BMI range: grade I obesity; caucasian ethnicity.
To further minimize subjects variability, the presence of
Type 2 diabetes or abnormal glucose tolerance was ex-
cluded by the oral glucose tolerance test (OGTT). Other
exclusion criteria for all subjects were: smoking or alcohol
consumption, pregnancy, hypothyroidism, hyperpro-
lactinemia, Cushing’s syndrome, non-classical congeni-
tal adrenal hyperplasia; previous (within the last 6 months)
use of oral contraceptives, glucocorticoids, anti-andro-
gens, ovulation induction agents, anti-obesity drugs, or
other hormonal drugs. None of the subjects was affected
by any neoplastic, metabolic, hepatic, and cardiovascu-
lar disorder or other concurrent medical illness (i.e. renal
disease, and malabsorptive disorders). Moreover, those
with acute and chronic inflammations based on medical
history, physical examination, and routine laboratory
tests, including measurement of body temperature, WBC
count and urinalysis, were excluded.
The diagnosis of PCOS was made according to the di-
agnostic criteria for PCOS (9). All PCOS women enrolled
in the study had clinical and/or biochemical hyperandro-
genism with IR, and showed increased PED/PEA-15 lev-
els in WBC (Table 1).
Patients received a low-dose MET treatment (1250
mg/day). The duration of follow-up was 6 months. The
control group consisted of 10 healthy female volunteers,
who were age- and BMI-matched with patients (age:
23.6±3.2 yr; BMI: 30±0.6 kg/m2), came from the same
geographical area, with regular menstrual cycles (defined
as 26-32 days in length), normal androgen levels and in-
sulin sensitivity, and normal PED/PEA-15 protein levels.
Specifically, 100% of controls were selected in Naples
and were young female doctors working in the Medical
School of University “Federico II” in Naples who sponta-
neously agreed to be investigated. Their health status
was determined by medical history, physical, and pelvic
examination, and complete blood chemistry.
Methods
The ovulatory state was investigated by pelvic or transvagi-
nal ultrasonography (TV-USG) and plasma progesterone
(P) levels. Both procedures were performed during the
luteal phase of the menstrual cycle (7 days before the ex-
pected menses). The presence of fluid in the cul-de-sac
at pelvic or TV-USG and a plasma P assay >32 nmol/l (>10
ng/ml) were considered to be the criteria to show that ovu-
lation had occurred (10). The controls were not genetical-
ly related to the PCOS group and without family history
of diabetes.
Hirsutism was assessed using the Ferriman-Gallwey (FG)-
score (11). A progesterone challenge test (100 mg natu-
ral progesterone im) was performed, which induced uter-
ine bleeding in all PCOS women. The normal glucose re-
sponse to the OGTT was defined according to the “Re-
port of the Expert Committee on the diagnosis and clas-
sification of diabetes mellitus” (12).
All anthropometric measurements were taken with sub-
jects wearing only light clothes and without shoes. In
each woman, weight and height were measured to cal-
Controls MET group
T0 T0 T6 p
Body weight (kg) 80.5±4.3 80.2±3.7 79.6±8.4 <0.930*; 0.839**
FPG (mg/dl) 82.6±3.5 97.0±9.6 85.4±6.1 <0.001*; 0.021**
FPI (µUI/ml) 7.2±3 21.3±5.9 11.6±1.4 0.001*;**
1/HOMA-IR 0.71±0.16 0.21±0.07 0.42±0.06 <0.001*;**
QUICKI 0.36±0.03 0.30±0.001 0.34±0.007 <0.001*;**
ISI 5.6±1.7 2. 5±0.6 4.7±0.7 <0.001*;**
Testosterone (nmol/l) 1.3± 0.2 3.6±0.4 3.2±0.5 <0.001*; 0.105**
SHBG (nmol/l) 66.1±5.0 43.4±4.5 54.7±11.4 <0.001*; 0.025**
FAI 1.9±0.2 8.3±1.5 6.3±2.2 <0.001*; 0.051**
Ferriman-Gallwey score 4.8±1.2 15±1.9 16±3 <0.001*; 0.093**
PED/PEA-15 protein 168.6±32.4 395.0±155.9 193.5±97.3 <0.001*; 0.004**
p*: MET group T0 vs controls; p**: MET group T0 vs T6. FPG: fasting plasma glucose; FPI: fasting plasma insulin; 1/HOMA-IR: reciprocal index of home-
ostasis model assessment of insulin resistance; QUICKI: quantitative insulin sensitivity check index; ISI: whole-body insulin sensitivity index; FAI: free
androgen index. Data are reported as mean±SD; PED/PEA-15 protein levels are expressed as arbitrary units.
Table 1 - Baseline clinical and metabolic features of 10 healthy normal-weight controls (Controls) and within-group changes between
baseline (T0) and after 6 months (T6) in clinical and metabolic features of 10 polycystic ovary syndrome (PCOS) women treated with
metformin (MET).
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culate the BMI [weight (kg) divided by height squared
(m2), kg/m2]. Height was measured to the nearest cm us-
ing a wall-mounted stadiometer. BW was determined to
the nearest 50 g using a calibrated balance beam scale.
Patients were given a standardized interview to obtain
information about the duration of obesity, eating pat-
terns, smoking habits, and physical exercise. In particular,
subjects were also asked to make a daily record of the
amount of physical activity (no exercise; ≤2-3 h/week; ≥2-
3 h/week). Pre-admission food intake and dietary history
were assessed by a skilled dietitian who used a comput-
er-assisted interview (Winfood 1.5, Medimatica srl, Mar-
tinsicuro, Italy). All PCOS women received a normo-
caloric diet.
Assays
Blood samples were obtained between 08:00 h and
09:00 h from an ante-cubital vein after an overnight fast,
with the patient in the resting position. The OGTT was
performed using 75 g dextrose. Blood samples were ob-
tained at 0, 30, 60, 90, 120 min for plasma glucose and
insulin measurements. FPG levels were determined by
the glucose oxidase method immediately after the
OGTT. FPI samples were promptly centrifuged, plasma
was separated and stored at –20 C until assay. FPI, SHBG,
and T levels were measured by a solid-phase chemilu-
minescent enzyme immunoassay using commercially
available kits (Immulite Diagnostic Products Co, Los An-
geles, CA). The intra- and inter-assay coefficients of vari-
ations were less than 5·5% for the insulin and SHBG as-
says, and 10% for total T assay. FAI was calculated as an
expression of peripheral androgen activity and estimated
as total T and SHBG serum concentration, according to
the formula FAI = T (nmol/l)/SHBG (nmol/l) × 100. The
HOMA-IR was calculated from FPG and FPI according to
the report by Matthews et al. (13), according to the for-
mula [FPI (µU/ml) × FPG (mmol/l)]/22.5] and reciprocal
index of HOMA-IR (1/HOMA-IR) was calculated. QUICKI
was calculated as: 1/[(log(I0)+log(G0)], where I0 is FPI
(µIU/ml), and G0 is FPG (mg/dl) (14). Whole-body ISI was
calculated as: ℘(FPG × FPI) × (mean glucose × mean in-
sulin), according to Matsuda and DeFronzo (15). Cut-off
points for 1/HOMA-IR, QUICKI, and ISI were ≤0.47,
≤0.33, ≤4.75, respectively (16).
PED/PEA-15 protein levels were measured at 3 and 6
months in WBC lysates obtained from 10 to 12 ml of
freshly collected uncoagulated whole blood, after sepa-
ration with dextran 6%, using Western blot analysis, as
previously reported (6). For Western blot analysis WBC
were solubilized at 4 C in TAT buffer, centrifuged at 500g
for 20 min, and supernatant fractions were stored at –20
C until used. The amount of 50 µg of lysate proteins were
heated at 100 C in Laemmli buffer. Proteins were sepa-
rated by 15% SDS-PAGE and then transferred to 0·45-
mm Immobilon-P membranes (Millipore, Bedfort, MA).
Filters were probed with PED/PEA-15 antiserum at
1:2000 dilution, revealed by enhanced chemilumines-
cence and autoradiography. The protein bands were
quantified by laser densitometry and expressed as per-
centage of pixels (arbitrary units). As reported previous-
ly (6), PED/PEA-15 protein levels in WBC detected by
Western blot analysis, correlated strongly with mRNA de-
tected by real time RT-PCR (p<0.001), and with PED/PEA-
15 protein amount in fat and in skeletal muscle tissues
(p<0.001). In addition, PED/PEA-15 protein stability was
also assessed by repeated testing, at 2, 4, and 6 months
after storage, displaying intra- and inter-assay coefficients
of variation <8 and <15%, respectively.
Statistical analysis
All results are expressed as mean±SD. Fasting insulin and
PED/PEA-15 protein values were not normally distribut-
ed and have been logarithmically transformed as loge.
Differences between groups were analysed by paired t-
test. Bivariate correlations between variables were ex-
amined using Pearson’s correlation coefficient. Values
≤5% were considered statistically significant. Data were
stored and analysed using the Statistical Package for So-
cial Science program (SPSS, release 13·01, Chicago, IL).
RESULTS
Clinical and metabolic features of 10 PCOS women and
10 age- and BMI-matched controls at baseline and after
treatment are reported in Table 1. As expected, FPG,
FPI, T levels, FAI, FG-score, and PED/PEA-15 protein ex-
pression were significantly higher in PCOS compared with
controls, while insulin sensitivity indices and SHBG lev-
els were significantly lower. All included subjects com-
pleted the study. During the follow-up, on the basis of
reported dietary intake, all subjects maintained their nor-
mo-caloric diet and their BW remained unchanged. All
subjects had a normal physical activity level. After treat-
ment, 1/HOMA-IR, QUICKI, and ISI increased, while FPI
and PED/PEA-15 protein level were reduced; no differ-
ence were observed in T levels and FG-score; however,
as SHBG levels increased, FAI was significantly reduced.
PED/PEA-15 protein levels correlated significantly with
ISI both before, as previously reported (7), than after
treatment (Fig.1A and B, respectively), but no significant
correlations were found with BMI. Moreover, while at
baseline, there was no correlation between PED/PEA-15
protein levels, 1/HOMA-IR, and SHBG after treatment a
negative correlation with these variables became evident
(Fig. 1C and D, respectively).
DISCUSSION
Despite limitations due to the small sample size, this pre-
liminary prospective study showed that PED/PEA-15 pro-
tein levels in hyperandrogenic obese PCOS women were
significantly reduced after a 6 months treatment with
MET. Interestingly, in line with the limited effects of MET
on weight loss, as also reported in a recently published
metanalysis (17), the reduction in PED/PEA-15 protein
levels was observed independently from any BW differ-
ences, and was also significantly correlated with the im-
provement of all mathematical indices for assessing in-
sulin sensitivity evaluated in this study. In particular,
PED/PEA-15 protein levels correlated with indices using
the values of fasting glucose and insulin, thus primarily
reflecting the hepatic insulin sensitivity, but that are like-
ly influenced by BW and metabolic or hormonal factors;
however PED/PEA-15 protein levels correlated also with
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ISI, an OGTT-derived index that provides a better esti-
mate of insulin sensitivity than fasting indices, as the plas-
ma glucose responses are the results of peripheral glu-
cose utilization and hepatic glucose production. To the
best of our knowledge, this paper is the first report on
the effect of MET treatment on PED/PEA-15 protein lev-
els and its correlations with IR indices.
PED/PEA-15 is a 15 kDa ubiquitously protein implicated
in a number of fundamental cellular functions, including
apoptosis, proliferation, and glucose metabolism (4). In
particular, PED/PEA-15 protein alteration was identified
early during the natural history of Type 2 diabetes and
might be involved in the progressive derangement of glu-
cose tolerance, by affecting both insulin action and insulin
secretion. We previously evaluated PED/PEA-15 protein
levels in a group of obese and non-obese PCOS women
evidencing that PCOS women presented an increased
amount of PED/PEA-15 protein levels (7). This increase,
similarly to healthy first-degree relatives of patients with
Type 2 diabetes (6), was independent of BW, but was as-
sociated with hyperandrogenism. In particular, PED/PEA-
15 protein levels showed a negative correlation with SHBG
levels and a positive correlation with T levels and FAI (7).
Thus, it was of interest to further evaluate in the present
setting the relationships between PED/PEA-15 protein lev-
els, IR, and androgens after MET treatment.
Concerning a possible relationship between PED/PEA-
15 protein, IR, and androgens, a link between a hyper-
androgenic, hyperinsulinemic environment in PCOS
women, and the development of IR has been reported
to occur, involving different steps of post-receptorial in-
sulin signaling pathway (1, 18). Data obtained in our study
showed that PED/PEA-15 protein levels reduction after
treatment was not associated to the improvement of hy-
perandrogenism. After treatment, only FAI showed a
slight but significant reduction associated with the in-
crease in SHBG, likely reflecting the reduction of IR evi-
denced in this group (19) or, to a lesser extent, a direct ef-
fect of MET (20). Thus, although bidirectional influences
between both variables are likely to take place in the pro-
gression of PCOS, our data supported the hypothesis of
the independence of PED/PEA-15 protein pathway from
hyperandrogenism. In that, the present study further ex-
tend the understanding of the mechanisms and conse-
quences of PED/PEA-15 protein levels in PCOS patho-
genesis.
Finally, a direct effect of MET on PED/PEA-15 protein
could be hypothesized. In our laboratory is under inves-
tigation whether induction of PED/PEA-15 cellular abun-
dance could be a direct effect of MET on its regulatory
mechanisms (gene expression, protein degradation).



























































































Fig. 1 - PED/PEA-15 protein levels correlated significantly with whole-body insulin sensitivity index (ISI) either before, than after treat-
ment (panels A and B, respectively). After treatment a negative correlation between PED/PEA-15 protein levels, reciprocal index of
homeostasis model assessment of insulin resistance (1/HOMA-IR), and SHBG became evident (panels C and D, respectively).
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parently exclude this possibility. Alternatively, indirect ef-
fects may be responsible for this mechanism. Cloning of
PED/PEA-15 promoter revealed nuclear factor-κB (NF-
κB) binding consensus sequence (our unpublished data).
NF-κB is a transcriptor factor, activated by tumour necro-
sis factor (TNF)-α, and involved in the regulation of genes
that control inflammation, cell proliferation and survival.
Thus, it might be speculated that PED/PEA-15 can be
overexpressed via TNF-α/NF-κB pathways. Since MET,
as previously reported, reduces TNF-α levels in PCOS
(21), it could downregulate PED/PEA-15 by affecting
TNF-α/NF-κB pathways.
Despite limitations due to the small sample size, the
strengths of this study include a) the subjects enrolled
were homogenous in age and BMI, also sharing the same
ethnicity, and all completed the study; b) the study has
been carried out at a single Institution; c) the average
time of the follow-up was sufficiently extended, and was
as long as most PCOS trials; d) finally, the high statistical
significance of the results obtained also in spite of the
low number of subjects is an added value of our study
and supported the association of MET with PED/PEA-15
protein pathway.
In conclusion, in line with well-known insulin-sensitizing
action of MET (22), and apart from its consolidated use in
the induction of ovulation (8), our findings provide sup-
port for the hypothesis that the reduction in PED/PEA-
15 protein levels might represent a further puzzle piece
in the complex framework of the effects on glucose
metabolism exerted by MET, and suggests a novel ad-
junctive advantage of MET as therapeutic option for
obese PCOS women. However, as long as most PCOS
trials, further investigations with long-term follow-up, and
larger sample series are still needed to confirm this hy-
pothesis, and the evaluation of the possible direct or in-
direct effects of MET on PED/PEA-15 expression and/or
degradation in target tissue will be the aim of our future
researches.
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Serum 25-Hydroxyvitamin D Levels,
phosphoprotein enriched in diabetes gene
product (PED/PEA-15) and leptin-to-adiponectin
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Abstract
Background: Polycystic ovary syndrome (PCOS) is frequently associated with hypovitaminosis D. Vitamin D is
endowed with pleiotropic effects, including insulin resistance (IR) and apoptotic pathway. Disruption of the
complex mechanism that regulated ovarian apoptosis has been reported in PCOS. Phosphoprotein enriched in
diabetes gene product (PED/PEA-15), an anti-apoptotic protein involved in type 2 diabetes mellitus (T2DM), is
overexpressed in PCOS women, independently of obesity. Leptin-to-adiponectin ratio (L/A) is a biomarker of IR and
low-grade inflammation in PCOS. The aim of the study was to investigate the levels of 25-hydroxy vitamin D (25
(OH)D), and L/A, in association with PED/PEA-15 protein abundance, in both lean and overweight/obese (o/o)
women with PCOS.
Patients and Methods: PED/PEA-15 protein abundance and circulating levels of 25(OH)D, L/A, sex hormone-
binding globulin, and testosterone were evaluated in 90 untreated PCOS patients (25 ± 4 yrs; range 18-34) and 40
healthy controls age and BMI comparable, from the same geographical area. FAI (free androgen index) and the
homeostasis model assessment of insulin resistance (HoMA-IR) index were calculated.
Results: In o/o PCOS, 25(OH)D levels were significantly lower, and L/A values were significantly higher than in lean
PCOS (p < 0.001), while there were no differences in PED/PEA-15 protein abundance. An inverse correlation was
observed between 25(OH)D and BMI, PED/PEA-15 protein abundance, insulin, HoMA-IR, FAI (p < 0.001), and L/A (p
< 0.05). At the multivariate analysis, in o/o PCOS L/A, insulin and 25(OH)D were the major determinant of PED/PEA-
15 protein abundance (b = 0.45, b = 0.41, and b = -0.25, respectively).
Conclusions: Lower 25(OH)D and higher L/A were associated to PED/PEA-15 protein abundance in PCOS,
suggesting their involvement in the ovarian imbalance between pro-and anti-apoptotic mechanisms, with high L/A
and insulin and low 25(OH)D levels as the main determinants of PED/PEA-15 protein variability. Further studies,
involving also different apoptotic pathways or inflammatory cytokines and granulosa cells are mandatory to better
define the possible bidirectional relationships between 25(OH)D, PED/PEA-15 protein abundance, leptin and
adiponectin in PCOS pathogenesis.
Keywords: 25-hydroxyvitamin D, PED/PEA-15, Leptin-to-adiponectin ratio, PCOS, apoptosis
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Background
Obesity, predominantly intra-abdominal visceral adipose
tissue, is observed in 30%-75% of women with polycystic
ovary syndrome (PCOS) [1], with hyperandrogenism
and insulin resistance (IR) as other common features of
this syndrome [2]. Obesity is considered to be a risk fac-
tor for hypovitaminosis D [3]. A number of cross-sec-
tional studies have evidenced the association between
obesity, hypovitaminosis D and PCOS cohorts [4-8],
although hypovitaminosis D have been considered as
the consequence of obesity and IR per se [7].
Vitamin D is endowed with pleiotropic effects on a
wide spectrum of intracellular regulatory mechanisms,
including insulin metabolism [9], or intrinsic apoptotic
pathway, on both classical and nonclassical tissues, such
as ovary [10]. Dysregulation of the complex mechanism
that regulated ovarian apoptosis has been reported in
PCOS [11].
Phosphoprotein enriched in diabetes gene product
(PED/PEA-15) is an anti-apoptotic protein involved in
IR and type 2 diabetes mellitus (T2DM) [12]. We pre-
viously reported that PED/PEA-15 is overexpressed in
T2DM patients [13] and in PCOS women [14]. In both
groups this association was independent of obesity, thus
suggesting that PED/PEA-15 overexpression might
represent a T2DM or PCOS specific feature, likely
linked to IR, although also different pathogenetic
mechanisms influencing PED/PEA -15 expression in
PCOS, such as apoptosis, have not been excluded.
Circulating levels of leptin and adiponectin, two adipose
tissue-derived hormones with opposing associations with
the metabolic syndrome (MetS) and coronary heart dis-
ease, are altered in PCOS [15], thus contributing through
the low-grade chronic inflammation to the long-term
metabolic consequence of the syndrome [16], and possibly,
to the dysregulation between apoptotic and antiapoptotic
mechanisms [17]. Finally, the ratio of leptin-to-adiponectin
(L/A), has been reported to represent a better marker for
obesity, IR, and MetS than each single adipokine [18], in
particular in female population [19]. Although there is still
some debate, a number of recent studies supported a role
for L/A as a biomarker of both IR and low-grade inflam-
mation also in women with PCOS [20].
Taking into account their involvement in obesity and
apoptosis, the aim of our study was to investigate the
balance between circulating levels of 25-hydroxy vitamin
D (25(OH)D), leptin, and adiponectin, and PED/PEA-15
protein abundance, in both lean and overweight/obese
(o/o) women with PCOS.
Materials and methods
Study design
This is an observational clinical study based on the eva-
luation of 25(OH)D, leptin, and adiponectin in both
lean and overweight/obese (o/o) women with PCOS.
The procedures used were in accordance with the
guidelines of the Helsinki Declaration on human experi-
mentation. The study was conducted without support
from the pharmaceutical industry, after approval by the
institutional review board of the University of Naples,
Italy. The purpose of the protocol was explained to both
the patients and the controls, and written consent was
obtained at the beginning of the study.
Subjects
Ninety untreated PCOS patients (25 ± 4 yrs; range 18-
34) were consecutively admitted to the Endocrinology
Unit of the Department of Molecular and Clinical Endo-
crinology and Oncology of the Federico II University of
Naples (Italy), and enrolled in this observational clinical
study according to following inclusion criteria: pre-
menopausal women, with a strict age range (20-40 yr)
with diagnosis of PCOS; anovulatory oligo-amenorrhea;
comparable clinical/biochemical hyperandrogenism; cau-
casian ethnicity. All subjects included in the study
resided in the Naples metropolitan area (latitude 40° 49’
N; elevation 17 m) and were evaluated from March
trough June 2011.
To further minimize subjects variability, the presence
of T2DM or abnormal glucose tolerance was excluded
by the oral glucose tolerance test (OGTT). Other exclu-
sion criteria for all subjects were: smoking or alcohol
consumption, pregnancy, hypothyroidism, hyperprolacti-
nemia, Cushing’s syndrome, non-classical congenital
adrenal hyperplasia; previous (within the last 6 months)
use of oral contraceptives, glucocorticoids, anti-andro-
gens, ovulation induction agents, anti-obesity drugs, or
other hormonal drugs. None of the subjects was affected
by any neoplastic, metabolic, hepatic, and cardiovascular
disorder or other concurrent medical illness (i.e. renal
disease, and malabsorptive disorders). Moreover, those
with acute inflammations based on medical history, phy-
sical examination, and routine laboratory tests, including
measurement of body temperature, white blood cell
count (WBC) and urinalysis, were excluded. The diagno-
sis of PCOS was made according to the diagnostic cri-
teria for PCOS [21]. All PCOS women enrolled in the
study had clinical and/or biochemical hyperandrogenism
with IR. Forty young women, among clerks, and medical
and paramedical personnel of the Department of Mole-
cular and Clinical Endocrinology and Oncology of the
University “Federico II” of Naples, age and BMI compar-
able with the patients, from the same geographical area,
with regular menstrual cycles (defined as 26-32 days in
length), agreed to participate in this study and were
used as controls. Exclusion criteria for controls were
the same of the patients. All participants gave their
informed consent before enrolment.
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Methods
The ovulatory state was investigated by pelvic or trans-
vaginal ultrasonography (TV-USG) and plasma proges-
terone (P) levels. Both procedures were performed
during the luteal phase of the menstrual cycle (7 days
before the expected menses). The presence of fluid in
the cul-de-sac at pelvic or TV-USG and a plasma P
assay >32 nmol/l (>10 ng/ml) were considered to be the
criteria to show that ovulation had occurred [22]. The
controls were not genetically related to the PCOS group
and without family history of diabetes.
Hirsutism was assessed using the Ferriman-Gallwey
(FG)-score, with a score >8 indicative of hyperandrogen-
ism [23]. A progesterone challenge test (100 mg natural
progesterone im) was performed, which induced uterine
bleeding in all PCOS women. The normal glucose
response to the OGTT was defined according to the
“Report of the Expert Committee on the diagnosis and
classification of diabetes mellitus” [24].
All anthropometric measurements were taken with
subjects wearing only light clothes and without shoes. In
each woman, weight and height were measured to calcu-
late the BMI [weight (kg) divided by height squared
(m2), kg/m2]. Height was measured to the nearest cm
using a wall-mounted stadiometer. Body weight was
determined to the nearest 50 g using a calibrated bal-
ance beam scale. The degree of normal weight, over-
weight, or obesity was established on the basis of BMI
cut-off points of 18-24.9 (lean subjects), 25-29.9, 30-
34.9, 35-39.9 and > 40 kg/m2, respectively (o/o).
Assays
Blood samples, obtained between 08:00 h and 09:00 h
from an ante-cubital vein after an overnight fast, with
the patient in the resting position, were promptly centri-
fuged, and serum separated and stored at -20°C until
assay. The OGTT was performed using 75 g dextrose.
Blood samples were obtained at 0, 30, 60, 90, 120 min
for plasma glucose and insulin measurements. Fasting
plasma glucose (FPG) levels were determined by the glu-
cose oxidase method immediately after the OGTT. Cir-
culating levels of 25(OH)D (LIAISON; DiaSorin,
Saluggia (VC), Italy), fasting plasma insulin (FPI), sex
hormone-binding globulin (SHBG), and testosterone (T)
levels (Immulite, Diagnostic Products Co, Los Angeles,
CA; n.v. 0.2-1.2 nmol/l) were measured by solid-phase
chemiluminescent enzyme immunoassays. The intra-
assay coefficients (CV) of variations were less than 5·5%
for the 25(OH)D, insulin, and SHBG assays, and 10%
for total T assay. FAI (free androgen index) was calcu-
lated as an expression of peripheral androgen activity
and estimated as total T and SHBG serum concentra-
tion, according to the formula FAI = T (nmol/l)/SHBG
(nmol/l) × 100. Leptin and total adiponectin (low,
middle, and high molecular weight) levels were deter-
mined with commercially available enzyme-linked
immunosorbent assay (ELISA) kits (AviBion: Orgenium
Laboratories, Helsinki, Finland), with sensitivity 1 and 3
ng/ml, respectively; intra- and inter- assay CVs were less
than 10% and 12%, respectively, for adiponectin and lep-
tin. Vit D deficiency and insufficiency were defined as
10-30 and <10 ng/ml, respectively. The homeostasis
model assessment of insulin resistance (HoMA-IR)
index was calculated from FPG and FPI according to
the report by the formula [FPI (μU/ml) × FPG (mmol/
l)]/22.5] [25]. As a stringent measure of IR, a value of
HoMA-IR > 2.0 was set (deriver by the mean ± 2 SD of
our lean population), in accordance with a previuos cut-
off [26].
PED/PEA-15 protein levels were measured in WBC
lysates obtained from 10 to 12 ml of freshly collected
uncoagulated whole blood, after separation with dextran
6%, using Western blot analysis, as previously reported
[13]. For Western blot analysis WBC were solubilized at
4 C in TAT buffer, centrifuged at 500 g for 20 min, and
supernatant fractions were stored at -20°C until used.
The amount of 50 μg of lysate proteins were heated at
100°C in Laemmli buffer. Proteins were separated by
15% SDS-PAGE and then transferred to 0·45 mm
Immobilon-P membranes (Millipore, Bedfort, MA). Fil-
ters were probed with PED/PEA-15 antiserum at 1:2000
dilution, revealed by enhanced chemiluminescence and
autoradiography. The protein bands were quantified by
laser densitometry and expressed as arbitrary units. As
reported previously [13], PED/PEA-15 protein levels in
WBC detected by Western blot analysis, correlated
strongly with mRNA detected by real time RT-PCR (p <
0.001). In addition, PED/PEA-15 protein stability was
also assessed by repeated testing, at 2, 4, and 6 months
after storage, displaying intra- and inter-assay coeffi-
cients of variation <8 and <15%, respectively.
Statistical analysis
All results are expressed as mean ± SD. Fasting 25(OH)
D, insulin, PED/PEA-15 protein abundance, leptin, and
adiponectin values were not normally distributed and
have been logarithmically transformed. Differences
between lean and overweight/obese subjects in both
PCOS and Control women were analysed by unpaired t
test. Bivariate correlations between variables were exam-
ined using Pearson’s correlation coefficient. Only vari-
ables significant on univariate analysis were included in
the multivariate analysis. Three multiple linear regres-
sion analysis (stepwise model, p to include <0.005, p to
remove >0.1, maxstep 15), were calculated with PED/
PEA-15, as dependent variable and BMI, insulin, 25
(OH)D, L/A and FAI as independent variables consider-
ing PCOS women as a whole, or according to BMI (lean
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and o/o). To avoid multicollinearity, variables with a tol-
erance of 0.2 were excluded. Values ≤5% were consid-
ered statistically significant. Data were stored and
analysed using the Statistical Package for Social Science
program (SPSS, release 13·01, Chicago, IL).\\
Results and Discussion
Metabolic and hormonal characteristics of the study
population were reported in Table 1. Testosterone levels
and FG score in PCOS women were 2.8 ± 1.1 nmol/l
and 16 ± 6, respectively. Grouping PCOS women
according to BMI, there were 42 lean and 48 o/o sub-
jects. Subgroup analysis of o/o and lean women revealed
differences between groups. In particular, apart from the
expected differences in insulin, HoMA-IR, and andro-
gens, 25(OH)D and adiponectin levels were significantly
lower, while leptin levels and L/A values were signifi-
cantly higher in o/o PCOS compared with lean PCOS.
No differences in PED/PEA-15 protein abundance were
evident between lean and o/o PCOS women.
Correlations between variables in the study popula-
tion were reported in Figure 1. In PCOS women, an
inverse correlation was observed between 25(OH)D
and BMI (a), PED/PEA-15 protein abundance (b), insu-
lin (c), HoMA-IR (d), and FAI (e) (r= -0.474, -0.553,
-0.380, -0.407, -0.374, respectively; p < 0.001), and L/A
(f) (r= -0.306, p < 0.05). At the multivariate analysis,
with PED/PEA-15 protein abundance as dependent
variable only insulin and 25(OH)D remained in the
model (b = 0.39 and b = -0.32, respectively) (Table 2).
The results of the analysis were different, however, in
the two group of PCOS women, as the major determi-
nants of PED/PEA-15 protein abundance were BMI
and insulin in lean PCOS (b = 0.65 and b = 0.26,
respectively) (Table 3), and L/A, insulin and 25(OH)D
in o/o PCOS (b = 0.45, b = 0.41 and b = -0.25, respec-
tively) (Table 4).
Our data evidenced that in women with PCOS low
levels of 25(OH)D and PED/PEA-15 protein abundance
are associated to high insulin, HoMA-IR, and L/A
values. According to previous data hypovitaminosis D
was evident in all PCOS women, with 25(OH)D levels
being significantly lower in o/o than in lean PCOS
women. Insulin was the major determinant of PED/
PEA-15 protein abundance, explaining about 26% of
PED/PEA-15 protein abundance variability, while 25
(OH)D levels added another 7% of its variability. In that
our data confirmed the association between insulin and
25(OH)D [7], but evidenced also a novel association
between 25(OH)D, PED/PEA-15 protein abundance, and
L/A in PCOS women.
A number of cross-sectional studies have evidenced
the association between hypovitaminosis D and PCOS
cohorts [4-8], although low serum 25(OH)D concentra-
tions have been considered as the consequence of obe-
sity and IR per se [5-7]. Also an altered L/A has been
already reported in PCOS women, as a biomarker of
both IR and low-grade inflammation [15,17,27,28]. How-
ever, to the best of our knowledge, all these variables in
PCOS women have been investigated in the setting of
IR or MS, while it is well-known that either 25(OH)D
or low-grade inflammation display strict relationships
with apoptotic and antiapoptotic mechanisms [29].
Thus, the association of 25(OH)D and L/A ratio with
the anti-apoptotic protein PED/PEA-15 might suggest a
different scenario in PCOS women.
Table 1 Metabolic and endocrine characteristics of the study population grouped according to BMI.










Age (yrs) 24.1 ± 4.6 24.8 ± 4.0 NS 23.9 ± 3.6 25.4 ± 4.6 NS
BMI 22.1 ± 2.6 33.1 ± 5.8 <0.001 22.1 ± 1.6 34.9 ± 4.1 <0.001
25(OH)D (ng/ml) 15.1 ± 7.6 11.1 ± 5.8 0.021 48.9 ± 11.3 10.2 ± 4.7 <0.001
PED/PEA-15 290 ± 102 295 ± 113 0.745 153 ± 29 177 ± 47 0.092
Leptin (ng/ml) 25.8 ± 6.6 40.3 ± 9.1 <0.001 9.9 ± 4.8 29.4 ± 6.6 0.003
Adiponectin (ng/ml) 13.2 ± 5.7 9.4 ± 6.3 <0.001 17.4 ± 3 11.6 ± 2.5 <0.001
Insulin (μUI/ml) 11.9 ± 4.6 17.1 ± 9.4 0.014 7.6 ± 1.9 11.5 ± 2.0 <0.001
Leptin-to-adiponectin ratio 2.5 ± 1.8 5.8 ± 2.7 <0.001 0.6 ± 0.4 2.0 ± 1.7 <0.001
HoMA-IR 2.4 ± 1 3.8 ± 2.2 <0.001 1.4 ± 0.3 2.2 ± 0.3 <0.001
SHBG (nmol/l) 45.7 ± 7.2 41.3 ± 6.9 0.001 69.5 ± 3.1 63.3 ± 10.5 0.016
FAI 4.6 ± 0.8 8.7 ± 3.8 <0.001 0.8 ± 0.2 0.9 ± 0.2 0.05
Data are reported as mean ± SD. BMI, body mass index; 25(OH)D, 25(OH) Vitamin D; PED/PEA-15, PED/PEA-15 abundance; HoMA-IR, homeostasis model
assessment of insulin resistance; SHBG, sex hormone binding globulin; FAI, free androgen index; FG, Ferriman-Gallwey. PED/PEA-15 protein levels are expressed as
arbitrary units. Fasting 25(OH)D, insulin, PED/PEA-15 protein abundance, leptin, and adiponectin values were not normally distributed and have been
logarithmically transformed. Differences between lean and overweight/obese subjects in both PCOS and Control women were analysed by unpaired t test.
Controls were age and BMI comparable.
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Loss of the ovarian apoptotic mechanism has been
reported to account PCOS appearance [11,30,31], with
hyperandrogenism as one of the proposed mechanisms
affecting the balance between the ovarian expression of
pro and anti-apoptotic proteins [32]. In particular, follicu-
lar atresia is associated with an imbalance in the antiapop-
totic effect of the Bcl-2 family members [33], while
gonadotropin treatment inhibits granulosa cell apoptosis
and follicular atresia through the reduction of the expres-
sion of the proapoptotic protein Bax [32]. Recent studies
have revealed that Vit D is involved in the control of var-
ious cellular processes, including apoptosis, via Bcl-family
up-regulation and Bax down-regulation, but the mechan-
isms underlying this action have not been fully explored
[10,34]. Similarly, leptin and adiponectin exherted opposite
effects also in the complex control of apoptosis-antiapop-
tosis mechanisms. In particular, leptin acts as a mitogenic
factor in a variety of cell types, including ovary [35], where
it has been found to interfere with ovulation rate [36]. On
the other hand, adiponectin, whose receptors are
expressed in ovary in human [37], has been recently
reported to activate the Mitogen-Activated Protein Kinase
(MAPK) cascade in granulosa cells, in the context of the
classical adiponectin anti-apoptotic effects [37-39].
Table 2 Multiple linear regression analysis in PCOS
women.
Independent variables:
BMI, insulin, 25(OH)D, L/A, FAI
Step Variables inserted in the model p R2






Variables excluded from the model:
BMI, L/A, FAI
Variations in PED/PEA-15 abundance explained by stepwise model (p to
include < 0.05, p to remove > 0.1), with selected variables in PCOS women (n
= 90). BMI, body mass index; 25(OH)D, 25(OH) Vitamin D; PED/PEA-15, L/A,
leptin-to-adiponectin ratio; FAI, free androgen index.
Table 3 Multiple linear regression analysis in lean PCOS
women.
Independent variables:
BMI, insulin, 25(OH)D, L/A, FAI
Step Variables inserted in the model p R2






Variables excluded from the model:
25(OH)D, L/A, FAI
Variations in PED/PEA-15 abundance explained by stepwise model (p to
include < 0.05, p to remove > 0.1) in lean PCOS women (n = 42). BMI, body
mass index; 25(OH)D, 25(OH) Vitamin D; PED/PEA-15, L/A, leptin-to-adiponectin
ratio; FAI, free androgen index.

































































































































Figure 1 Correlations between variables in the study population. 25(OH)D, 25(OH) Vitamin D; BMI, body mass index; HoMA-IR, homeostasis
model assessment of insulin resistance; FAI, free androgen index; L/A, leptin-to-adiponectin ratio. Fasting 25(OH)D, insulin, PED/PEA-15 protein
abundance, leptin, and adiponectin values were not normally distributed and have been logarithmically transformed. PED/PEA-15 protein bands
were quantified by laser densitometry and expressed as arbitrary units [13]. Bivariate correlations between variables were examined using
Pearson’s correlation coefficient and their values are singularly evidenced.
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In that, our data evidenced that, hypovitaminosis D
and impaired L/A played an adjunctive role to insulin in
influencing the increase in the anti-apoptotic protein
PED/PEA-15 abundance and, therefore, contributing to
alter the equilibrium between anti and pro-apoptotic
factors in PCOS.
Of interest, grouping PCOS women according to BMI
there were different associations between the study vari-
ables. In particular, in lean PCOS BMI explained 52% of
PED/PEA-15 protein abundance variability, and insulin
added only another 6% of its variability; in o/o PCOS
women L/A, insulin and 25(OH)D explained 37%, 22%
and 5% of PED/PEA-15 protein abundance variability,
respectively. Thus, it is tempting to speculate that in
PCOS women, along with the progressive increase in
BMI, A/L and IR induced by increased amount of dys-
functional adipocytes are involved in the higher activa-
tion of anti-apoptotic pathways, such as PED/PEA-15
protein.
The alteration of the dynamics of the loss of preantral
follicle by atresia might contribute to increase androgen
secretion from atresic follicles, that on turn, resulted not
only in further increase in follicle atresia [32], but also
in IR and PED/PEA-15 protein abundance. In line with
hypothesis, we found opposite correlations between 25
(OH)D, PED/PEA-15 protein and L/A with FAI, the
main biochemical endocrine PCOS features. In particu-
lar, 25(OH)D exhibited an inverse, while PED/PEA-15
protein and L/A showed a positive correlation with FAI.
Apart from a clear effect of gender differences [40], the
inverse association of 25(OH)D with testosterone and
FAI in the setting of PCOS, despite some controversies
[8], and the positive association of PED/PEA-15 protein
abundance with hyperandrogenism, were according to
previously published data [14], further suggesting the
involvement of bidirectional influences between both
variables in the progression of the disease.
Due to the cross-sectional design of the study, these
results must be regarded as preliminary data and cannot
be generalized beyond the cases studied, nor we can
draw conclusions on the natural progression of these
relationships over time. Moreover, we evaluated PED/
PEA-15 protein abundance in WBC and not in ovary
cells; thus, although we previously reported that PED/
PEA-15 protein levels in WBC correlated strongly with
mRNA detected by real time RT-PCR PED/PEA- 15
protein amount in fat and in skeletal muscle tissues
[13], we need to be aware of possible unexplored differ-
ences between WBC and ovary cell PED/PEA-15 protein
expression. Taking into account that laparoscopy is not
routinely performed in PCOS for ethical considerations,
we did not obtain granulosa cells preparations from
women with PCOS in this preliminary investigation.
Conclusions
Although further studies are mandatory, involving also
different apoptotic pathways or inflammatory cytokines
and PCOS granulosa cells, the correlations between 25
(OH)D, PED/PEA-15 protein abundance, L/A ratio, and
hyperandrogenism in our sample of PCOS women, with
high insulin and low 25(OH)D levels as the main deter-
minants of PED/PEA-15 protein abundance, suggested
the involvement of all these variables in the imbalance
between pro-and anti-apoptotic factors responsible for
the increased follicular atresia in PCOS.
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Abstract
Aims/hypothesis Type 2 diabetes and obesity are associated
with increased risk of site-specific cancers. We have inves-
tigated whether metabolic alterations at the level of adipose-
derived differentiating cells may affect specific phenotypes
of breast cancer cells.
Methods Growth profiles of breast cancer cell lines were
evaluated in co-cultures with differentiated adipocytes or
their precursor cells and upon treatment with adipocyte
conditioned media. Production and release of cytokines
and growth factors were assessed by real-time RT-PCR
and multiplex-based ELISA assays.
Results Co-cultures with either differentiated mouse 3T3-
L1 or human mammary adipocytes increased viability of
MCF-7 cells to a greater extent, when compared with
their undifferentiated precursors. Adipocytes cultured in
25 mmol/l glucose were twofold more effective in promoting
cell growth, compared with those grown in 5.5 mmol/l
glucose, and activated mitogenic pathways in MCF-7 cells.
Growth-promoting action was also enhancedwhen adipocytes
were incubated in the presence of palmitate or oleate. Inter-
estingly, 3T3-L1 and human adipocytes released higher
amounts of keratinocyte-derived chemokine/IL-8, the protein
‘regulated upon activation, normally Texpressed, and secreted’
(RANTES), and IGF-1, compared with their precursor cells.
Their levels were reduced upon incubation with low glucose
and enhanced by fatty acids. Moreover, both undifferentiated
cells and differentiated adipocytes from obese individuals
displayed about twofold higher IGF-1 release and MCF-7
cell growth induction than lean individuals. Finally, inhi-
bition of the IGF-1 pathway almost completely prevented
the growth-promoting effect of adipocytes on breast cancer
cells.
Conclusions/interpretation IGF-1 release by adipocytes is
regulated by glucose and fatty acids and may contribute to
the control of cancer cell growth in obese individuals.
Keywords Adipocytes . Breast cancer . IGF-1
Abbreviations
Adipo 3T3-L1 3T3-L1 adipocytes
AU Arbitrary units
bFGF Basic fibroblast growth factor
CM Conditioned medium
ER Oestrogen (estrogen) receptor
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ERK Extracellular signal-regulated kinase








MAPK Mitogen-activated protein kinase
MCP-1 Monocyte chemoattractant protein 1




PDGF Platelet-derived growth factor
PI3K Phosphatidylinositol 3-kinase
PKB/Akt Protein kinase B
RANTES Regulated upon activation normally T
expressed, and secreted
STAT Signal transducer and activator of
transcription
SVF Stromal vascular fraction
TBS Tris-buffered saline
VEGF Vascular endothelial growth factor
Introduction
It has recently become clear that obesity and type 2 diabe-
tes are associated with an increased frequency of many
cancers [1, 2]. For instance, increased adiposity is associ-
ated with an increased risk of several cancers [3]. Similar-
ly, epidemiological data link type 2 diabetes with an
increased incidence of multiple types of cancer, including
breast, colorectal, hepatocellular, endometrial and pancre-
atic malignancies [4, 5]. Both obesity and diabetes can also
lead to poorer treatment outcome and increase cancer-
related mortality rates [6–8].
The adipocyte may represent a candidate to integrate
energy and nutrient metabolism with cancer cell growth by
regulating cell functions through a complex network of
endocrine, paracrine and autocrine signals [9–11]. Indeed,
in addition to storing excess calories in the form of lipid,
adipose tissue is an active endocrine organ that can have far-
reaching effects on the physiology of other tissues [12]. It
has been shown that several hormones, growth factors and
cytokines are produced or generated in white adipose tissue
[13]. Recent interest has centred on the role of adipokines,
chiefly leptin and adiponectin, and inflammatory cytokines
[14]. However, all of the adipocyte factors may be envi-
sioned as contributing factors for cancer onset or progres-
sion [15]. Moreover, adipocytes are largely represented in
the microenvironment of several tumours, possibly provid-
ing a number of signals and resources to tumour cells.
The adipocyte represents one of the most abundant cell
types surrounding breast cancer cells and may prove to be a
key player in the stromal–ductal epithelial cell interactions
within the mammary microenvironment [16]. In this regard,
several in-vitro and in-vivo studies demonstrated that adi-
pocytes can directly influence breast tumour growth [17].
Obesity has been consistently shown to increase the rate
of breast cancer occurrence in postmenopausal women by
30–50% [11]. Studies of breast cancer mortality rates and
survival illustrate that adiposity is associated both with
poorer survival and increased likelihood of recurrence
among those with the disease, regardless of menopausal
status and after adjustment for disease stage and treatment.
Very obese women (BMI ≥40.0) have breast cancer death
rates that are three times higher than very lean (BMI<20.5)
women [3, 18]. Moreover, case–control and cohort studies
showed that women with diabetes may have a 20% in-
creased risk of breast cancer [19] and increased cancer-
related mortality rate [20].
Nevertheless, whether adipocyte-derived factors are di-
rectly involved in breast cancer onset or progression is still
poorly understood [21]. The effect on tumour phenotype of
metabolic alterations at the level of the adipose tissue is
also unclear.
Here, we show that adipocytes may integrate inputs from
the metabolic environment and promote growth of breast
cancer cells. Indeed, both glucose and fatty acids enhance
the ability of adipocytes to produce factors, including IL-8,
RANTES (regulated upon activation, normally T expressed,
and secreted) and IGF-1, involved in the control of cancer
cell phenotypes. Finally, both stromal vascular fraction
(SVF) cells and differentiated adipocytes from obese indi-
viduals release more IGF-1 than those from lean individuals,
suggesting that obesity per se may enhance breast cancer
cell growth.
Methods
Materials Media, sera and antibiotics for cell culture were
from Lonza (Basel, Switzerland). Antibodies against
phospho-Ser473 protein kinase B (PKB/Akt1), forms of ex-
tracellular signal-regulated kinase (ERK), signal transducer
and activator of transcription (STAT)3 and actin were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Phospho-Thr202/Tyr204 ERK and phospho-Tyr705
STAT3 antibodies were obtained from Cell Signaling Tech-
nology (Danvers, MA, USA). PKB/Akt antibody was from
Millipore (Billerica, MA, USA). Anti-leptin antibodies were
a generous gift from G. Matarese (CNR, Naples, Italy).
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
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(SDS-PAGE) reagents were from Bio-Rad (Hercules, CA,
USA). All the other chemicals were from Sigma-Aldrich (St
Louis, MO, USA).
Cell cultures MCF-7 (ERα positive) and MDA-MB-231
(ERα negative) human breast cancer cells and 3T3-L1
mouse fibroblasts were cultured in DMEM supplemented
with 10% fetal bovine serum (FBS) and 2 mmol/l glutamine,
100 IU/ml penicillin and 100 IU/ml streptomycin. Cultures
were maintained in a humidified atmosphere of 95% air and
5% CO2 at 37°C. 3T3-L1 differentiation was achieved as
previously described [22]. Human adipose tissue samples
were obtained from mammary adipose tissue and from
abdominal subcutaneous adipose tissue biopsies. In detail,
mammary adipose tissue specimens were obtained from
women (n012; age 25–63 years; BMI 24.2–29) undergoing
surgical mammary reduction. All women were otherwise
healthy and free from metabolic or endocrine diseases.
Abdominal adipose tissue was obtained from obese (n010;
age 45–65 years; BMI 30–35) and lean women (n010; age
32–60 years; BMI 20–25) by abdominal biopsy in the
periumbilical region under local anaesthesia (2% lidocaine).
Informed consent was obtained from every study participant
before the surgical procedure. This procedure was approved
by the ethical committee of the University of Naples. Adi-
pose tissue was digested with collagenase and then adipose-
derived SVF cells were isolated and differentiated as previ-
ously reported [23]. Conditioned media were obtained by
incubating the cells for 8 h with serum-free DMEM con-
taining 0.25% BSA after two washes with PBS. After the
incubation, mediumwas collected and centrifuged at 14,000 g
to remove cellular debris and placed onto recipient cells for
different times, as indicated, or analysed for cytokines and
growth factor content, as described below. For co-cultures,
8×104 MCF-7 cells were seeded in the upper chamber of a
transwell culture system (4 μm pore size, Costar plates, Corn-
ing Life Sciences, Lowell, MA, USA) in a complete medium.
The following day, the cells were incubated in serum-free
DMEM 0.25% BSA with or without adipocytes in the lower
chamber. Sodium oleate and sodium palmitate were dissolved
in NaOH at 100 mmol/l final concentration and conjugated
with 10% fatty acid-free BSA (as a physiological carrier) at a
molar ratio of 3:1 [24].
Cell proliferation and viability MCF-7 (1×105 cells/well)
and MDA-MB-231 (1×105 cells/well) cells were seeded
in six-well culture plates in a complete medium. The
following day, the cells were starved in serum-free
DMEM 0.25% BSA for 16 h and incubated with condi-
tioned media obtained as described above for different
times. Cell count was performed either by Bürker cham-
ber and with the TC10 Automated Cell Counter (Bio-Rad)
according to the manufacturer’s protocol. Sulforhodamine
assay or crystal violet staining were used for cell viability
determination [25, 26].
Flow cytometry MCF-7 cells were kept in the presence or in
the absence of serum or incubated with conditioned media,
as indicated. Cell cycle phases were then assayed by cyto-
metric analysis as previously described [27].
Cytokine and growth factor assay 3T3-L1 and human pre-
adipocyte and adipocyte conditioned media were screened
for the concentration of IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5,
IL-6, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-17,
eotaxin, granulocyte-colony stimulating factor (G-CSF),
granulocyte–macrophage colony stimulating factor (GM-
CSF), IFN-γ, keratinocyte-derived chemokine (KC)/IL-8,
monocyte chemoattractant protein 1 (MCP-1), macrophage
inflammatory protein 1-alpha/beta (MIP-1α, MIP-1β),
RANTES, TNF-α, platelet-derived growth factor (PDGF),
vascular endothelial growth factor (VEGF), basic fibroblast
growth factor (bFGF) and IGF-1, using the Bio-Plex multi-
plex Mouse and Human Cytokine and Growth factor kits
(Bio-Rad) according to the manufacturer’s protocol.
Real-time RT-PCR analysis Total RNA was isolated from
3T3-L1 and human pre-adipocytes and adipocytes by using
the Rneasy Kit (Qiagen Sciences, Germantown, MD, USA)
according to the manufacturer’s instruction. For real-time
RT-PCR analysis, 1 μg cell RNA was reverse transcribed
using SuperScript II Reverse Transcriptase (Invitrogen,
Carlsbad, CA, USA). PCRs were analysed using SYBR
Green mix (Invitrogen). Reactions were performed using
Platinum SYBRGreen Quantitative PCR Super-UDG using
an iCycler IQ multicolor Real-Time PCR Detection System
(Bio-Rad). All reactions were performed in triplicate and
β-actin was used as an internal standard. Primer sequences
used are described in electronic supplementary material
(ESM) Table 1.
Immunoblot procedure Total cell lysates were obtained and
separated by SDS-PAGE as previously described [27].
Phosphoprotein assay Protein lysates were prepared by us-
ing Cell lysis kit (Bio-Rad) and the presence of phosphory-
lated Akt/PKB, ERK, STAT3 and IGF-1R was detected by
Bio-Plex Phospho- Ser473 Akt1/PKB, Phospho-Thr202/
Tyr204 ERK, Phospho-Tyr705 STAT3 and Phospho-Tyr1131
IGF-1R Assay kits and the Phosphoprotein Testing Reagent
kit (Bio-Rad) according to the manufacturer’s protocol. The
total proteins for Akt1/PKB, ERK and STAT3 were tested
using the Bio-Plex 3-plex assay kit (Bio-Rad).
Statistical analysis Data were analysed with Statview soft-
ware (Abacus concepts) by one-factor analysis of variance.
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A p-value of less than 0.05 was considered statistically
significant.
Results
Adipocytes promote breast cancer cell survival We first
analysed the impact of adipocyte-secreted factors on breast
cancer cell growth, in comparison with factors released by
undifferentiated fibroblasts. Conditioned medium (CM) from
3T3-L1 adipocytes induced a time-dependent increase of cell
growth, which was significantly more effective than that in-
duced by CM from 3T3-L1 fibroblasts (Fig. 1a) and similar to
that observed for cells incubated with 10% FBS-medium
(Fig. 1a). Consistent results were obtained with the ERα-
negative MDA-MB-231 cells (Fig. 1b), suggesting that the
effect was independent of oestrogen release. To investigate
whether human adipocytes were as effective as murine cell
lines in promoting breast cancer cell growth, we obtained
adipose tissue from breast surgery. As shown in Fig. 1c, CM
from adipocytes, either differentiated from SVF or directly
isolated from mammary specimens, induced growth of MCF-
7 cells, by 1.5 fold and twofold, respectively, while CM from
undifferentiated SVF cells had no significant effect. Similar
data were also obtained with MDA-MB-231 cells (data not

































































































































































































































Fig. 1 Effect of adipocyte-released factors on breast cancer cell
growth. (a) Undifferentiated mouse 3T3-L1 cells or mature 3T3-L1
adipocytes were incubated with serum-free DMEM for 8 h. Media
were collected from undifferentiated 3T3-L1 cells and from mature
3T3-L1 adipocytes (respectively, 3T3-L1 CM [grey diamonds] and
Adipo 3T3-L1 CM [black squares]) and added to serum-starved
MCF-7 breast cancer cells for 6, 12, 24 and 48 h. As a control,
MCF-7 cells were also incubated with DMEM without serum supple-
mentation (DMEM-BSA [white triangles]) or with 10% FBS (DMEM
10% FBS [white circles]). The cells were then counted as described in
the Methods and the results reported as fold increase over basal (cell
count in DMEM-BSA). (b) 3T3-L1 CM and Adipo 3T3-L1 CM were
added to serum-starved MDA-MB-231 breast cancer cells for 24 h. As
a control, MDA-MB-231 cells were also incubated with DMEM-BSA
or with DMEM 10% FBS. Cells were then counted as described in the
Methods and the results reported as fold increase over basal (cell count
in DMEM-BSA). (c) Adipose-derived SVF, differentiated adipocytes
(hAdipo) or mature adipocytes (Isol. Adipo) isolated from breast
surgery (n012) were incubated with serum-free medium for 8 h. Media
were collected (CM) and added to serum-starved MCF-7 cells for 24 h.
As a control, MCF-7 cells were also incubated with medium without
serum supplementation (basal medium). Cells were then counted and
the results reported as fold increase over basal (cell count in basal
medium). (d) 3T3-L1 CM, Adipo 3T3-L1 CM, SVF CM and hAdipo
CM were added to serum-starved MCF-7 for 48 h. Cell viability was
then assessed by sulforhodamine assay as described in the Methods
and the results reported as percentage of viable cells compared with
cells in DMEM 10% FBS, considered as 100% viable cells. (e) MCF-7
cells were seeded in the upper chamber of a transwell culture system
with or without 3T3-L1, Adipo 3T3-L1, SVF or hAdipo in the lower
chamber and cell viability was determined by crystal violet staining as
described in the Methods. The results are reported as percentage of
stained cells. *p<0.05, **p<0.01, ***p<0.001 compared with basal;
†p<0.05; ††p<0.01 compared with 3T3-L1 or SVF CM. (f) MCF-7
cells were starved in serum-free DMEM for 18 h and incubated with
3T3-L1 CM, Adipo 3T3-L1 CM, SVF CM and hAdipo CM for 24 h.
Cells were stained with propidium iodide and the ratio of cells in sub-
G1 phase was determined by cytometric analysis, as described in the
Methods. *p<0.05, comparing indicated data For all the panels in the
figure, data in the graphs represent the mean ± SD of at least four
independent triplicate experiments
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cell viability was increased by 3T3-L1 and human mammary
adipocyte CM by 1.6 and 2.6 fold, respectively comparedwith
their undifferentiated precursors (Fig. 1d).
Again, when co-cultured with 3T3-L1 and human adipo-
cytes, MCF-7 displayed higher viability, comparable with
that observed for cells cultured in DMEM–10% FBS. A
much lower effect was observed when MCF-7 cells were
co-cultured with either 3T3-L1 fibroblasts or SVF undiffer-
entiated cells (Fig. 1e).
To further investigate whether growth-promoting action
was dependent on oestrogen release by mature adipocytes,
MCF-7 cells were incubated with mammary adipocyte CM
in the presence of 1 μmol/l Tamoxifen, a selective oestrogen
receptor antagonist (ESM Fig. 1). No significant effect was
elicited by tamoxifen on the adipocyte growth-promoting
action. Also, exposure of the cells to anti-leptin antibodies
did not change the effect of adipocyte CM on cancer cell
growth (ESM Fig. 1).
Moreover, incubation of MCF-7 cells with CM from
3T3-L1 fibroblasts only slightly decreased the number of
cell deaths induced by growth factor deprivation, reducing
the number of cells in sub-G1 phase by 25% (Fig. 1f).
Interestingly, cell death was substantially rescued by incu-
bation with CM from 3T3-L1 adipocytes, at levels similar to
those achieved with 10%FBS medium (Fig. 1f). Again, the
number of cell deaths was decreased following incubation
with CM from mammary adipocytes, and from undifferen-
tiated SVF cells (Fig. 1f), although the effect of the latter
CM was lower.
Adipocyte factors induce MAPK, PI3K and JAK/STAT acti-
vation in MCF-7 cells To gain further insight into the mo-
lecular mechanism by which adipocytes promote breast
cancer cell growth, we tested the ability of adipocyte con-
ditioned media to induce mitogen-activated protein kinase
(MAPK), phosphatidylinositol 3-kinase (PI3K) and JAK/
STAT activation. To this aim, MCF-7 cells were treated with
CM from 3T3-L1 or from mammary adipocytes for 12 h
(ESM Fig. 2). Western blot and phosphoprotein assay
revealed that CM induced the phosphorylation of ERK,
Akt and STAT3 (ESM Fig. 2).
Release of cytokines/chemokines and growth factors by 3T3-
L1 and human mammary adipocytes Based on the observed
induction of signalling pathways, we have screened for the
ability of 3T3-L1 and mammary adipocytes to release cyto-
kines/chemokines and growth factors. Both 3T3-L1 fibro-
blasts and undifferentiated SVF cells released detectable
amounts of IL-4, IL-6, IL-10, IFNγ, KC/IL-8, MIP-1β,
RANTES and TNF-α; MIP-1α was exclusively detected
in the medium of 3T3-L1 pre-adipocytes and not of human
SVF cells. However, the levels of KC/IL-8 and RANTES
were higher both in 3T3-L1 and human adipocytes,
compared with their respective precursors. Moreover, in-
creased levels of IL-6 and MIP-1β were detected in the
CM of human adipocytes while not in the CM of 3T3-L1
adipocytes.
We also screened for growth factor release and found that
VEGF, bFGF, PDGF and IGF-1 were detectable in both pre-
adipocytes and adipocytes. However, while there was no
significant difference in the content of PDGF and bFGF, the
amount of VEGF was significantly reduced in the CM of
both 3T3-L1 and human mammary adipocytes. At variance,
IGF-1 was about fivefold higher in the CM of differentiated
3T3-L1 and mammary adipocytes (Table 1).
Similar to protein levels in the conditioned media, Kc
(also known as Cxcl1)/IL-8, RANTES and IGF-1 mRNA
levels were higher by 5, 6 and 6.5 fold, and 4, 4.5 and 7.5
fold, respectively, in differentiated 3T3-L1 cells and in
human adipocytes, compared with their undifferentiated
counterparts (Fig. 2).
Glucose and fatty acids modify adipocyte growth-promoting
action Next, 3T3-L1 adipocytes were cultured for 24 h
either in 5.5 mmol/l glucose (LG, low glucose), a concen-
tration corresponding to normal fasting glucose levels in
humans, or in 25 mmol/l glucose (HG, high glucose),
corresponding to the regular culture condition for this cell
line, but resembling hyperglycaemia in humans. Moreover,
we added to culture media either 0.5 μmol/l oleate or
10 μmol/l palmitate, two major fatty acids whose plasma
levels are increased in dysmetabolic conditions. Media were
changed and cells were allowed to secrete factors into fresh-
ly added serum-free medium. After 8 h, media were collect-
ed and tested for the content of cytokines/chemokines and
growth factors. No significant change was detected for IL-4,
IL-6, IL-10, IFN-γ, MIP-1α, MIP-1β, TNF-α, PDGF,
bFGF and VEGF (data not shown). However, 3T3-L1 adi-
pocytes cultured in HG medium released significantly
higher levels of KC (Fig. 3a), RANTES (Fig. 3b) and
IGF-1 (Fig. 3c), compared with those cultured in LG medi-
um. Very similar results were obtained for IL-8 (Fig. 3d),
RANTES (Fig. 3e) and IGF-1 (Fig. 3f) in differentiated
mammary adipocytes. Interestingly, culturing 3T3-L1 and
human adipocytes with either oleate or palmitate in LG
medium was accompanied by a significant increase of KC/
IL-8, RANTES and IGF-1 (Fig. 3a–f).
We next addressed whether regulation of those
adipocyte-produced factors occurred at the transcriptional
level. Kc and Igf-1 mRNA levels were about twofold higher
in 3T3-L1 adipocytes cultured in HG medium compared
with LG medium (Fig. 4). Similarly, in differentiated human
adipocytes, both IL-8 and IGF-1 levels were higher in HG
medium than in LG medium. At variance, RANTES (also
known as CCL5) mRNA levels were comparable in HG and
LG media, both in 3T3-L1 and human adipocytes.
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However, when oleate or palmitate were added to LG
medium, significant increases of RANTES and IGF-1 (also
known as IGF1) mRNA levels, while not of Kc/IL-8, were
observed both in 3T3-L1 and human adipocytes.
Thus, these data suggest that glucose may upregulate Kc/
IL-8 and IGF-1, while fatty acids may induce RANTES and
IGF-1 at mRNA levels.
Therefore, we tested whether glucose and fatty acids may
change the growth-promoting action of murine and human
adipocytes. To this end, MCF-7 cells were incubated for
24 h in the presence of either LG or HG conditioned media
from 3T3-L1 and human mammary adipocytes. Pre-
incubation of adipocytes (both 3T3-L1 and human) with
HG medium enhanced, by about twofold, their ability to
induce MCF-7 cell growth, compared with LG medium
(Fig. 5). Moreover, the presence of palmitate or oleate in
the LG medium (from both 3T3-L1 and human adipocytes)
significantly increased breast cancer cell growth (Fig. 5).
Induction of breast cancer cell growth by adipocytes from
lean and obese individuals SVF cells were isolated from
abdominal liposuctions carried out in lean (n010) and obese
(n010) individuals. These cells were differentiated into
mature adipocytes and conditioned media were collected
as previously described (see Methods). As for mammary-
derived specimens (see Fig. 1c), abdominal subcutaneous
differentiated adipocytes induced MCF-7 cell growth to a
larger extent, compared with undifferentiated SVF cells
(Fig. 6) from both lean and obese individuals. However,
CM from both undifferentiated SVF cells and differentiated
adipocytes obtained from obese individuals were signifi-
cantly more effective than those obtained from lean individ-
uals in inducing MCF-7 cell growth.
Again, as for mammary adipocytes, the release of IL-8,
RANTES and IGF-1 was more abundant in mature subcu-
taneous adipocytes, compared with their undifferentiated
Table 1 Adipocyte-released cytokines and growth factors
Cytokine/growth factor 3T3-L1 CM (pg/ml) Adipo 3T3-L1 CM (pg/ml) SVF CM (pg/ml) hAdipo CM (pg/ml)
IL-2 ND ND ND ND
IL-4 0.7±0.008 0.10±0.02 1.12±0.66 1.36±0.66
IL-6 23.6±1.13 22.37±3.47 2,705.58±541 5,005.06±1,200†
IL-10 3.70±0.86 15±2.6* 10.47±2.24 6.53±1.66†††
GM-CSF ND ND ND ND
IFN-γ 3.73±0.38 5.59±0.80 46.70±9.2 41.64±19.8
KC/IL-8 989.14±100.62 10,343.72±1,551.53* 2,975.59±300 15,647.85±190.2††
MIP-1α 226.31±18,27 280±22.32 ND ND
MIP-1β 10.33±1.53 11.4±2 3.37±1.02 25.88±9.01††
RANTES 1,960±235.2 4,770±524.7* 12.27±1.5 52.99±10††
TNF-α 143.54±18.66 162.88±25.92 1.54±0.80 2.17±1.10
PDGF ND ND 1.20±0.90 2.65±1.32
bFGF 200±18 660.70±2.67* 19.37±3.87 25.58±5.37
VEGF 11,479.20±1,262.71 4,682.46±607.71* 526.53±105.30 295.58±65.02††
IGF-1 79.37±0.88 334.37±40.41* 28.85±0.50 136.66±5.7††
Data represent the mean ± SD of at least four independent triplicate experiments. Supernatants from mouse 3T3-L1 pre-adipocytes (3T3-L1 CM),
3T3-L1 adipocytes (Adipo 3T3-L1 CM), human SVF (SVF CM) and differentiated adipocytes (hAdipo CM were collected for 8 h and tested by
using the Bio-Plex multiplex cytokine assay kit and the Bio-Plex multiplex growth factor assay kit as described in the Methods

















































Fig. 2 Kc/IL-8, RANTES and IGF-1 expression in differentiated adi-
pocytes vs undifferentiated precursors. Undifferentiated 3T3-L1 and
SVF cells or mature 3T3-L1 and human adipocytes were tested for the
levels of mouse Kc, Rantes and Igf-1 mRNA, or of human IL-8,
RANTES and IGF-1 mRNA by real-time RT-PCR analysis, as de-
scribed in the Methods. Dark grey columns represent 3T3-L1 adipo-
cytes; light grey columns represent human adipocytes. Bars represent
the mean ± SD of four independent experiments and show the mRNA
levels in these cells relative to those in 3T3-L1/human adipocyte
precursor cells. *p<0.05, **p<0.01, ***p<0.001, in comparison with
the respective measurement in precursor cells
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counterparts (Table 2), both for lean and obese individuals.
No difference in IL-4, IL-8, IL-10, IFN-γ, MIP-1α, MIP-
1β, RANTES, TNF-α, PDGF, bFGF and VEGF content
was found in the media of SVF cells and mature adipocytes
from lean and obese individuals. Nevertheless, IL-6 and
IGF-1 were significantly more abundant in CM of obese
compared with lean adipocytes (Table 2). Moreover, only
IGF-1 levels were higher in SVF cells from obese individ-
uals than in those from lean individuals.
Effect of IGF-1 pathway inhibition on cell growth To ad-
dress the biological relevance of IGF-1 as an adipocyte-
derived growth-promoting factor, MCF-7 cells were treated
with HG CM in the presence of 10 μmol/l AG1024, a
specific inhibitor of IGF-1R kinase activity.
AG1024 almost completely prevented the effect of 3T3-
L1 CM on MCF-7 cell growth (Fig. 7a). Very similar results
were obtained for the prevention of the effect induced by
mammary (Fig. 7b) as well as subcutaneous abdominal
adipocytes, both from lean and from obese individuals
(Fig. 7c). Indeed, the induction of MCF-7 cell growth by
lean and obese adipocytes was reduced at comparable lev-
els, following treatment with AG1024 (Fig. 7c). Moreover,
the increased growth induced by SVF cells from obese
individuals was fully rescued by AG1024 (Fig. 7c) and
returned to levels similar to those achieved by SVF cells
from lean individuals. Similarly, conditioned media from
obese adipocytes induced IGF-1R phosphorylation twofold
more effectively than those from lean individuals (Fig. 7d).
Also, only SVF cells from obese, and not from lean, indi-
viduals were able to increase IGF-1R phosphorylation. Fi-
nally, these effects were completely blocked by AG1024,
indicating a major involvement of IGF-1 (Fig. 7d).
Discussion
Convincing evidence links obesity and diabetes to the risk
of several forms of cancer [4, 11, 14]. We now describe that
differentiated adipocytes, both of mouse and of human
origin, have a significant impact in enhancing breast cancer
cell survival and proliferation. Consistent with previous
reports [16], the effect of adipocytes is larger than that of
their precursor cells. Interestingly, however, their growth-
promoting action is paralleled by a specific secretory pattern
of inflammatory cytokines, chemokines and growth factors,
which is also affected by culture conditions. In particular,










































































































































































































































































Fig. 3 Effect of glucose and fatty acids on adipocyte-released cyto-
kines and growth factors. Mouse 3T3-L1 adipocytes (a–c) and human
adipocytes (d–f) were pre-incubated with high glucose DMEM
(25 mmol/l glucose, HG) or with low glucose DMEM (5.5 mmol/l
glucose, LG) for 24 h in the presence or absence of 10 μmol/l palmitate
(PAL) or 0.5 μmol/l oleate (OLE) for 18 h. They were then further
incubated with serum-free DMEM for 8 h. Media were collected (CM)
and tested by using the Bio-Plex multiplex cytokine assay kit and the
Bio-Plex multiplex growth factor assay kit. Values ± SD for mouse KC
(a), RANTES (b) and IGF-1 (c), and for human IL-8 (d), RANTES
(e) and IGF-1 (f) are reported in the bar graph *p<0.05, comparing
indicated data and represent the mean ± SD of at least four independent
triplicate experiments
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adipocytes to induce the growth of breast cancer cells. When
cultured in 25 mmol/l glucose (HG), a condition mimicking
hyperglycaemia, both 3T3-L1 and human breast mammary
adipocytes were more effective in inducing growth of MCF-7
and MDA-MB-231 cells, compared with when they were
cultured in 5.5 mmol/l glucose (LG), which represents normal
glycaemia in humans.
Incubation of adipocytes with fatty acids also led to in-
creased growth-promoting action, suggesting that metabolic
perturbations may change their secretory pattern. This effect
was observed with palmitate or oleate, either individually or in
combination (data not shown). Higher concentrations of fatty
acids (up to 100 μmol/l palmitate and 10 μmol/l oleate) had a
slightly higher effect on both cancer cell growth and secretory
profile (data not shown). Moreover, it is known that high
concentrations of fatty acids impair insulin sensitivity [28]
and this may further affect adipocyte functions.
It has been reported that adipocyte-derived molecules can
affect cancer cell growth. For instance, leptin has been
shown to induce proliferation of breast cancer cells [29].
However, we found that glucose and fatty acids had no
effect on leptin release by mammary adipocytes (data not
shown). Nevertheless, treatment of MCF-7 cells with anti-
leptin blocking antibodies did not rescue the effect of HG
adipocyte CM on cell growth (ESM Fig. 1). Adipocyte-
derived oestrogens have also been related to breast cancer
development and progression [30]. It seems unlikely that
oestrogens could mediate the effect of glucose and fatty
acids, however, since adipocyte CM elicited a similar effect
in the oestrogen-independent MDA-MB-231 cells and it
was unchanged following tamoxifen treatment of MCF-7
cells. We therefore tested whether glucose and fatty acids
could modify the release of cytokines, chemokines and
growth factors by adipocytes. The secretory patterns
obtained by mouse 3T3-L1 and human mammary adipo-
cytes were somewhat different. For example, MIP-1α and
TNF-α were more abundant in 3T3-L1 cells, while IL-6 and
IFN-γ were more abundant in human cells. However,
IL-8 and RANTES were released to a larger extent by
both differentiated 3T3-L1 cells and human adipocytes,
compared with their precursors, indicating that common
changes were present in the differentiation process. The
increased release of IL-8 and RANTES was paralleled
by a similarly sized increase in their mRNA levels.
Interestingly, both glucose and fatty acids increased the



























































































































































































































































Fig. 4 Glucose and fatty acids control Kc/IL-8, RANTES and IGF-1
expression. Mouse 3T3-L1 adipocytes (a–c) and human adipocytes
(hAdipo) (d–f) were pre-incubated with either HG DMEM or with
LG DMEM for 24 h in the presence or absence of 10 μmol/l palmitate
(PAL) or 0.5 μmol/l oleate (OLE) for 18 h. Following this, mRNA
levels of mouse Kc (a), Rantes (b) and Igf-1 (c), and of human IL-8 (d),
RANTES (e) and IGF-1 (f) were determined by real-time RT-PCR
analysis. Data were normalized on β-actin as internal standard. Bars
represent the mean ± SD of four independent experiments and show the
mRNA levels in these cells relative to those in 3T3-L1/hAdipo HG
cells, reported as 1 in the first column of each bar graph. *p<0.05,
**p<0.01, comparing indicated data. Rel. expr., relative expression
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environment could further modify adipocyte releasing prop-
erties. Similar results were also found for IGF-1, which was
more abundant in the medium of mature adipocytes and
upregulated by glucose and fatty acids. bFGF also tended
to be detected in higher amounts in the mature adipocytes,
while VEGF levels were more elevated in the undifferenti-
ated precursors. However, neither bFGF nor VEGF were
significantly regulated by nutrients.
We have obtained evidence that glucose and fatty acids
may regulate IL-8, RANTES and IGF-1 at different levels.
Culturing adipocytes in HG is accompanied by a significant
upregulation of IL-8 and IGF-1, while not of RANTES
mRNA, compared with low glucose. At variance, both
oleate and palmitate enhance IGF-1 and RANTES, while
not IL-8 mRNA levels. Altogether, these data raise the
possibility that, beside regulating gene expression, nutrients
may control adipocyte secretion process.
Thus, these findings are consistent with the hypothesis
that adipocytes, in an appropriate metabolic environment,
may contribute to tumour growth and progression by
releasing factors that may function to promote cancer cell
proliferation. In particular, RANTES, IL-8 and IGF-1 rep-
resent good candidates since: (1) they are produced in the
adipocytes and released in the culture medium; (2) their
production/release is induced by nutritional factors, such
as glucose and fatty acids; and (3) they have been implicated
in the control of cancer cell phenotypes. For instance,
RANTES and IL-8 are elevated in plasma of obese individ-
uals [31–33] and have been largely implicated in obesity-
related health complications [34–36] as well as in the mech-
anisms of cancer progression [37–39].
IGF-1 also plays a pivotal role in the progression of many
forms of cancer, including breast cancer [40–42]. Indeed IGF-1
is involved in the development of normal mammary gland and
in the onset and/or progression of mammary tumours [42], as
well as in the development of drug resistance [43].
It was recently reported that, in pancreatic cancer, auto-
crine production of IGF-1 by cancer cells enhances the
production of RANTES by stromal cells, thereby providing
a paracrine loop to facilitate tumour progression [44]. More-
over, expression profile studies indicate that IL-8 and IGF-1
are produced at higher levels in tissues from patients with
high-grade breast cancer than in tissues from patients with
low-grade breast cancer [45].
We have also found that adipocytes obtained from sub-
cutaneous fat specimens from obese individuals were capa-
ble of producing larger amounts of IGF-1 compared with
lean controls. This is consistent with higher circulating IGF-
1 levels often found in obesity [46]. Surprisingly, the differ-
ence was also significant when IGF-1 was measured in the
conditioned media of undifferentiated SVF cells from obese
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Fig. 5 Effect of glucose and fatty acids on adipocyte growth-
promoting action. Mouse 3T3-L1 adipocytes (a) and human adipocytes
(b) were pre-incubated with either HG DMEM or with LG DMEM for
24 h in the presence or absence of 10 μmol/l palmitate or 0.5 μmol/l
oleate for 18 h. They were then further incubated with serum-free DMEM
for 8 h. Media were collected (CM) and added to serum-starved MCF-7
cells for 24 h. Cells were then counted and the results reported as fold
increase over basal (cell count in DMEM-BSA). *p<0.05, **p<0.01,
comparing indicated data. Data in the bar graphs represent the mean ± SD
































BMI 20−25 kg/m2 BMI 30−35 kg/m2
Fig. 6 Cancer cell growth induced by adipocytes from lean and obese
individuals. SVF cells and human adipocytes isolated from obese (BMI
30–35) and lean women (BMI 20–25) were incubated with serum-free
medium for 8 h. Media were collected (CM) and added to serum-
starved MCF-7 cells for 24 h. Then, cells were counted and the results
reported as fold increase over basal (cell count in medium without
serum supplementation). Dark grey columns represent SVF CM; light
grey columns represent human adipocyte (hAdipo) CM. *p<0.05,
comparing indicated data. Data in the bar graphs represent the mean
± SD of at least four independent triplicate experiments
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during adipocyte differentiation, is enhanced in obesity and
is maintained in cultured mesenchymal stem cells. This
could possibly be due to epigenetic changes in IGF-1 gene
expression regulation [47]. Interestingly, however, upregu-
lation was only observed for IGF-1 and not for other chemo-
kines and growth factors, both in undifferentiated SVF and
in mature adipocytes.
IGF-1 in the adipose tissue may act either as an autocrine
factor [48], regulating adipose tissue development and
homoeostasis, or in a paracrine manner, regulating survival
and function of the surrounding cells, including cancer cells.
Inhibition of IGF-1 function, indeed, almost completely
abolished the effect of adipocyte-released factors, thereby
indicating that IGF-1 is a pivotal factor in adipocyte
Table 2 Cytokines and growth factors released by adipocytes from lean and obese individuals
Cytokine/growth factor BMI 21–25 BMI 30–35
SVF CM (pg/ml) hAdipo CM (pg/ml) SVF CM (pg/ml) hAdipo CM (pg/ml)
IL-2 ND ND ND ND
IL-4 1.09±0.60 1.49±0.53 0.79±0.06 0.96±0.006
IL-6 2,446.87±489.37 6,420.31±1,348.26* 2,180.64±436.12 12,367.95±2,597.26*††
IL-10 11.40±2.66 6.75±1.48* 9.61±2.32 5.90±1.99*
GM-CSF ND ND ND ND
IFN-γ 45.82±9.62 46.7±10.27 38.86±12.72 41.64±18.80
IL-8 2,556.45±350.45 25,019.32±1,264.48** 1,229.32±380.12 22,271.66±5,308.75**
MIP-1α 58.82±7.98 136.23±9.62 54.14±4.80 52.95±7.83
MIP-1β 10.33±3.46 27.96±3.27* 3.52±0.58 34.62±8.44*
RANTES 17.98±3.40 73.65±9.68* 12.45±2.27 45.26±11.35**
TNF-α 204.08±15.35 291.65±35.82 173.49±18.52 200.04±21.71
PDGF 2.48±1.35 3.04±0.88 2.80±0.52 3.16±0.71
bFGF 28.63±11.90 36.88±12.66 14.68±3.74 24.55±6.27
VEGF 620.53±165.61 178.54±85.01** 483.06±29.48 322.20±71.55
IGF-1 115±54.46 666±40.42* 193.33±64.29† 1,073.33±22.30**†
SVF cells and differentiated SVF (hAdipo) isolated from obese (BMI 30–35; n010) and lean women (BMI 20–25; n010) were incubated with
serum-free medium for 8 h. Media were collected (CM) and analysed by using the Bio-Plex multiplex human cytokine assay kit and the Bio-Plex
multiplex human growth factor assay kit. Determinations were done in triplicate
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Fig. 7 Effect of IGF-1 pathway inhibition on cell growth. Conditioned
media collected from mouse 3T3-L1 adipocytes (a) and mammary
adipocytes (b) and subcutaneous abdominal SVF and adipocytes iso-
lated from obese (BMI 30–35) and lean women (BMI 20–25) (c) were
added to serum-starved MCF-7 cells for 24 h in the presence or
absence of 10 μmol/l AG1024. Cells were then counted and the results
reported as fold increase over basal (cell count in serum-free medium).
White columns, SVF CM; light grey columns, SVF CM + Ag1024;
dark grey columns, human adipocyte (hAdipo) CM; black columns,
hAdipo CM + Ag1024. (d) MCF-7 cells were exposed to conditioned
media collected from subcutaneous abdominal SVF and adipocytes
isolated from obese (BMI 30–35) and lean women (BMI 20–25) for
24 h and proteins extracted were tested for the presence of phosphor-
ylated IGF-1R by using the Bio-Plex phosphoprotein assay kit as
described in Methods. White columns, SVF CM; light grey columns,
SVF CM + Ag1024; dark grey columns, hAdipo CM; black columns,
hAdipo CM + Ag1024. *p<0.05, **p<0.01, comparing indicated data.
Data in the bar graphs represent the mean ± SD of at least four
independent triplicate experiments
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regulation of cancer cell growth. However, these results are
limited to breast cancer models, in which the importance of
the local environment, including adipocyte function, has
been largely documented. Further studies are needed to
assess the relevance of adipose-related factors in the control
of other cancer types. Moreover, the communications be-
tween cancer cells and adipocytes may be bidirectional.
Release of TNF-α from cancer cells may affect adipocyte
differentiation and function, possibly increasing NEFA re-
lease, to provide additional feed for the cancer cells [49, 50].
Thus, we have described that IGF-1 release by adipocytes
is enhanced in obesity and is regulated by metabolic pertur-
bations. Other factors, such as RANTES and IL-8, which are
not primarily upregulated in obese individuals, are also
enhanced by glucose and fatty acids and may as well con-
tribute to adipocyte control of breast cancer cell growth.
Acknowledgements The authors are grateful to S. Libertini (Univer-
sity of Naples, Naples, Italy) and C. Passaro (University of Naples,
Naples, Italy) for technical help with cytofluorimetric assays and to
G. Perruolo (CNR, Naples, Italy) and G. Portella (University of
Naples, Naples, Italy) for helpful discussion and advice.
Funding This study was supported in part by the European Com-
munity’s FP6 PREPOBEDIA (201681), the European Foundation for
the Study of Diabetes (EFSD), the Associazione Italiana per la Ricerca
sul Cancro (AIRC) and by the Ministero dell’Università e della Ricerca
Scientifica (grants PRIN and FIRB-MERIT).
Duality of interest The authors declare that there is no duality of
interest associated with this manuscript.
Contribution statement VD’E was the main contributor in terms of
conception, design, acquisition and interpretation of data and in draft-
ing the article. FP, AH, DL, DT, GM, LC and CM mainly contributed
in conceptual design and acquisition of data. FB and US mainly
contributed in terms of conceptual design, analysis, interpretation and
discussion of the results. PF mainly contributed in terms of conceptual
design, interpretation and discussion of the results and supervision of
the overall work. All the authors critically revised the article and
approved the final version.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any non-
commercial use, distribution, and reproduction in any medium, provided
the original author(s) and the source are credited.
References
1. La Vecchia C, Giordano SH, Hortobagyi GN, Chabner B (2011)
Overweight, obesity, diabetes, and risk of breast cancer: interlock-
ing pieces of the puzzle. Oncologist 16:726–729
2. Khandekar MJ, Cohen P, Spiegelman BM (2011) Molecular mecha-
nisms of cancer development in obesity. Nat Rev Cancer 11:886–895
3. Calle EE, Thun MJ (2004) Obesity and cancer. Oncogene
23:6365–6378
4. Renehan A, Smith U, Kirkman MS (2010) Linking diabetes and
cancer: a consensus on complexity. Lancet 375:2201–2202
5. Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L,
Renehan AG (2012) Diabetes and cancer (1): evaluating the tem-
poral relationship between type 2 diabetes and cancer incidence.
Diabetologia 55:1607–1618
6. Chen J (2011) Multiple signal pathways in obesity-associated
cancer. Obes Rev 12:1063–1070
7. Barone BB, Yeh HC, Snyder CF et al (2010) Postoperative mor-
tality in cancer patients with preexisting diabetes: systematic re-
view and meta-analysis. Diabetes Care 33:931–939
8. Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Møller
H (2012) Diabetes and cancer (2): evaluating the impact of
diabetes on mortality in patients with cancer. Diabetologia 55:
1619–1632
9. Poulos SP, Hausman DB, Hausman GJ (2010) The development
and endocrine functions of adipose tissue. Mol Cell Endocrinol
323:20–23
10. Carswell KA, Lee MJ, Fried SK (2012) Culture of isolated
human adipocytes and isolated adipose tissue. Meth Mol Biol
806:203–214
11. Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epide-
miological evidence and proposed mechanisms. Nat Rev Cancer
4:579–591
12. Rajala MW, Scherer PE (2003) Minireview: the adipocyte—at the
crossroads of energy homeostasis, inflammation, and atherosclero-
sis. Endocrinology 144:3765–3773
13. Frühbeck G, Gómez-Ambrosi J, Muruzábal FJ, Burrell MA (2001)
The adipocyte: a model for integration of endocrine and metabolic
signaling in energy metabolism regulation. Am J Physiol Endo-
crinol Metab 280:E827–E847
14. Park J, Euhus DM, Scherer PE (2011) Paracrine and endocrine
effects of adipose tissue on cancer development and progression.
Endocr Rev 32:550–570
15. Feldmann M (2008) Many cytokines are very useful therapeutic
targets in disease. J Clin Invest 118:3533–3536
16. Iyengar P, Combs TP, Shah SJ et al (2003) Adipocyte-secreted
factors synergistically promote mammary tumorigenesis through
induction of anti-apoptotic transcriptional programs and protoon-
cogene stabilization. Oncogene 22:6408–6423
17. Macciò A, Madeddu C, Mantovani G (2009) Adipose tissue as
target organ in the treatment of hormone-dependent breast cancer:
new therapeutic perspectives. Obes Rev 10:660–670
18. Petrelli JM, Calle EE, Rodriguez C, Thun MJ (2002) Body mass
index, height, and postmenopausal breast cancer mortality in a pro-
spective cohort of US women. Cancer Causes Contr 13:325–332
19. Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and
risk of breast cancer: a meta-analysis. Int J Cancer 121:856–862
20. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE
(2008) The impact of diabetes on survival following breast cancer.
Breast Cancer Res Treat 109:389–395
21. Lorincz AM, Sukumar S (2006) Molecular links between obesity
and breast cancer. Endocr Relat Cancer 13:279–292
22. Chavey C, Mari B, Monthouel MN et al (2003) Matrix metal-
loproteinases are differentially expressed in adipose tissue during
obesity and modulate adipocyte differentiation. J Biol Chem
278:11888–11896
23. Isakson P, Hammarstedt A, Gustafson B, Smith U (2009) Impaired
preadipocyte differentiation in human abdominal obesity: role of
Wnt, tumor necrosis factor-alpha, and inflammation. Diabetes
58:1550–1557
24. Spector AA (1975) Fatty acid binding to plasma albumin. J Lipid
Res 16:165–179
25. Skehan P, Storeng R, Scudiero D (1990) New colorimetric cyto-
toxicity assay for anticancer-drug screening. J Natl Cancer Inst
82:1107–1112
Diabetologia (2012) 55:2811–2822 2821
26. Chiba K, Kawakami K, Tohyama K (1998) Simultaneous evalua-
tion of cell viability by neutral red, MTT and crystal violet staining
assays of the same cells. Toxicol Vitro 12:251–258
27. Alberobello AT, D'Esposito V, Marasco D (2010) Selective disrup-
tion of insulin-like growth factor-1 (IGF-1) signaling via
phosphoinositide-dependent kinase-1 prevents the protective effect
of IGF-1 on human cancer cell death. J Biol Chem 285:6563–6572
28. Guilherme A, Virbasius JV, Puri V, Czech MP (2008) Adipocyte
dysfunctions linking obesity to insulin resistance and type 2 dia-
betes. Nat Rev Mol Cell Biol 9:367–377
29. Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, Leneveu
MC, Pecquery R, Giudicelli Y (2002) Leptin mediates a prolifer-
ative response in human MCF7 breast cancer cells. Biochem Bio-
phys Res Commun 293:622–628
30. Cleary MP, Grossmann ME (2009) Minireview: obesity and breast
cancer: the estrogen connection. Endocrinology 150:2537–2542
31. Wu H, Ghosh S, Perrard XD et al (2007) T cell accumulation and
regulated on activation, normal T cell expressed and secreted upre-
gulation in adipose tissue in obesity. Circulation 115:1029–1038
32. Herder C, Illig T, Baumert J, Müller M et al (2008) RANTES/
CCL5 gene polymorphisms, serum concentrations, and incident
type 2 diabetes: results from the MONICA/KORA Augsburg case-
cohort study, 1984-2002. Eur J Endocrinol 158:R1–R5
33. Straczkowski M, Dzienis-Straczkowska S, Stêpieñ A, Kowalska I,
Szelachowska M, Kinalska I (2002) Plasma interleukin-8 concen-
trations are increased in obese subjects and related to fat mass and
tumor necrosis factor-alpha system. J Clin Endocrinol Metab
87:4602–4606
34. Braunersreuther V, Zernecke A, Arnaud C et al (2007) Ccr5 but not
Ccr1 deficiency reduces development of diet-induced atheroscle-
rosis in mice. Arterioscler Thromb Vasc Biol 27:373–379
35. Veillard NR, Kwak B, Pelli G (2004) Antagonism of RANTES
receptors reduces atherosclerotic plaque formation in mice. Circ
Res 94:253–261
36. Herder C, Haastert B, Müller-Scholze S et al (2005) Association of
systemic chemokine concentrations with impaired glucose toler-
ance and type 2 diabetes: results from the Cooperative Health
Research in the Region of Augsburg Survey S4 (KORA S4).
Diabetes 54(Suppl 2):S11–S17
37. Murooka TT, RaHbAr R, Fish EN (2009) CCL5 promotes prolif-
eration of MCF-7 cells through mTOR-dependent mRNA transla-
tion. Biochem Biophys Res Commun 387:381–386
38. Raman D, Baugher PJ, Thu YM, Richmond A (2007) Role of
chemokines in tumor growth. Cancer Lett 256:137–165
39. Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer.
Clin Cancer Res 14:6735–6741
40. Clayton PE, Banerjee I, Murray PG, Renehan AG (2011) Growth
hormone, the insulin-like growth factor axis, insulin and cancer
risk. Nat Rev Endocrinol 7:11–24
41. Hankinson SE, Willett WC, Colditz GA et al (1998) Circulating
concentrations of insulin-like growth factor-I and risk of breast
cancer. Lancet 351:1393–1396
42. Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like
growth factors and neoplasia. Nat Rev Cancer 4:505–518
43. Ryan PD, Goss PE (2008) The emerging role of the insulin-like
growth factor pathway as a therapeutic target in cancer. Oncologist
13:16–24
44. Makinoshima H, Dezawa M (2009) Pancreatic cancer cells activate
CCL5 expression in mesenchymal stromal cells through the
insulin-like growth factor-I pathway. FEBS Lett 583:3697–3703
45. Razmkhah M, Jaberipour M, Hosseini A, Safaei A, Khalatbari B,
Ghaderi A (2010) Expression profile of IL-8 and growth factors in
breast cancer cells and adipose-derived stem cells (ASCs) isolated
from breast carcinoma. Cell Immunol 265:80–85
46. Frystyk J, Skjaerbaek C, Vestbo E, Fisker S, Orskov H (1999)
Circulating levels of free insulin-like growth factors in obese
subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev
15:314–322
47. Sanchez C, Oskowitz A, Pochampally RR (2009) Epigenetic
reprogramming of IGF1 and leptin genes by serum deprivation in
multipotential mesenchymal stromal cells. Stem Cell 27:375–382
48. Klöting N, Koch L, Wunderlich T et al (2008) Autocrine IGF-1
action in adipocytes controls systemic IGF-1 concentrations and
growth. Diabetes 57:2074–2082
49. Meng L, Zhou J, Sasano H, Suzuki T, Zeitoun KM, Bulun SE
(2001) Tumor necrosis factor alpha and interleukin 11 secreted by
malignant breast epithelial cells inhibit adipocyte differentiation by
selectively down-regulating CCAAT/enhancer binding protein al-
pha and peroxisome proliferator-activated receptor gamma: mech-
anism of desmoplastic reaction. Cancer Res 61:2250–2255
50. Guerrero J, Tobar N, Cáceres M et al (2010) Soluble factors derived
from tumor mammary cell lines induce a stromal mammary adipose
reversion in human and mice adipose cells. Possible role of TGF-
beta1 and TNF-alpha. Breast Cancer Res Treat 119:497–508
2822 Diabetologia (2012) 55:2811–2822
O R I G I N A L A R T I C L E
Bisphenol A in polycystic ovary syndrome and its association
with liver–spleen axis
Giovanni Tarantino*, Rossella Valentino†, Carolina Di Somma‡, Vittoria D’Esposito**, Federica Passaretti**,
Genoveffa Pizza§, Valentina Brancato§, Francesco Orio¶, Pietro Formisano**, Annamaria Colao§ and Silvia
Savastano§
*Department of Clinical and Experimental Medicine, University Federico II of Naples, †IEOS-CNR, ‡IRCCS SDN Foundation
Naples, §Division of Endocrinology, Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of
Naples, ¶Department of Endocrinology, University Parthenope of Naples, and **Department of Cellular and Molecular Biology and
Pathology, University Federico II of Naples, Naples, Italy
Summary
Context Bisphenol A, one of the highest-volume chemicals cur-
rently available, is known to act as endocrine disruptor and
alters several metabolic functions, including inflammatory path-
ways. Elevated serum levels of bisphenol A have been found in
women with polycystic ovary syndrome (PCOS) and a role of
low-grade chronic inflammation has been recently reported in
the pathogenesis of this syndrome. Increased spleen volume, a
reliable and stable index of chronic inflammation, was strictly
associated with the severity of hepatic steatosis (HS) in obese
subjects, determining the so-called liver–spleen axis.
Objective To evaluate the contribution of increased serum
bisphenol A levels to low-grade chronic inflammation, HS and
hyperandrogenism in women with PCOS.
Design, setting and participants Forty lean and overweight/
obese premenopausal women with PCOS and 20 healthy age-
matched women were consecutively enrolled in a cross-sectional
study from 2009 to 2011 at the Federico II University Hospital
in Naples.
Measurements Bisphenol A, homoeostasis model assessment of
insulin resistance (HoMA-IR), laboratory liver tests, testosterone,
sex hormone-binding globulin, free androgen index (FAI),
C-reactive protein, interleukin-6, and the ultrasound quantifica-
tion of HS and spleen longitudinal diameter.
Results Independently of body weight, higher bisphenol A lev-
els in PCOS women were associated with higher grades of insu-
lin resistance, HS, FAI and inflammation, spleen size showing
the best correlation. At multivariate analysis, spleen size and FAI
were the best predictors of bisphenol A (b coefficients 0379,
P = 0007 and 0343, P = 0014, respectively).
Conclusions In premenopausal women with PCOS, we evi-
denced an association of serum bisphenol A levels with HS and
markers of low-grade inflammation, in particular with spleen
size, unravelling the presence of the liver–spleen axis in this syn-
drome.
(Received 3 May 2012; returned for revision 4 July 2012; finally
revised 9 July 2012; accepted 10 July 2012)
Introduction
Bisphenol A is one of the highest-volume chemicals currently
available. This lipophilic compound is in fact detectable world-
wide at nanomolar levels in human serum and is known to act
as endocrine disruptor.1 Bisphenol A, at very low doses, alters
several metabolic functions, including oxidative stress, a key
component of inflammatory reactions, thus contributing to the
global rise in the prevalence of obesity, type 2 diabetes and car-
diovascular diseases.2,3 It is not known, however, whether bi-
sphenol A is associated with inflammation markers in humans.
A role for bisphenol A as endocrine disruptor has been recently
proposed in the pathogenesis of polycystic ovary syndrome
(PCOS),4 the most common endocrinopathy among women of
reproductive age, characterized by hyperandrogenism, insulin
resistance and chronic anovulation.5 In particular, a bidirectional
underlying mechanism has been hypothesized to occur in the
relationship between PCOS and bisphenol A, involving both
androgens6 and bisphenol A metabolism.7 The existence of low-
grade chronic inflammation8–11 and the association with auto-
immune diseases12 have also been reported in PCOS. The
increased androgen bioavailability estimated by the free andro-
gen index (FAI) has been extensively examined in the mecha-
nisms underlying the low-grade chronic inflammation in
PCOS.10,11 On the other hand, the incidence of autoimmune
thyroid diseases, such as Hashimoto’s thyroiditis, has been
reported to be threefold higher in women with PCOS than in
the general female population.13
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So far, no single circulating marker has been detected to spe-
cifically reflect the presence and/or severity of inflammation.
Nevertheless, a key role in low-grade chronic inflammation has
been depicted for Interleukin (IL)-6, which is produced by mac-
rophages infiltrating adipose tissue and the spleen. This pro-
inflammatory cytokine induces the production of C-reactive
protein (CRP) by the liver.14 Increased spleen volume has been
recently proposed as a reliable and a stable index of chronic
inflammation strictly associated with severity of nonalcoholic
fatty liver disease, otherwise known as hepatic steatosis (HS), in
obesity,15 determining the so-called liver–spleen axis.16
The aim of this pilot study was to evaluate in premenopausal
women with PCOS the possible contribution of increased serum
bisphenol A levels to the concurrent presence of low-grade
chronic inflammation, HS and hyperandrogenism, by analysing
the size of the spleen, an organ whose role in the mechanisms of
inflammation/immune disorders,17 is well known.
Materials and methods
Study design
This is a cross-sectional study carried out in accordance with
the guidelines of the Helsinki Declaration on human experimen-
tation, after approval by the Institutional Review Board of the
University of Naples, Italy (#231/05, 20 February 2006). All par-
ticipants gave their informed consent before enrolment.
Subjects
Forty women with a diagnosis of PCOS, from 1st November
2009 to 31st October 2011, were consecutively selected from
a pool of patients referred to the outpatient clinic of our
University Hospital. The diagnosis of PCOS was based on the
Rott-PCOS criteria (Rotterdam ESHRE/ASRM-Sponsored PCOS
Consensus Workshop Group, 2004), as reported elsewhere18 and
were enrolled according to the following criteria: premenopausal
status; anovulatory oligo-amenorrhoea; Caucasian ethnicity.
None of the participants were neither on hypocaloric diet nor
taking weight loss drugs at least 3 weeks before the admission.
Controls
Twenty healthy, normal weight women among clerks, paramedi-
cal and medical personnel of our Department, matched for age
with the patients, accounting for the possible progressive
increase in bisphenol A exposure with age, from the same
geographical area, with regular menstrual cycles (defined as 26
–32 days in length) and no hyperandrogenaemia, hirsutism or
acne, were recruited; they all agreed to participate in this study
and acted as controls to set range of bisphenol A.
Exclusion criteria
The following exclusion criteria were defined: smoking or alco-
hol consumption, pregnancy, hypothyroidism, hyperprolactina-
emia, Cushing’s syndrome, nonclassical congenital adrenal
hyperplasia; previous (within the last 6 months) use of oral
contraceptives, insulin sensitizing agents, glucocorticoids, anti-
androgens, ovulation inducing agents, anti-obesity drugs; the
presence of any acute viral, bacterial or fungal infection, any
type of chronic liver disease, arthritis, bronchial asthma; chronic
inflammatory bowel; cancer.19
Methods
Ovulatory state and hirsutism, assessed using the Ferriman–Gall-
wey score, were investigated as previously reported elsewhere.18
The degree of normal weight, overweight or obesity was estab-
lished on the basis of body mass index (BMI) cut-off points of
18–249 (lean subjects), 25->40 kg/m2, respectively (overweight/
obese: O/O).
Assays
Fasting plasma glucose (FPG) levels were determined by the glu-
cose oxidase method. Fasting plasma insulin (FPI), sex hormone-
binding globulin (SHBG) and testosterone levels (Immulite, Diag-
nostic Products Co, Los Angeles, CA, USA; manufacturer’s range
02–12 nM) were measured by solid-phase chemiluminescent
enzyme immunoassays. The intra-assay coefficients (CV) of varia-
tions were less than 55% for insulin and SHBG assays and 10% for
total T assay. FAI was calculated according to the formula = Tes-
tosterone (nM)/SHBG (nM) 9 100. Among women with PCOS,
the cut-off values used were 35 nM for testosterone (sensitivity
926 and specificity 923) and 81 for FAI (sensitivity 100 and speci-
ficity 100) to identify less vsmore severe biochemical hyperandrog-
enism. The homoeostasis model assessment index of insulin
resistance (HoMA-IR) was calculated according to the formula
[FPI (lU/ml) 9 FPG (mM)]/225], as previously reported.18 As
stringent measure of insulin resistance, a value of HoMA-IR > 20
was set.18 Liver enzymes (alanine aminotransferase, aspartate ami-
notransferase, gamma-glutamyl transferase, c-GT) were measured
by in-house procedures. CRP was determined with a nephelomet-
ric assay with CardioPhase from Siemens Healthcare Diagnostics
(Marburg, Germany). IL-6 was measured by an enzyme-linked
immunosorbent assay kit (Biosurce, Camarillo, CA, USA). Its sen-
sitivity was <2 pg/ml, and the range was 78–500 pg/ml. The intra-
assay CV for low concentration was <5%.
Bisphenol A analysis
Serum concentrations of bisphenol A were determined using a
kit from IBL Co., Ltd., Gunma, Japan, characterized by a mea-
surement range of 03–100 ng/ml bisphenol A and based on a
competitive ELISA protocol using the anti-rabbit IgG antibody
solid-phase method. All standards and samples were measured
in duplicate. The assay shows 100% cross-reactivity with bisphe-
nol A, 85% with bisphenol A–glucuronide, 68% with bisphenol
A–Na-sulphate and 85% with bisphenol. The ranges of the
intra- and interassay coefficients of variation were <14% and
5%, respectively. The bisphenol A values were considered
© 2012 Blackwell Publishing Ltd
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increased when they were above the 95th percentile of those
detected in controls (045 ng/ml).
US analyses
Sonographic measurements were performed in both control
and PCOS women by the same operator, blinded to patients’
data, using a Vivid system (General Electric Healthcare Com-
pany, Milan, Italy). Briefly, spleen longitudinal diameter, the
best single measurement well related to spleen size, was mea-
sured by postero-lateral scanning. Maximum and cranio-caudal
lengths were measured and then averaged. A cut-off for spleen
longitudinal diameter was set at 103 mm.15 The classification
of ‘bright liver’ or HS severity was based on the following scale
of hyperechogenity: 0 = absent, 1 = light, 2 = moderate,
3 = severe, pointing out the difference between the densities of
the liver and the right kidney.19 Technically, echo intensity can
be influenced by many factors, particularly by gain intensity.
To avoid confounders that could modify echo intensity and
thus bias the comparisons, the mean brightness levels of both
liver and right kidney cortex were obtained on the same longi-
tudinal sonographic plane. The levels of brightness of liver and
right kidney were calculated three times directly from the
frozen images.
Statistical analysis
Results are expressed as mean ± SD or as median plus range
according to variable distributions. Differences between groups
were analysed by unpaired t test or Mann–Whitney U-test when
appropriate. Frequencies were analysed by chi-squared. Correla-
tions between variables were performed using Spearman’s rho
correlation coefficient. Multiple linear regression analysis (step-
wise method) was calculated using the predictive value of
bisphenol A levels on HoMA index, HS severity, FAI or spleen
size in the whole study population. To avoid multicollinearity,
variables with a tolerance of 02 were excluded. Values  5%
were considered statistically significant. Data were stored and
analysed using the MedCalc® package (Version 12.3.0 -  1993-
2012 MedCalc Software bvba - MedCalc Software, Mariakerke,
Belgium).
Results
The characteristics of our study population, that is, control and
PCOS women, are expressed in Table 1. Apart from the signifi-
cant differences in anthropometric and metabolic data between
the two groups, serum bisphenol A levels and low-grade inflam-
mation markers were higher in PCOS women than in controls.
Interestingly, bisphenol A values were higher in all subjects with
increased spleen size (4 controls and 26 PCOS) than in those
with normal spleen size: 01 (01–10) vs 13 (01–6) ng/ml;
P < 0001. However, as bisphenol A levels were higher than the
cut-off value in only one control compared to the 29 (73%)
women with PCOS, the subsequent subgroup analyses were per-
formed taking into account only PCOS women.
Subgroup analyses
Comparisons between the main study variables according to the
serum bisphenol A cut-off value (bisphenol A+ and bisphenol
A) are reported in Fig. 1. In particular, while age and BMI
were not significantly different between the two groups, the sub-
group of PCOS women with higher serum bisphenol A levels
displayed more severe insulin resistance and hyperandrogenism,
increased prevalence of HS, and higher CRP, IL-6 and spleen
size than the bisphenol A counterpart (Fig. 1).
Grouping PCOS for BMI (lean 222 ± 22 vs O/O 340 ± 67;
P < 0001), there were no significant differences in terms of age.
Conversely, HoMA index and FAI remained higher in O/O
Table 1. Comparisons of bisphenol A plasma levels, anthropometric,
metabolic, endocrine variables and inflammatory markers in the study




(n = 40) P-values
Age (years) 262 ± 39 277 ± 68 0382




1 29 (73%) <00001*
BMI (kg/m2) 221 ± 18 281 ± 77 0001
Waist circumference
(cm)
738 ± 45 871 ± 152 <00001
Plasma glucose (mM) 44 ± 03 50 ± 05 <00001
Insulin (pM) 502 (359–718) 861 (409–2439) <00001
HoMA-IR 14 ± 03 30 ± 12 <00001
No. patients with
HoMA-IR > 2
0 27 (68%) <00001†
Testosterone (nM) 06 ± 01 38 ± 08 <00001
SHBG (nM) 695 ± 31 400 ± 49 <00001
FAI 08 ± 02 97 ± 29 <00001
AST (U/l) 24 ± 7 34 ± 7 <00001
ALT (U/L) 24 ± 9 38 ± 10 <00001
cGT (mU/ml) 29 (7–40) 42 (9–140) <00001
No. patients with
hepatic steatosis
0 26 (65%) <00001‡
CRP (ng/ml) 02 (01–20) 17 (0–84) <00001
IL-6 (pg/ml) 57 (35–83) 106 (21–794) 0004
Spleen size (mm) 990 ± 68 1100 ± 76 <00001
No. patients with ↑
spleen size
4 (20%) 26 (65%) 0003§
Values are expressed as mean ± SD or median plus range. Differences
between control and PCOS women were analysed by unpaired t-test or
Mann–Whitney U-test when appropriate. Frequencies were analysed by
chi-squared. As a stringent measure of IR, a value of HoMA-IR > 20
was set, as reported elsewhere.18 Hepatic steatosis (HS) and spleen size
were determined by ultrasound. A cut-off for spleen longitudinal diame-
ter was set at 103 mm.15
BMI, body mass index; HoMA-IR, homoeostasis model assessment of
insulin resistance; SHBG, sex hormone-binding globulin; FAI, free
androgen index; AST, aspartate aminotransferase; ALT, alanine amino-
transferase; c-GT, gamma-glutamyltransferase; CRP, C-reactive protein;
IL-6, interleukin-6.
*v2 = 2168; †v2 = 2189; ‡v2 = 2037; §v2 = 900.
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PCOS than in their lean counterpart, while differences in HS
prevalence, CRP and IL-6 levels and spleen size were no longer
evident (Fig. 2).
Again, grouping PCOS for insulin resistance, HS, FAI or
spleen size, bisphenol A levels were higher in those with insulin
resistance (139 ± 135 vs 057 ± 111 ng/ml; P = 00003), HS
(166 ± 156 vs 054 ± 047 ng/ml; P = 0027), more severe
hyperandrogenism evaluated only by FAI (062 ± 054 vs 162 ±
150 ng/ml; P = 0025), and with larger spleen size (164 ± 150
vs 023 ± 026 ng/ml; P < 00001) than in their counterparts
without insulin resistance, HS, less severe hyperandrogenism or
normal spleen (Fig. 3).
Correlation analysis
The correlations between bisphenol A and transaminases or
c-GT and BMI are shown in Fig. 4a–d. At the multivariate anal-
ysis, adjusted for BMI, with HoMA index, HS severity, FAI or
spleen size as independent variables in the whole study popula-
tion, spleen size and FAI were the strongest predictors of bisphe-
nol A levels (b coefficients 0379, P = 0007 and 0343,
P = 0014, respectively).
Discussion
The main finding of the present study was the strong association
of bisphenol A levels with HS and the markers of low-grade
inflammation in premenopausal women with PCOS, in particu-
lar with spleen size, thus unravelling the presence of the liver–
spleen axis in this syndrome. In particular, independently of age
and BMI, higher serum bisphenol A levels identified a quite dif-
ferent subgroup of PCOS women with more severe insulin resis-
tance and hyperandrogenism, increased prevalence of HS, and
evidence of a low-grade chronic inflammation status. Notewor-
thy, spleen size was the unique discriminating parameter of high
circulating bisphenol A concentrations, in as much as the high-
est bisphenol A values were associated with the largest spleen
sizes. To the best of our knowledge, this association is novel
within the context of PCOS and was still evident when PCOS
women were grouped according to insulin resistance or HS.
In line with the well-known influence of oestrogens on several
effectors of the immune system, there is a considerable burden
of evidence in vitro and in animal models that they may exert
also immunotoxic effects.20 In particular, bisphenol A has been
reported to stimulate cytokine productions and proliferative
responses of murine spleen and thymus cells in vitro.21 More-
over, bisphenol A was involved in autoantibody production by
B1 cells.22 Thus, it is possible that oestrogen-mimicking environ-
mental factors, such as bisphenol A, may cause increased inci-
dence of autoimmune diseases.20
The first observation of increased levels of bisphenol A in
women with ovarian dysfunction was reported by Takeuchi
et al.23 in 2004 on a small group of women with PCOS; this find-
ing was subsequently confirmed by Kandaraki et al.24 in 2011. In
particular, these authors found that serum bisphenol A levels in
women with PCOS were significantly higher in comparison with
controls independently of the degree of obesity. Accordingly,
despite a weak positive correlation between bisphenol A and BMI,
otherwise no more evident at multivariate analysis, our data con-
firm the lack of differences in serum bisphenol A levels between
lean and O/O women with PCOS. This finding is apparently in
contrast with the positive association between urinary bisphenol A
concentration and the prevalence of obesity very recently reported
Fig. 1 Comparisons in polycystic ovary syndrome women between the
main study variables according to bisphenol A. Values of serum
bisphenol A were considered increased when they were above the 95th
percentile of those detected in controls (045 ng/ml). BPA, bisphenol A;
BMI, body mass index; HoMA-IR, homoeostasis model assessment of
insulin resistance; FAI, free androgen index; HS, number of subjects with
hepatic steatosis; CRP, C-reactive protein; IL-6, interleukin-6; SLD,
spleen longitudinal diameter. For graphic limitations, spleen size is
expressed in cm.
Fig. 2 Comparisons in polycystic ovary syndrome women between the
main study variables according to body mass index. O/O, overweight/
obese; BPA, bisphenol A; HoMA-IR, homoeostasis model assessment of
insulin resistance; FAI, free androgen index; HS, number of subjects with
hepatic steatosis; CRP, C-reactive protein; IL-6, interleukin-6; SLD,
spleen longitudinal diameter. For graphic limitations, spleen size is
expressed in cm.
© 2012 Blackwell Publishing Ltd
Clinical Endocrinology (2013), 78, 447–453
450 G. Tarantino et al.
in a cross-sectional study on a large sample of Chinese adult popu-
lation.25 This discrepancy could be likely due to differences in the
setting of the population study (general vs PCOS), in the age of
the population samples, mainly taking into account the possible
progressive increase in bisphenol A exposure with age and, last








































































Fig. 3 Bisphenol A (BPA) levels in polycystic ovary syndrome grouped according to the presence or absence of IR (a) or hepatic steatosis (HS)
(b), more severe hyperandrogenism (c) or increased spleen size (d). As a stringent measure of IR, a value of HoMA-IR > 20 was set, as reported
elsewhere.18 HS was evaluated by ultrasound. A cut-off value of 81 for FAI (sensitivity 100 and specificity 100) was used to identify less vs more severe
biochemical hyperandrogenism. A cut-off for spleen longitudinal diameter was set at 103 mm.15 IR, insulin resistance; FAI, free androgen index; SLD,
spleen longitudinal diameter.













































































Fig. 4 Correlations between bisphenol A (BPA) and AST (a), ALT (b), cGT (c) and BMI (d), respectively, in polycystic ovary syndrome women.
Correlations are expressed as Pearson’s correlation coefficient (r) or Spearman’s rho coefficient, when appropriate, and corresponding P-values. BPA,
bisphenol A; AST, aspartate aminotransferase; ALT, alanine aminotransferase; c-GT, gamma-glutamyltransferase; BMI, body mass index.
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as also previously reported,6 the urinary excretion of bisphenol A
is affected by the androgen-related increase in the glucuronidation
of bisphenol A by liver microsomes. Conversely, serum bisphenol
A assays, evaluating the total (conjugated and unconjugated) bi-
sphenol A, could minimize the effect of androgens on bisphenol A
metabolism.
Interestingly, in the group of women with PCOS in our study
population, the increased bisphenol A levels were highly corre-
lated with HS and laboratory liver tests, as well as with the
markers of low-grade chronic inflammation, such as CRP, IL-6
and spleen enlargement. A number of endocrine disruptors have
been considered responsible for the alterations similar to those
encountered in nonalcoholic fatty liver disease, either directly
through a hepatotoxic effect and/or indirectly by triggering
hepatic and systemic insulin resistance.26 Moreover, the associa-
tion between bisphenol A and HS has been previously reported
in animal models,27 and has been related to increased expression
of lipogenic genes, thus contributing to HS. In addition, in ani-
mal models, bisphenol A caused oxidative damage in the liver
by disturbing the balance between reactive oxygen species and
the antioxidant defence system,28 independently of oestrogen
receptors.29 In the United States, bisphenol A concentrations
were associated with cardiovascular diseases and metabolic dis-
orders, including altered blood markers of liver function.30
Finally, a significant association of bisphenol A with oxidative
stress and inflammation markers has been reported among post-
menopausal women, likely due to their low oestrogen levels
compared with available oestrogen receptors.31
The prevalence of HS was reported to be increased in women
with PCOS.32 Although insulin resistance has been accounted for
the common underlying pathophysiological mechanism, the rela-
tive role of obesity in this association still remains unravelled.32,33
The low-grade chronic inflammation has been involved in the
pathogenesis of HS through the autocrine/paracrine/endocrine
production of adipokines.14,15 Apart from its clinical significance
in the pathogenesis of HS and its link to both obesity, namely vis-
ceral obesity, and insulin resistance,34 the low-grade inflammation
process has been emphasized as a main pathophysiological mecha-
nism in PCOS.8–11 This has been shown to occur also indepen-
dently of obesity,11,35 and recently, the role of hyperandrogenism
per se, in particular the increased androgen bioavailability esti-
mated by FAI, has been extensively examined as grassroot of low-
grade chronic inflammation in PCOS.8–11
Except for low-grade chronic inflammation and HS, our data
are also largely confirmatory of the association in PCOS women
between bisphenol A and androgens or HoMA index. Accord-
ingly, Diamanti-Kandarakis et al., 201124 evidenced the positive
correlation between bisphenol A and insulin resistance using the
Matsuda index, a different surrogate index of insulin sensitivity.
This association was in line with experimental data evidencing
insulin resistance in intact animals exposed to relevant doses of
bisphenol A owing to disturbance of b-cell physiology.36
In line with the suggested role of bisphenol A as endocrine
disruptor for the ‘environmental obesogen hypothesis’,37 a possi-
ble pathway involving bisphenol A, low-grade inflammation,
hyperandrogenism and liver–spleen axis in PCOS pathogenesis
might be hypothesized. Besides the direct hepatotoxic26 and adi-
pogenic effects,28,37 bisphenol A could act as pro-inflammatory
primer, via macrophage activation and pro-inflammatory cyto-
kine hypersecretion.20 Within this context, the spleen enlarge-
ment could represent a marker of this process,14 possibly linked
to the recently discovered immune/autoimmune derangement in
women with PCOS.12 The possible exposure in utero to low-
chronic bisphenol A doses4 might trigger not only obesity and
insulin resistance, but might also contribute to the low-grade
chronic inflammation in women who will develop PCOS, per se
or through hyperandrogenism.8–11
In conclusion, our study adds a further tile to the emerging
evidence of the role of environmental exposure to bisphenol A
on polycystic ovary syndrome, by describing a so far unreported
association between bisphenol A exposure, inflammation, liver–
spleen axis and hyperandrogenism in the polycystic ovary syn-
drome setting, a major health condition for women.
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F. (2011) Circulating inflammatory markers in polycystic ovary
syndrome: a systematic review and metaanalysis. Fertility and
Sterility, 95, 1048–1058.
10 Repaci, A., Gambineri, A. & Pasquali, R. (2011) The role of low-
grade inflammation in the polycystic ovary syndrome. Molecular
and Cellular Endocrinology, 335, 30–41.
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Abstract
Platelet derivatives are commonly used in wound healing and tissue regeneration. Different
procedures of platelet preparation may differentially affect growth factor release and cell
growth. Preparation of platelet-rich fibrin (PRF) is accompanied by release of growth factors,
including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and
transforming growth factor b1 (TGFb1), and several cytokines. When compared with the
standard procedure for platelet-rich plasma (PRP), PRF released 2-fold less PDGF, but415-fold
and42-fold VEGF and TGFb1, respectively. Also, the release of several cytokines (IL-4, IL-6, IL-8,
IL-10, IFNg, MIP-1a, MIP-1b and TNFa) was significantly increased in PRF-conditioned medium
(CM), compared to PRP-CM. Incubation of both human skin fibroblasts and human umbilical
vein endothelial cells (HUVECs) with PRF-derived membrane (mPRF) or with PRF-CM enhanced
cell proliferation by42-fold (p50.05). Interestingly, PRP elicited fibroblast growth at a higher
extent compared to PRF. At variance, PRF effect on HUVEC growth was significantly greater
than that of PRP, consistent with a higher concentration of VEGF in the PRF-CM. Thus, the
procedure of PRP preparation leads to a larger release of PDGF, as a possible result of platelet
degranulation, while PRF enhances the release of proangiogenic factors.
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Introduction
Platelet products have been extensively used for clinical and
surgical applications which require tissue regeneration [1]. Thus,
platelet derivatives represent promising therapeutic tools offering
opportunities for periodontal, oral, maxillo-facial, orthopedic and
dermatological procedures [2, 3]. Indeed, platelets represent a
known source of cytokines and growth factors involved in wound
healing and tissue repair [4, 5]. Many platelet-derived factors are
considered important players in wound healing processes.
In particular, beside their known functions in hemostasis and
clot formation, platelet granules contain growth factors, including
platelet-derived growth factor (PDGF), transforming growth
factor b (TGFb), IGF-1, involved in cell proliferation and
differentiation [6]. It should also be considered that, among
platelet-released factors, no individual growth factor has proven
per se effectiveness both in soft and in hard tissue regeneration
[7]. Therefore, most probably, the mixture of more platelet-
derived factors contained in platelet releasates, could be respon-
sible for the tissue-regeneration potential of platelet derivatives
[8]. There is also a large body of evidence that the cross-talk
between factors released by platelets and those released by
recipient cells mediates the propagation of the tissue repair
mechanisms [9]. Indeed, many cell types, including blood cells,
fibroblasts and endothelial cells participate to the final healing
process and each cell type may specifically affect the function of
the other cell types, both by cell-cell and cell-matrix contacts and
by producing and releasing soluble factors [10]. Thus, under-
standing the complex mechanisms regulating tissue repair and
regeneration, is still incomplete.
Platelet-rich plasma (PRP) has long been used as a source of
platelet growth factors [11]. Several different products have been
developed in the last years [6]. All available PRP procedures have
some points in common. A first centrifugation step is needed to
separate red blood cells (RBC), buffy coat and platelet-poor
plasma (PPP). Then, different procedures have been used to
discard RBC and PPP and to collect the buffy coat. The platelets
could be eventually activated by thrombin and calcium and
applied to the injured/surgical site [12]. More recently, an
alternative approach has also been adopted. It requires blood
collection in tubes without anticoagulant and immediate centri-
fugation for the formation of a fibrin clot, which includes platelets
and leucocytes (L-PRF) [13].
Leucocytes are also a significant source of cytokines and
growth factors which may synergistically interact with those
released by platelets [14]. However, whether the combined use of
platelets- and leucocytes-derived products is beneficial still
represents a matter of controversy.
Here, we have compared the effect of two different procedures
on the release of cytokines and growth factors and on the ability to
induce the growth of fibroblasts and endothelial cells.
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Subject recruitment and preparation of biomaterials
Fourteen healthy blood donors (M/F:6/8; age 24–40 years) were
enrolled in the study. All were non-smokers, non-obese (BMI
range: 20.4–26.3) and with a platelet count4180.000/mm3. None
of them was under any medication for the last 21 days. Informed
consent was obtained from every subject before blood drawing.
The protocol has been approved by the Ethical Committee of the
University of Naples.
Blood was drawn from each individual and two 9-ml aliquots
were obtained. One aliquot was collected in tubes without
anticoagulant for the preparation of leukocyte- and platelet-rich
fibrin (L-PRF). The other was collected in a vacutainer tube
(Vacutainer; Becton Dickinson, East Rutherford, NJ) containing
10% trisodium citrate anticoagulant solution for the preparation
of PRP.
L-PRF was prepared through a single 12-min step of
centrifugation of whole blood (PRF production kit, Process,
Nice, France) according to manufacturer’s instruction. Each 9 ml
tube produced one L-PRF clot. Where indicated, the L-PRF clot
was separated from the RBC base and condensed through sterile
gauzes in order to obtain a membrane-like structure (mPRF) [13].
For PRP preparation, the whole blood was initially centrifuged
at 350 g for 15 min. The supernatant was transferred into
another tube and a second centrifugation step was performed for
10 min at 980 g. After centrifugation, the upper fraction
containing PPP was discarded and the lower fraction containing
PRP was used for the experimental procedures [9, 15, 16]. For
platelet gel preparations, autologous thrombin (0.1 NIH unit/ml
final concentration) and calcium gluconate (10 mg/ml final
concentration) were added to PRP for 5 min at room temperature
to allow clot formation.
Conditioned media (CM) were obtained by incubating the
platelet preparations for 24 hours with serum-free Dulbecco’s
modified Eagle medium (DMEM)-F12 (1:1). 0.25% BSA was
added to the medium in order to prevent osmotic cell death. After
the incubation, the medium was collected and centrifuged at
14 000 g to remove cellular debris and analyzed for cytokines
and growth factor content or placed onto recipient cells for
different times, as described below.
Determination of cytokines and growth factors released
by platelet-based biomaterials
PRP, PRF and mPRF CM were screened for the concentration of
IL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF, IFNg, MIP-1a, MIP-1b,
RANTES, TNFa, bFGF, PDGF, vascular endothelial growth
factor (VEGF) using the Bioplex Multiplex human cytokine assay
kit and the Bioplex Multiplex human growth factor kit (Bio-Rad,
Hercules, CA) according to the manufacturer’s instructions.
Cell culture and growth
Skin fibroblasts were obtained by punch biopsy and cultures
established as described previously [17]. The cells were grown at
37 C in DMEM supplemented with 10% fetal calf serum in a 5%
CO2–95% air-humidified atmosphere. For the experimental
procedures, the cultures were used between the 8th and 15th
passage, and, for each individual experiment, cells were main-
tained in culture for an equal number of generations. Primary
human umbilical vein endothelial cells (HUVECs) were obtained
and cultured as previously described. HUVECs were cultured
under 37 C and 5% CO2–95% air-humidified atmosphere in the
endothelial cell medium (ECM, ScienCell) according to the
manufacturer’s instruction. The ECM was consisted of 500 ml of
basal medium, 25 ml of fetal bovine serum, 5 ml of endothelial
cell growth supplement and 5 ml of penicilin/streptomycin
solution. For all experiments HUVEC up to passage five were
used [18].
For cell growth determination, the studies were performed as
previously described [19]. Briefly, either skin fibroblasts or
HUVEC cells were seeded in 6-well culture plates in a complete
medium. The following day, the cells were starved in serum-free
DMEM 0.25% BSA for 16 hours and incubated with either
platelet preparations or CM obtained as described above for
different times. Cell count was performed by both Bürker
chamber counting and the TC10 Automated Cell Counter
(Bio-Rad, Hercules, CA) according to the manufacturer’s
instruction.
Statistical analysis
Data were analyzed with Statview software (Abacus concepts) by
one-factor analysis of variance. p values of50.05 were considered
statistically significant.
Results
Release of cytokines and growth factors by PRF
We have first evaluated the ability of PRF, obtained as described
in ‘‘Methods’’ section to release cytokines/chemokines. To this
end, PRF has been allowed to release factors into serum-free
medium for 24 hours. PRF released detectable amounts of IL-2,
IL-4, IL-6, IL-8, IL-10, IFNg, MIP-1a, MIP-1 b, RANTES and
TNFa (Table I). Similarly, detectable levels of bFGF, PDGF,
VEGF and TGFb1 were found in PRF-CM (Table II).
Comparison of PRF- and PRP-released factors
Next we have compared the release of cytokines/chemokines and
growth factors by PRF (as membrane, mPRF – see ‘‘Methods’’
section) and PRP (as platelet gel). The use of mPRF was preferred
to that of PRF since, when the latter was incubated in serum-free
Table I. Cytokines released by PRF. PRF was incubated with serum-free
DMEM-F12 (1:1). After 24 hours, the media were collected and tested by













Table II. Growth factors released by PRF. PRF was incubated with
serum-free DMEM-F12 (1:1). After 24 hours, the media were collected
and tested by using the Bioplex multiplex growth factor assay kit as


























































medium, many cells (mainly RBC) and cellular debris were found
floating, possibly interfering with the evaluation of the function of
PRF-released factors. PRF and PRP were obtained by equal
amounts of blood drawn by the same individual. mPRF and PRP
gels were then applied onto culture dishes and incubated with
serum-free medium for 24 hours to obtain CM. The amount of
several inflammatory cytokines such as IL-6, IL-8, IL-10, IFNg,
MIP-1a, MIP-1b, TNFa, was higher in the mPRF-CM compared
to PRP-CM. At variance, the levels of RANTES were 3-fold
higher in PRP-CM compared to mPRF-CM (Table III).
Concerning the concentration of growth factors, the levels of
bFGF were detectable in small amounts compared to the other
growth factors both in mPRF-CM and in PRP-CM (Table IV).
VEGF and TGFb1 levels were 11- and 2.6-fold higher, respect-
ively, in mPRF-CM compared to PRP-CM. Instead, the amount of
PDGF was 2-fold lower in mPRF-CM compared to PRP-CM
(Table IV).
Induction of cell growth by PRF- and PRP-released factors
In order to address whether PRF and PRP may have different
effects on different cell types, we tested the ability of those
preparations to induce the growth of primary cultures of human
fibroblasts and vascular endothelial cells (HUVEC). To this end,
PRP gel and mPRF were directly applied onto the culture plate
containing either skin fibroblasts or endothelial cells. Indeed,
clinical applications of PRF and PRP often require fibroblast
proliferation and angiogenesis [1, 11]. Interestingly, PRP gel and
mPRF-induced proliferation of both cell types. However, PRP was
significantly more effective than mPRF in inducing fibroblast
growth (Figure 1). Very similar results were also obtained with
mesenchymal stem cells obtained from human subcutaneous
adipose tissue (data not shown). At variance, mPRF effect on
proliferation of endothelial cells was slightly higher than that of
PRP, suggesting a prevalent pro-angiogenic function (Figure 2).
In order to verify if released factors rather than the particulate
fraction of mPRF and PRP were responsible for the growth
promoting action, mPRF-CM and PRP-CM were obtained as
previously described and added onto cultured human fibroblasts
for 24 ours. Again, both mPRF- and PRP-released factors induced
fibroblast growth with PRP significantly more effective than
mPRF in inducing fibroblast growth (Figure 3). Next, we have
evaluated the effect of mPRF-CM and PRP-CM on the growth of
endothelial cells. Interestingly, mPRF induced growth of HUVEC
to a significantly greater extent compared to PRP releasate
(Figure 4).
Discussion
It is well established that platelet derivatives may play a key role
in soft and hard tissue regeneration and in enhancing hemostasis
in patients receiving anti-coagulating agents [1, 3, 8, 11, 13, 20–
22]. Nevertheless, many procedures have been used to obtain
platelet factors alone or in combination with other factors
eventually derived from white blood cells or circulating stem
cells [12, 23]. Much less is known about the biological activity of
Figure 2. Effect of mPRF and PRP on endothelial cell growth. mPRF and
PRP gels were directly applied onto the culture plates containing serum-
starved primary human umbilical vein endothelial cells (HUVEC) for 24
hours. As a control, endothelial cells were incubated with DMEM F12
(1:1) without serum supplementation (MEDIUM BSA) or with 10% fetal
bovine serum (MEDIUM 10% FBS). The cells were then counted as
described in ‘‘Methods’’ section. Results are presented as fold-increase
over basal (cell count in MEDIUM BSA). * denotes statistically
significant values (***p50.001).
Table III. Cytokines released by mPRF and PRP. mPRF and PRP (as
platelet gel) were incubated with serum-free DMEM-F12 (1:1). After 24
hours, the media were collected and tested by using the Bioplex multiplex
cytokine assay kit as described in ‘‘Methods’’ section.
mPRF (pg/ml) PRP (pg/ml)
IL-2 3.05 0.45 2.34 0.30
IL-4 10.56 0.1 1.78 0.43***
IL-6 10093.55 1064.03 6.20 0.55**
IL-8 43407.34 5011 1303.01 126***
IL-10 79.01 7.9# 3.91 0.42***
IFNg 484.04 57.6 37.30 3.40*
MIP-1a 479.56 28.6 0.25 0.03**
MIP-1b 822.18 82.2# 6.90 0.57***
RANTES 2818.57 281# 5505.29 530*
TNFa 73.55 5.3 2.21 0.35*
*denotes statistically significant differences (*p50.05; **p50.01;
***p50.001). # denotes statistically significant differences of mPRF
vs. PRF conditioned media (#p50.05).
Figure 1. Effect of mPRF and PRP on fibroblast cell growth. mPRF and
PRP gels were directly applied for 24 hours onto the culture plates
containing serum-starved skin fibroblasts, previously obtained by punch
biopsy (n¼ 10). As a control, fibroblasts have been incubated with
DMEM F12 (1:1) without serum supplementation (MEDIUM BSA) or
with 10% fetal bovine serum (MEDIUM 10% FBS). The cells were then
counted as described in ‘‘Methods’’ section. Results are presented as fold-
increase over basal (cell count in MEDIUM BSA). * denotes statistically
significant values (*p50.05; **p50.01; ***p50.001).
Table IV. Growth factors released by mPRF and PRP. mPRF and PRP (as
platelet gel) were incubated with serum-free DMEM-F12 (1:1). After 24
hours, the media were collected and tested by using the Bioplex multiplex
growth factor assay kit as described in ‘‘Methods’’ section.
mPRF (pg/ml) PRP (pg/ml)
bFGF 7.29 0.80 1.40 0.14**
PDGF 2225.69 333.85 4708.19 601.89*
VEGF 2330.89 233# 125.48 12.5***
TGFb1 261886 9282.9 102817.60 15422.64*
*denotes statistically significant differences of PRP vs. mPRF conditioned
media (*p50.05; **p50.01; ***p50.001). # denotes statistically
significant differences of mPRF vs. PRF conditioned media (#p50.05).




















































the individual platelet preparations, in particular with the aim of
defining their involvement in selected clinical applications.
In this work, we have addressed whether different procedures
to obtain platelet products may lead to the release of a differential
spectrum of molecules and may differentially control the growth
of specific cell types. To this end, we have determined the
concentration of several growth factors and cytokines/chemokines
in the media exposed to either PRP gels or PRF membranes.
Indeed, platelet gels were obtained by treating PRP with calcium
and thrombin and PRF membranes were obtained by condensing
PRF clots (see ‘‘Methods’’ section). Interestingly, while PRP
released a significantly higher amounts of PDGF and RANTES,
the amount of several cytokines, typically involved in wound
healing and re-vascularization, was more abundant in the releasate
of PRF membranes. It is conceivable that the enrichment of
platelets obtained in the standard procedure for PRP is responsible
for the higher release of PDGF [9, 24]. Also, RANTES, a pro-
inflammatory chemokine, is very abundant in platelets [25]. On
the other end, the clot obtained by the PRF procedure is most
likely enriched in white blood cells, which may represent major
producers of inflammatory cytokines (IL-6, IL-8, IL-10, IFNg,
MIP-1a, MIP-1b, TNFa) and of pro-angiogenic factors (VEGF
and TGFb1).
It should also be noticed that mPRF released higher levels of
IL-10, MIP-1b, RANTES and VEGF, compared to PRF clot. The
mechanism responsible for these events has not been completely
explained, but it may involve activation of the cells embedded in
the clot, following condensation and mechanical stress.
The differences in the release of specific cytokines and growth
factors prompted us to investigate whether mPRF and PRP may
have differential growth effect in fibroblasts and endothelial cells.
According to previous reports, platelet derived products can
increase cellular survival and proliferation [26–28]. Indeed, both
preparation procedures were able to induce cell growth (either in
fibroblast or in endothelial cells). Interestingly, however, direct
application of PRP gel was significantly more effective in
inducing fibroblast growth, compared to mPRF. Similarly, when
PRP was enabled to release factors and CM added to fibroblasts,
greater effectiveness than with mPRF CM was observed. On the
other hand, growth of endothelial cells was slightly more effective
following direct application of mPRF, compared to PRP, while,
the effect of mPRF CM on HUVEC growth was significantly
more pronounced than that of PRP CM.
These data indicate that different procedures to obtain platelet
products display quantitative differences in the content of growth
factors and cytokines. This may be relevant for the choice of the
appropriate tool. For example, standard procedures for PRP, more
efficiently release PDGF and RANTES, most likely because of
the higher enrichment in platelets occurring trough the prepar-
ation and, perhaps, following the activation with thrombin and
calcium which facilitates platelet degranulation. On the other
hand, PRF procedures allow a better yield of several growth
factors (bFGF, VEGF, TGFb1) and cytokines, which derive from
white blood cells and, possibly, circulating progenitor cells, which
are embedded in the fibrin clot.
This is a relevant issue, since it may recommend the use of one
or the other method, based on the specific goal to achieve. Indeed,
if the expansion of connective tissue is mainly required, the use of
a higher concentration of PDGF, to increase the number of the
fibroblast component, is more indicated. Alternatively, if reduced
angiogenesis is a major obstacle to tissue regeneration, one may
choose preparations containing higher levels of bFGF and VEGF,
thereby stimulating endothelial cell recruitment and vessel
formation. In addition, procedures for PRF production enable
the achievement of an higher concentration of several cytokines,
which may play important roles in many events involved in the
tissue regeneration process.
Conclusion
We have reported that different procedures to obtain blood
derivatives for regenerative medicine applications may yield
different products. When platelet activation is achieved via
thrombin stimulation, platelets release greater amounts of PDGF
and other factors, mainly involved in fibroblast growth. At
variance, when clot is directly and rapidly obtained without
anticoagulation, the enrichment of VEGF and pro-angiogenic
cytokines, possibly released by the embedded white blood cells,
facilitates endothelial cell growth.
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Abstract
Current evidence indicates that chemical pollutants may interfere with the homeostatic control of nutrient metabolism,
thereby contributing to the increased prevalence of metabolic disorders. Bisphenol-A (BPA) is a lipophilic compound
contained in plastic which is considered a candidate for impairing energy and glucose metabolism. We have investigated
the impact of low doses of BPA on adipocyte metabolic functions. Human adipocytes derived from subcutaneous adipose
tissue and differentiated 3T3-L1 cells were incubated with BPA, in order to evaluate the effect on glucose utilization, insulin
sensitivity and cytokine secretion. Treatment with 1nM BPA significantly inhibited insulin-stimulated glucose utilization,
without grossly interfering with adipocyte differentiation. Accordingly, mRNA levels of the adipogenic markers PPARc and
GLUT4 were unchanged upon BPA exposure. BPA treatment also impaired insulin-activated receptor phosphorylation and
signaling. Moreover, adipocyte incubation with BPA was accompanied by increased release of IL-6 and IFN-c, as assessed by
multiplex ELISA assays, and by activation of JNK, STAT3 and NFkB pathways. Treatment of the cells with the JNK inhibitor
SP600125 almost fully reverted BPA effect on insulin signaling and glucose utilization. In conclusion, low doses of BPA
interfere with inflammatory/insulin signaling pathways, leading to impairment of adipose cell function.
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Introduction
Overweight, obesity and insulin resistance epidemics are
significant human health problems in adults, but also in children
and adolescents [1,2]. They are associated with increased risk of
diseases related to metabolic dysfunctions, including metabolic
syndrome (MS), type 2 diabetes mellitus (T2D), coronary heart
disease (CHD), and some forms of cancer [3–6]. Chronic
inflammation often accompanies obesity and related disorders,
suggesting that inflammatory factors might be a crucial culprit
connecting adipose tissue dysfunction with insulin resistance and
diabetes as well as with cardiovascular disease and cancer [5–9].
Environmental signals, including chemical pollutants, are now
considered contributing factors for insulin resistance [10–13].
Most of chemical pollutants potentially accumulate into adipose
tissue [14], and could be responsible, in addition to the well-known
dietary and lifestyle habits, for overweight and obesity epidemic,
driving the parallel T2D epidemic [13,15–17].
The ‘‘environmental obesogen hypothesis’’ has been associ-
ated to the adipose tissue inflammatory phenotype, with hyper-
secretion of pro-inflammatory and decrease of anti-inflamma-
tory cytokines, and considered as a major contributing factor for
the decreased insulin sensitivity [7–10]. Indeed, the exponential
rise of obesity-related pathologies worldwide is associated with
the marked increase of toxic chemicals in the environment. In
the modern world, in fact, the environment has been largely
affected by an ever increasing number of synthetic chemical
lipophilic pollutants, such as pesticides, organophosphates,
polychlorinated bisphenyls, phthalates, solvents etc., that per-
meate the diet, the air and the ground [15,16,18–20]. An even
larger impact could be exerted by those which are resistant to
biological and chemical degradation, also termed Persistent
Organic Pollutants(POPs), most of them also classified as
endocrine disruptors [15–20].
Bisphenol-A (BPA) represents a potential obesogen compound
and has been studied for its estrogen mimetic activity and
endocrine disruption [21–24]. BPA is found in products contain-
ing polycarbonate plastics and in resins, as lining for metal cans
and as an additive in other widely used plastics [25–27]. It is a
lipophilic compound detectable at nanomolar levels not only in
food and tap water, in rivers, lakes and sea, but also in human
blood samples and urine worldwide, as well as in the placenta,
amniotic fluid of pregnant women and in human milk [28,29]. In
animal models, BPA has been shown to disrupt the major weight
controlling hormones, such as thyroid hormones, estrogens,
testosterone, corticosteroids, growth hormone and leptin, and to
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alter adipogenesis, beta-cell and endocrine pancreas function
[24,30–32]. The relationship between BPA, inflammation and
insulin sensitivity in adipose tissue is still not well understood.
Thus, we have investigated whether BPA, at nanomolar doses,
consistent with those found in the human bloodstream and/or in
environment, could interfere with adipose tissue function. We
found that, in cultured adipose cells derived from human
subcutaneous tissue and in 3T3-L1 adipocytes, BPA exposure
impaired insulin sensitivity and glucose utilization and enhanced
the release of pro-inflammatory compounds, even in the absence
of major derangement of adipocyte differentiation.
Materials and Methods
Materials
Media, sera, and antibiotics for cell culture were from Lonza
(Lonza Group Ltd, Basel, Switzerland). Antibodies against
phospho-Ser473PKB/Akt1, ERK,phospho-Thr183/Tyr185c-Jun
N-terminal kinase (JNK), STAT3, NFkB, Laminin A/C and actin
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Phospho-Thr202/Tyr204ERK, Phospho-IGF1-Receptor beta
Tyr1131/Insulin Receptor beta Tyr1146, Insulin Receptor beta
and Phospho-Tyr705 STAT3 antibodies were obtained from Cell
Signaling Technology (Danvers, MA). PKB/Akt antibody was
Table 1. Primer sequences used in Real-time RT-PCR analysis.
PPARc Forward 59- TGG TGC CTTCGCTCATGC -39
PPARc Reverse 59- CTG TGG TAA AGG GCT TGA TGTC -39
GLUT4 Forward 59- CAG AAG GTG ATT GAA CAG AG- 39
GLUT4 Reverse 59- AAT GAT GCC AAT GAG AAA GG-39
GLUT1 Forward 59- GGG AAT GTC CTC ATC TTG GA -39
GLUT1 Reverse 59- TGA GGC TCT GTG TGG TTC TG -39
LEPTIN Forward 59-ACTCCACAATGCTTGACTC -39
LEPTIN Reverse 59-CCTACCTCACCTCTCCTG -39
b-actin Forward 59- CGC CCT AGG CAC CAG GGT GTG -39
b-actin Reverse 59- TCG GTG AGC AGC ACA GGG TG -39
doi:10.1371/journal.pone.0082099.t001
Figure 1. Effect of BPA on adipocyte glucose utilization. Human adipocytes (a) and 3T3-L1 adipocytes (b) were incubated in serum free-media
with 1 nM or 100 nM BPA and 100 nM insulin for 24 and 48h as indicated. Next, supernatants were collected and glucose consumption was
determined as described in Materials and Methods. Bars represent the mean 6 SD of three independent experiments. Data were analyzed with
Statview software (Abacus concepts) by one-factor analysis of variance. p values of less than 0.05 were considered statistically significant. Asterisks
indicate statistically significant differences (* p,0.05). Error bars indicate mean 6 S.D.
doi:10.1371/journal.pone.0082099.g001
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from Millipore (Billerica, MA). BPA in ethanol was a generous gift
of Prof. C. Crescenzi (Department of Pharmaceutic Science,
University of Salerno, Italy). Sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) reagents were from Bio-
Rad (Hercules, CA). All the other chemicals were from Sigma-
Aldrich (St. Louis, MO).
Cell cultures
Human adipose tissue samples were obtained by abdominal
biopsy in the periumbilical region under local anesthesia (2%
lidocaine) from patients undergoing elective abdominal surgery for
gall bladder disease. The study was approved by the Ethic
Committee of the University of Napoli ‘‘Federico II’’. The written
informed consent with respect to taking the samples and making
the cell lines was obtained before the bioptical procedure. The
study protocol was conducted in accordance to the principles of
the Declaration of Helsinki as revised in 2000. Adipose tissue was
digested with collagenase and Adipose-derived Stromal Vascular
Fraction cells (SVF) were isolated and differentiated as previously
reported [6].
table-1-caption3T3-L1 mouse embryonic fibroblasts (ATCC-
CL-173, American Type Culture Collection, Manassas, VA) were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and 2 mmol/l
glutamine, 100 IU/ml penicillin, 100 IU/ml streptomycin. Cul-
tures were maintained in humidified atmosphere of 95% air and
5% CO2 at 37 C. 3T3-L1 differentiation has been achieved as
previously described [6].
Conditioned media were obtained by incubating the cells for 8 h
with serum-free DMEM 0.25% BSA after two washes with PBS.
After the incubation, medium was collected and centrifuged at
14000g to remove cellular debris and analyzed for cytokine
content, as described below.
Glucose Utilization
table-1-captionFor glucose utilization studies, the method
previously described [33] was modified for human adipocytes
and 3T3-L1 adipocytes. Adipocytes were incubated in serum-free
media containing 0.25% BSA in the absence or presence of 1 nM–
100 nM BPA and 100 nM insulin for 24–48h. Glucose concen-
tration was measured in the medium before and after the
incubation.
table-1-captionThe difference in glucose concentration was
considered to be utilized by the cells. Quantitative analysis of
glucose concentration was performed with a ABX Pentra 400
clinical chemistry analyzer using the reagent ABX Pentra Glucose
CP (ABX-Horiba, Montpellier, France) according to the manu-
facturer’s instructions.
Immunoblot procedure
Total cell lysates and, where indicated, cytosolic and nuclear
fractions were obtained, separated by SDS-PAGE and immuno-
blotted with specific antibodies as previously described [34–35].
Cytokine Assay
Human and 3T3-L1 adipocytes conditioned media were
screened for the concentration of IL-1a, IL-1b, IL-2, IL-3, IL-
4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), IL-12(p70), IL-13, IL-
17, Eotaxin, G-CSF, GM-CSF, IFN-c, KC/IL-8, MCP-1,
MIP-1a, MIP-1b, RANTES and TNF-a using the Bioplex
multiplex Mouse and Human Cytokine kits (Bio-Rad)
according to the manufacturer’s protocol as previously
described [6].
Real-time RT-PCR analysis
table-1-captionTotal RNA was isolated from 3T3-L1 adipocytes
by using the RNeasy Kit (Qiagen Sciences) according to the
manufacturer’s instruction. For real-time RT-PCR analysis, 1 mg
cell RNA was reverse transcribed using Super Script II Reverse
Transcriptase (Invitrogen). PCR were analyzed using SYBR
Figure 2. Effect of BPA on adipocyte gene expression. 3T3-L1
cells have been differentiated in mature adipocytes in presence of BPA
1 nM. Next, mRNA levels of PPARc (a), GLUT4 (b) and GLUT1 (c) during
adipogenic differentiation were determined by real-time RT-PCR
analysis. Bars represent the mean 6 SD of four independent
experiments and show the mRNA levels in these cells relative to those
in 3T3-L1 cells in absence of BPA at day 2 of differentiation. Data were
analyzed with Statview software (Abacus concepts) by one-factor
analysis of variance. p values of less than 0.05 were considered
statistically significant. Asterisks indicate statistically significant differ-
ences (* p,0.05). Error bars indicate mean 6 S.D.
doi:10.1371/journal.pone.0082099.g002
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Green mix (Invitrogen). Reactions were performed using Platinum
SYBR Green Quantitative PCR Super-UDG using an iCycler
IQmulticolor Real-Time PCR Detection System (Bio-Rad). All
reactions were performed in triplicate and b-actin was used as an
internal standard. Primer sequences used were described in Table
1.
Figure 3. Effect of BPA on insulin transduction pathways. Human (a) and 3T3-L1 adipocytes (c) were incubated with 1 nM BPA for 24 and 48h
as indicated and exposed to 100 nM insulin for 10 min and then solubilized as described in Materials and Methods. Cell lysates (50 mg protein/
sample) were blotted with phospho- Tyr1146 Insulin Receptor b (pIR), phospho- Ser473Akt/PKB and phospho-Thr202/Tyr204Extracellular signal-
Regulated Kinases (pERK) antibodies and then reblotted with anti-IR, Akt/PKB and ERK antibodies. To ensure the equal protein transfer, membranes
were blotted with actin antibodies. The filters were revealed by ECL and autoradiography. The autoradiographs shown are representative of four
independent experiments. b-d) Filters obtained in a and c have been analyzed by laser densitometry as described under Materials and Methods. Data
were analyzed with Statview software (Abacus concepts) by one-factor analysis of variance. p values of less than 0.05 were considered statistically
significant. Asterisks indicate statistically significant differences (*p, 0.05). Error bars indicate mean 6 S.D.
doi:10.1371/journal.pone.0082099.g003
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Statistical analysis
Data were analyzed with Statview software (Abacus concepts)
by one-factor analysis of variance. p values of less than 0.05 were
considered statistically significant.
Results
BPA down-regulates insulin-stimulated glucose
utilization in differentiated adipocytes
We have first investigated whether BPA could affect glucose
utilization in differentiated adipocytes. To this end, human
adipocytes, obtained following differentiation of adipose tissue-
derived stromal vascular fraction (SVF) cells, were incubated with
BPA (1 nM or 100 nM), for 8, 24 and 48h, in the absence or in the
presence of insulin (100 nM). Following BPA treatment, glucose
utilization tended to be increased, at each time point (data not
shown). As expected, in the absence of BPA, insulin induced a
significant 4.5 fold increase of glucose utilization. Insulin
stimulatory effect was still detectable after 8h incubation with
1 nM BPA, while after 24h of incubation with BPA, insulin effect
on glucose utilization was reduced by 55% (Fig 1a).Within the
same time frame, 100 nM BPA decreased insulin stimulatory
action by .70%. Prolonging BPA pre-exposure to 48h, further
reduced insulin effect. Consistent results were obtained following
identical treatment of differentiated 3T3-L1 adipocytes (Fig 1b).
Thus, 1 nM BPA treatment for 24h was sufficient to inhibit insulin
effect on glucose utilization both in differentiated human
adipocytes and in 3T3-L1 cells. Therefore, for the next
experimental settings we have used 1 nM BPA, as the lowest
non toxic dose.
No relevant morphological abnormalities were observed
following BPA exposure (up to 48 h) both for human and 3T3-
L1 adipocytes.
Moreover, 1 nM BPA did not roughly affect adipocyte
differentiation. Indeed, when 3T3-L1 pre-adipocytes were incu-
bated with BPA along with the differentiation mix, during early
(day 2), medium (day 6) and late (day 10) adipogenesis phases,
PPARc (Fig.2a) and GLUT4 (Fig.2b) mRNA levels were
unchanged. At variance, GLUT1 levels were increased, following
BPA exposure (Fig.2c). Consistent results were obtained with
human pre-adipocytes (data not shown).
BPA inhibits insulin receptor phosphorylation and
downstream signalling in differentiated adipocytes
We have therefore analyzed the effect of BPA on insulin
signalling in mature adipocytes. Human (Fig. 3a-b) and 3T3-L1
(Fig.3c-d) adipocytes were pre-incubated with 1 nM BPA for 24h
and 48h and then stimulated with insulin for 10 min. BPA
exposure led to a time-dependent decrease of insulin-stimulated
Figure 4. Effect of BPA on leptin mRNA levels. 3T3-L1 adipocytes
were incubated with 1 nM BPA for 24h and leptin mRNA levels were
determined by real-time RT-PCR analysis. Bars represent the mean 6 SD
of three independent experiments and show the leptin mRNA levels
relative to those in 3T3-L1 cells in absence of BPA. Data were analyzed
with Statview software (Abacus concepts) by one-factor analysis of
variance. p values of less than 0.05 were considered statistically
significant. Asterisks indicate statistically significant differences (*p,
0.05). Error bars indicate mean 6 S.D.
doi:10.1371/journal.pone.0082099.g004
Table 2. BPA interference on adipocyte-released cytokines.
Human Adipo (pg/ml) Human Adipo + BPA (pg/ml) Adipo3T3-L1(pg/ml) Adipo3T3-L1 +BPA (pg/ml)
IL-1b ND ND 60.58±9 55.36±7.4
IL-2 9.63±1.2 9.68±0.8 ND ND
IL-4 8.23±0.9 8.55±0.9 0.13±0.02 0.9±0.008
IL-6 689.7±72.5 884.9±93.4* 0.98±0.03 5.27±0.7**
IL-10 85.01±9.2 83.15±9.7 3.70±0.4 4.39±0.8
GM-CSF 112.31±15.6 114.41±13.1 ND ND
IFN-c 393.79±42.6 481.71±45.7* 0.25±0.09 0.86±0.05*
KC/IL-8 56.81±6.9 63.63±6.1 20566±215 21283±200.3
MIP-1a 2.44±0.9 2.52±0.7 26.22±3.2 43.48±5.6*
MIP-1b 13.68±1.9 14.07±2 2.35±0.52 1.26±0.3
RANTES 25.08±3.1 25.94±2.3 362.75±39.2 333.3±27.9
TNF-a 11.12±1.3 11.37±1 255.91±27.1 222.07±21.9
Supernatants from 3T3-L1 and human adipocytes treated with or without 1 nM BPA for 24h were collected and tested by using the Bioplex multiplex cytokine assay kit
as described in Materials and Methods. Data were analyzed with Statview software (Abacus concepts) by one-factor analysis of variance. p values of less than 0.05 were
considered statistically significant. Asterisks indicate statistically significant differences (* p,0.05; ** p,0.01).
doi:10.1371/journal.pone.0082099.t002
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insulin receptor (IR) tyrosine phosphorylation and to a significant
reduction of PKB/Akt and ERK1/2phosphorylation. No signif-
icant BPA-dependent change was observed for IR, PKB/Akt and
ERK1/2 total protein or basal phosphorylation levels.
BPA exposure affects adipocyte secretion and induces
activation of inflammation-related pathways in
adipocytes
We assessed whether BPA could affect the expression of specific
adipokines. To this end, we have measured leptin mRNA levels in
3T3-L1 cells. A significant decrease in leptin mRNA levels was
found following treatment with 1 nM BPA, compared the control
cells (Fig.4).
We have next analyzed the impact of 1 nM BPA on adipocyte
secretory function, in terms of release of inflammatory cytokines
(Table 2). Both human and 3T3-L1 differentiated adipocytes
displayed higher levels of IL-6 and IFN-c. No significant difference
was found for several other cytokines (IL-1b, IL-2, IL-4, IL-6, IL-
10, GM-CSF, IFN-c, KC/IL-8, MIP-1a, MIP-1b, RANTES and
TNF-a) with the exception of MIP-1a, which was significantly
elevated in BPA-treated 3T3-L1, while not in human adipocytes.
Some other cytokines (IL-1a, IL-3 IL-5, IL-9, IL-12 p40, IL-
12p70, IL-13, IL-17, Eotaxin, G-CSF, MCP-1) were not detected
Figure 5. Effect of BPA on JNK and STAT3 activation. Human (a) and 3T3-L1 (c) adipocytes were incubated with 1 nM BPA for 24h and then
solubilized as described in Materials and Methods. Cell lysates (50 mg protein/sample) were blotted with phospho- Thr183/Tyr185 JNK and Phospho-
Tyr705 STAT3 antibodies and then reblotted with anti-JNK and STAT3 antibodies. To ensure the equal protein transfer, membranes were blotted with
actin antibodies. The filters were revealed by ECL and autoradiography. The autoradiographs shown are representative of four independent
experiments. b-d) Filters obtained in a and c have been analyzed by laser densitometry as described under Materials and Methods. Data were
analyzed with Statview software (Abacus concepts) by one-factor analysis of variance. p values of less than 0.05 were considered statistically
significant. Asterisks indicate statistically significant differences (*p,0.05). Error bars indicate mean 6 S.D.
doi:10.1371/journal.pone.0082099.g005
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in the conditioned media of either human and 3T3-L1 differen-
tiated adipocytes.
This led us to hypothesize that BPA may elicit an inflammatory-
like response in adipocytes. We also observed a significantly
increased detection of the phosphorylated forms of JNK and
STAT3 in human (Fig. 5a-b) and 3T3-L1 (Fig. 5c-d) adipocytes
upon treatment with BPA for 24h.
Consistently, 1 nM BPA treatment led to a significantly
increased detection of NF-kB in nuclear extracts, paralleled by a
decreased cytosolic abundance (Fig.6).
Next, human adipocytes were treated with 20mM SP600125. At
this concentration the compound inhibited BPA-stimulated JNK
phosphorylation (Fig. 7a-b). We also observed a slight inhibition of
STAT3 phosphorylation, however. Interestingly, the treatment
with SP600125 largely rescued insulin effect on IR, PKB/Akt and
ERK1/2 phosphorylation in BPA-stimulated cells (Fig.7c-d). We
therefore tested the effect of SP600125 on glucose utilization on
BPA-and insulin-stimulated cells (Fig. 8). Consistent with the effect
on insulin signalling pathway, the compound reverted BPA
inhibitory effect. Indeed, in the presence of SP600125 insulin
action appeared inhibited by only 30%, compared to 55%
inhibition occurring after BPA treatment alone.
Discussion
Many environmental pollutants, including BPA, are lipophilic
compounds with small size and with the ability to mimic or block
the natural action of endogenous hormones [26]. For this
capability, they may affect several endogenous pathways,
including those regulating energy and glucose metabolism,
thereby contributing to insulin resistance and metabolic dysfunc-
tion [36]
Moreover, environmental pollutants, as well as excessive
nutrients, can trigger inflammatory signals. There is a large body
of evidence indicating that obesity is accompanied by inflamma-
tion in metabolically relevant tissues, particularly in adipose tissue
[7–10,37]. It is therefore possible that pollutants may participate in
deranging the function of adipose tissue, contributing to the
inflammatory condition and to insulin resistance.
We have now provided evidence that nanomolar BPA
concentrations may induce an inflammation-like response in
human adipocytes. BPA exposure of human adipocytes increases
the release of inflammatory factors, such as IL-6 and IFN-c,
raising the possibility that it may directly elicit a pseudo-
inflammatory response in adipose tissue. Another consistent
finding is the activation of typical inflammatory pathways. Indeed,
JNK, JAK/STAT and NF-kB pathways have been found
activated in BPA-treated adipocytes. Thus, both secretion of
cytokines and activation of intracellular pathways, suggestive of an
inflammatory response, occur after treatment with very low doses
of BPA, comparable to those commonly found in the environment
and in biological samples [28,29]. The direct stimulation of BPA
on inflammatory pathways in adipocytes could also be accompa-
nied, in vivo, by an effect on inflammatory infiltrates in the adipose
tissue [8–10,38].
It has been hypothesized that BPA can trigger Toll-like
Receptors (TLR), which in turn may induce JNK and NF-kB
pathways, leading to up-regulation of pro-inflammatory factors,
including IL-6 and IFN-c [38,39]. Alternatively, BPA may act
through estrogen receptors both at genomic and at non-genomic
level [39,40]. Recent evidence also indicates that BPA specifically
binds G protein-coupled receptor 30 (GPR30), a novel non-
classical membrane ER, by which estrogenic compounds might
induce biological effects in different cell types, including adipocytes
[39,41,42].
Thus, one might speculate that BPA elicits intracellular
signalling pathways (either via TLR, ER or GPR30) leading to
up-regulation of IL-6 and IFN-c, which in turn may contribute to
activate typical inflammatory pathways, such as JNK and JAK/
STAT. Consistent with our findings, other groups have shown that
IL-6 release is increased following BPA exposure of human pre-
adipocytes [39,43]. To the best of our knowledge, this is the first
report of IFN-c release elicited by BPA in adipocytes, while it has
been described in dendritic cells and in CD4+ lymphocytes
[39,43].
In parallel with the pseudo-inflammatory profile, we observed
that BPA-treated adipocytes were less sensitive to insulin in
terms of glucose utilization. Interestingly, the effect was already
detectable upon treatment of the cells with 1 nM BPA. At this
concentration, we failed to observe any gross abnormality in
adipocyte morphology and differentiation markers, including
GLUT4, suggesting that the alteration specifically occurred at
the level of the insulin signalling machinery. Other laboratories
have reported that BPA stimulated an increase in GLUT4 and
glucose uptake in adipocytic cell models [44]. However, these in
vitro effects required doses considerably higher than those found
in human tissues [28]. Nonetheless, we observed increased basal
glucose utilization, accompanied by increased levels of GLUT1.
The possibility of reduced total glucose uptake is, therefore, not
supported by data. At variance, we observed reduced insulin-
stimulated tyrosine phosphorylation of insulin receptor and a
consistent reduction of downstream signalling. In agreement
with Kidani et al [45], these alterations can be responsible for a
worsening in insulin signalling via PKB/Akt and ERK, causing
a reduction in insulin sensitivity and in insulin-mediated glucose
uptake in adipose tissue. This also raises the possibility that
BPA-induced insulin sensitivity may contribute to worsen the
pro-inflammatory profile. Indeed, an emerging body of evidence
suggests that insulin suppresses the inflammatory process, not
only through preventing hyperglycemia but also by modulating
Figure 6. Effect of BPA on NFkB activation. 3T3-L1 adipocytes
were incubated with 1 nM BPA for 24h. Next, subcellular fractionation(-
nuclear and cytoplasmic) was performed and proteins were extracted
and subjected to SDS–PAGE and immunoblotted with anti-NFKB
antibody. Actin and Laminin A/C were used as loading control for the
cytosolic and nuclear fractions, respectively. Blots were revealed by ECL
and autoradiography. The autoradiographs shown are representative of
four independent experiments.
doi:10.1371/journal.pone.0082099.g006
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key inflammatory molecules [46]. Moreover, the decrease of
leptin levels observed in BPA-treated adipocytes may be due to
reduced insulin promotion of leptin gene expression, as
previously reported in human adipocytes [47,48].
Interestingly, however, inhibition of JNK activity almost
completely restored insulin receptor signalling and largely rescued
insulin-stimulated glucose utilization in BPA-treated adipocytes,
suggesting a primary involvement of inflammatory factors.
Although no gross effect on adipocyte morphology and
differentiation was observed, we cannot exclude the possibility
that pre-natal or early post-natal exposure to BPA may affect
adipogenesis as well, as has also been reported [49–53].
Figure 7. Effect of JAK2/STAT3 and JNK inhibition on BPA-impaired inflammatory and insulin pathways. Human adipocytes were
incubated with 1 nM BPA for 24h and exposed to 20 mM SP600125 for 1 h. a) Cell lysates (50 mg protein/sample) were blotted with phospho-JNK and
Phospho-Tyr705 STAT3 antibodies and then reblotted with anti- JNK and STAT3 antibodies. c) Cells were treated with 100 nM insulin for 10 min and
then solubilized. Cell lysates (50 mg protein/sample) were blotted with phospho- IR, phospho- Ser473Akt/PKB and phospho-Thr202/ERK and then
reblotted with anti-IR, Akt/PKB and ERK antibodies. To ensure the equal protein transfer, membranes were blotted with actin antibodies. The filters
were revealed by ECL and autoradiography. The autoradiographs shown are representative of four independent experiments. b-d) Filters obtained in
a and c have been analyzed by laser densitometry as described under Materials and Methods. Data were analyzed with Statview software (Abacus
concepts) by one-factor analysis of variance. p values of less than 0.05 were considered statistically significant. Asterisks indicate statistically
significant differences (* p,0.05). Error bars indicate mean6 S.D.
doi:10.1371/journal.pone.0082099.g007
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Thus, exposure to BPA impairs insulin sensitivity and
induces the release of inflammatory factors in adipocytes.
One possible mechanism is that BPA activates JNK, via TLRs
or ERs, and this may directly impair insulin action [39,54].
Alternatively, the release of IL-6 and IFN-c may, in turn,
contribute to JNK activation in the adipocytes and either
directly or indirectly down-regulate insulin-stimulated glucose
uptake [54].
It should be also pointed out that an associations between
serum and urinary concentrations of persistent organic pollutants
and diabetes have been described [13,55,56]. Moreover, we have
recently reported that women with Polycystic Ovary Syndrome
(PCOS), characterized by insulin resistance and low-grade
chronic inflammation, displayed elevated serum BPA levels
[57]. These observations indicate a relevant role for BPA in
impairing energy and nutrient metabolism, and, together with
our current report, suggest that adipocytes may integrate BPA
signals and further derange insulin sensitivity and inflammatory
pathways.
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